Monitoring Selected National HIV Prevention and Care Objectives By Using HIV Surveillance Data United States and 6 Dependent Areas, 2020: Tables

Related Pages
All Tables
Report Contents
Table 1a. Stage of Disease at Time of HIV Diagnosis During 2020 (COVID-19 Pandemic) Among Persons Aged ≥13 Years, by Selected Characteristics—45 States and the District of Columbia
Stage 0a Stage 1
(CD4 ≥ 500 cells/µL or ≥ 26%)		 Stage 2
(CD4 = 200–499 cells/µL or 14%–25%)		 Stage 3 (AIDS)
(OI or CD4 < 200 cells/µL or <14%)		 Stage unknownb
Total No. No. % No. % No. % No. % No. %
Gender
Male 22,727 1,600 7.0 5,678 25.0 7,098 31.2 4,866 21.4 3,485 15.3
Female 5,042 289 5.7 1,451 28.8 1,349 26.8 1,161 23.0 792 15.7
Transgender womanc 599 53 8.8 194 32.4 177 29.5 74 12.4 101 16.9
Transgender manc 38 9 23.7 12 31.6 12 31.6 2 5.3 3 7.9
Additional gender identityd 16 2 12.5 3 18.8 8 50.0 2 12.5 1 6.3
Age at diagnosis (yr)
13–24 5,728 581 10.1 1,588 27.7 2,117 37.0 518 9.0 924 16.1
25–34 10,570 783 7.4 2,976 28.2 3,354 31.7 1,840 17.4 1,617 15.3
35–44 5,545 309 5.6 1,389 25.0 1,573 28.4 1,390 25.1 884 15.9
45–54 3,644 163 4.5 810 22.2 895 24.6 1,267 34.8 509 14.0
≥55 2,935 117 4.0 575 19.6 705 24.0 1,090 37.1 448 15.3
Race/ethnicity
American Indian/Alaska Native 195 18 9.2 48 24.6 50 25.6 42 21.5 37 19.0
Asian 612 30 4.9 140 22.9 217 35.5 164 26.8 61 10.0
Black/African American 12,069 807 6.7 2,912 24.1 3,766 31.2 2,421 20.1 2,163 17.9
Hispanic/Latinoe 7,498 519 6.9 1,949 26.0 2,434 32.5 1,709 22.8 887 11.8
Native Hawaiian/other Pacific Islander 63 2 3.2 13 20.6 29 46.0 13 20.6 6 9.5
White 7,256 533 7.3 2,081 28.7 1,920 26.5 1,604 22.1 1,118 15.4
Multiracial 729 44 6.0 195 26.7 228 31.3 152 20.9 110 15.1
Transmission categoryf
Male-to-male sexual contact 19,414 1,438 7.4 4,958 25.5 6,265 32.3 3,873 20.0 2,880 14.8
Injection drug use 1,846 128 6.9 465 25.2 462 25.0 410 22.2 381 20.7
Male 1,052 72 6.9 252 24.0 256 24.3 250 23.8 222 21.1
Female 794 56 7.0 213 26.8 206 25.9 160 20.2 159 20.1
Male-to-male sexual contact and injection drug use 1,023 79 7.7 321 31.4 273 26.7 170 16.6 179 17.5
Heterosexual contactg 6,058 303 5.0 1,571 25.9 1,626 26.8 1,629 26.9 929 15.3
Male 1,826 65 3.6 338 18.5 482 26.4 640 35.1 301 16.5
Female 4,231 238 5.6 1,233 29.1 1,144 27.0 988 23.4 628 14.8
Otherh 82 5 6.4 24 28.9 17 21.4 23 28.1 12 15.2
Male 27 1 3.4 6 23.2 6 21.7 9 32.6 5 19.1
Female 55 4 7.8 17 31.7 12 21.3 14 25.9 7 13.3
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 22,809 1,601 7.0 6,004 26.3 7,029 30.8 4,737 20.8 3,438 15.1
Metropolitan areas (pop. 50,000–499,999) 3,629 253 7.0 873 24.1 1,065 29.3 851 23.4 587 16.2
Nonmetropolitan areas (pop. <50,000) 1,846 91 4.9 435 23.6 521 28.2 495 26.8 304 16.5
Total 28,422 1,953 6.9 7,338 25.8 8,644 30.4 6,105 21.5 4,382 15.4

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; OI, opportunistic infection (i.e., AIDS-defining condition); CDC, Centers for Disease Control and Prevention [footnotes only].
Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Stage of disease at diagnosis of HIV infection is based on first CD4 test performed or documentation of an AIDS-defining condition ≤3 months after a diagnosis of HIV infection. Data are based on residence at time of diagnosis. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to the CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kentucky, Pennsylvania, Vermont, and Puerto Rico.
a First positive HIV test result is within 6 months after a negative HIV test result. The diagnosis of an AIDS-defining condition or a low CD4 test result before the 6 months have elapsed does not change the stage from stage 0 to stage 3.
b Includes persons with no CD4 information.
c “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
d Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
e Hispanic/Latino persons can be of any race.
f Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
g Sexual contact with a person known to have, or with a risk factor for, HIV infection.
h Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

Table 1b. Stage of Disease at Time of HIV Diagnosis During 2020 (COVID-19 Pandemic) Among Persons Aged ≥13 Years, by Area of Residence—45 States and the District of Columbia
Stage 0a Stage 1
(CD4 ≥ 500 cells/µL or ≥ 26%)		 Stage 2
(CD4 = 200–499 cells/µL or 14%–25%)		 Stage 3 (AIDS)
(OI or CD4 < 200 cells/µL or <14%)		 Stage unknownb
Total No. No. % No. % No. % No. % No. %
Alabama 585 39 6.7 134 22.9 188 32.1 127 21.7 97 16.6
Alaska 29 6 20.7 5 17.2 12 41.4 3 10.3 3 10.3
Arizona 662 57 8.6 180 27.2 179 27.0 148 22.4 98 14.8
Arkansas 242 6 2.5 54 22.3 73 30.2 59 24.4 50 20.7
California 3,924 322 8.2 1,094 27.9 1,176 30.0 839 21.4 493 12.6
Colorado 324 8 2.5 93 28.7 114 35.2 77 23.8 32 9.9
Connecticut 171 11 6.4 48 28.1 47 27.5 42 24.6 23 13.5
Delaware 93 2 2.2 23 24.7 26 28.0 25 26.9 17 18.3
District of Columbia 197 9 4.6 50 25.4 73 37.1 41 20.8 24 12.2
Florida 3,408 162 4.8 1,031 30.3 995 29.2 714 21.0 506 14.8
Georgia 1,977 65 3.3 501 25.3 678 34.3 433 21.9 300 15.2
Hawaii 51 0 0.0 20 39.2 8 15.7 18 35.3 5 9.8
Illinois 1,096 101 9.2 231 21.1 318 29.0 225 20.5 221 20.2
Indiana 433 1 0.2 128 29.6 112 25.9 104 24.0 88 20.3
Iowa 100 4 4.0 26 26.0 37 37.0 25 25.0 8 8.0
Kansas 138 7 5.1 39 28.3 45 32.6 35 25.4 12 8.7
Louisiana 722 81 11.2 160 22.2 197 27.3 162 22.4 122 16.9
Maine 16 0 0.0 4 25.0 3 18.8 8 50.0 1 6.3
Marylandc 706 66 9.3 195 27.6 227 32.2 153 21.7 65 9.2
Massachusetts 434 18 4.1 127 29.3 142 32.7 100 23.0 47 10.8
Michigan 519 63 12.1 133 25.6 159 30.6 96 18.5 68 13.1
Minnesota 229 20 8.7 52 22.7 78 34.1 48 21.0 31 13.5
Mississippi 402 14 3.5 60 14.9 89 22.1 90 22.4 149 37.1
Missouri 359 10 2.8 73 20.3 108 30.1 65 18.1 103 28.7
Montana 14 2 14.3 4 28.6 2 14.3 5 35.7 1 7.1
Nebraska 73 4 5.5 17 23.3 22 30.1 18 24.7 12 16.4
Nevada 392 13 3.3 125 31.9 146 37.2 70 17.9 38 9.7
New Hampshire 33 4 12.1 10 30.3 8 24.2 8 24.2 3 9.1
New Mexico 131 4 3.1 33 25.2 39 29.8 25 19.1 30 22.9
New York 1,963 183 9.3 495 25.2 647 33.0 430 21.9 208 10.6
North Carolina 1,079 112 10.4 207 19.2 307 28.5 225 20.9 228 21.1
North Dakota 36 3 8.3 3 8.3 12 33.3 15 41.7 3 8.3
Ohio 888 16 1.8 250 28.2 298 33.6 190 21.4 134 15.1
Oklahoma 333 19 5.7 63 18.9 79 23.7 72 21.6 100 30.0
Oregon 180 27 15.0 56 31.1 51 28.3 28 15.6 18 10.0
Rhode Island 53 4 7.5 18 34.0 16 30.2 9 17.0 6 11.3
South Carolina 655 34 5.2 178 27.2 227 34.7 162 24.7 54 8.2
South Dakota 34 2 5.9 12 35.3 12 35.3 4 11.8 4 11.8
Tennessee 647 45 7.0 152 23.5 200 30.9 110 17.0 140 21.6
Texas 3,548 284 8.0 839 23.6 1,060 29.9 740 20.9 625 17.6
Utah 131 3 2.3 35 26.7 46 35.1 30 22.9 17 13.0
Virginia 628 55 8.8 163 26.0 162 25.8 165 26.3 83 13.2
Washington 421 41 9.7 121 28.7 135 32.1 88 20.9 36 8.6
West Virginia 139 14 10.1 30 21.6 21 15.1 24 17.3 50 36.0
Wisconsin 213 12 5.6 62 29.1 62 29.1 48 22.5 29 13.6
Wyoming 14 0 0.0 4 28.6 8 57.1 2 14.3 0 0.0
Region of residenced
Northeast (excluding NJ, PA, VT) 2,670 220 8.2 702 26.3 863 32.3 597 22.4 288 10.8
Midwest 4,118 243 5.9 1,026 24.9 1,263 30.7 873 21.2 713 17.3
South (excluding KY) 15,361 1,007 6.6 3,840 25.0 4,602 30.0 3,302 21.5 2,610 17.0
West (excluding ID) 6,273 483 7.7 1,770 28.2 1,916 30.5 1,333 21.2 771 12.3

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; OI, opportunistic infection (i.e., AIDS-defining condition); CDC, Centers for Disease Control and Prevention [footnotes only].
Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Stage of disease at time of HIV diagnosis is based on first CD4 test performed or documentation of an AIDS-defining condition ≤3 months after a diagnosis of HIV infection. Data are based on residence at diagnosis. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to the CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kentucky, Pennsylvania, Vermont, and Puerto Rico.
a First positive HIV test result is within 6 months after a negative HIV test result. The diagnosis of an AIDS-defining condition or a low CD4 test result before the 6 months have elapsed does not change the stage from stage 0 to stage 3.
b Includes persons with no CD4 information.
c Data should be interpreted with caution due to incomplete reporting of case information to CDC during December 2021.
d Data should be interpreted with caution and are based on areas with laws and complete reporting to CDC.

Table 1c. Stage of Disease at Time of HIV Diagnosis During 2020 (COVID-19 Pandemic) Among Persons Aged ≥13 Years, by Race/Ethnicity and Selected Characteristics—45 States and the District of Columbia
Stage 0a Stage 1
(CD4 ≥ 500 cells/µL or ≥ 26%)		 Stage 2
(CD4 = 200–499 cells/µL or 14%–25%)		 Stage 3 (AIDS)
(OI or CD4 < 200 cells/µL or <14%)		 Stage unknownb
Total No. No. % No. % No. % No. % No. %
American Indian/Alaska Native
Gender
Male 144 17 11.8 31 21.5 38 26.4 33 22.9 25 17.4
Female 43 1 2.3 14 32.6 12 27.9 7 16.3 9 20.9
Transgender womanc 8 0 0.0 3 37.5 0 0.0 2 25.0 3 37.5
Transgender manc 0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Additional gender identityd 0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Male sex at birth (≥13 yrs at diagnosis)
Age at diagnosis (yr)
13–24 33 6 18.2 11 33.3 11 33.3 0 0.0 5 15.2
25–34 54 4 7.4 12 22.2 11 20.4 14 25.9 13 24.1
35–44 33 6 18.2 6 18.2 9 27.3 4 12.1 8 24.2
45–54 22 1 4.5 3 13.6 4 18.2 13 59.1 1 4.5
≥55 10 0 0.0 2 20.0 3 30.0 4 40.0 1 10.0
Transmission categorye
Male-to-male sexual contact 121 14 11.3 28 23.4 29 24.3 28 23.4 21 17.6
Injection drug use 8 1 12.5 1 6.3 3 40.0 2 25.0 1 16.3
Male-to-male sexual contact and injection drug use 20 2 11.9 5 23.4 5 26.4 3 12.4 5 25.9
Heterosexual contactf 3 0 0.0 1 17.9 0 0.0 2 71.4 0 0.0
Otherg 0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 80 8 10.0 22 27.5 14 17.5 21 26.3 15 18.8
Metropolitan areas (pop. 50,000–499,999) 30 5 16.7 3 10.0 9 30.0 8 26.7 5 16.7
Nonmetropolitan areas (pop. <50,000) 42 4 9.5 9 21.4 15 35.7 6 14.3 8 19.0
Subtotal 152 17 11.2 34 22.4 38 25.0 35 23.0 28 18.4
Female sex at birth (≥13 yrs at diagnosis)
Age at diagnosis (yr)
13–24 0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
25–34 16 1 6.3 6 37.5 4 25.0 1 6.3 4 25.0
35–44 18 0 0.0 7 38.9 5 27.8 4 22.2 2 11.1
45–54 5 0 0.0 1 20.0 1 20.0 1 20.0 2 40.0
≥55 4 0 0.0 0 0.0 2 50.0 1 25.0 1 25.0
Transmission categorye
Injection drug use 20 1 5.1 6 28.9 8 40.1 1 5.6 4 20.3
Heterosexual contactf 23 0 0.0 8 35.6 4 17.6 6 25.3 5 21.5
Otherg 0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 20 0 0.0 10 50.0 4 20.0 3 15.0 3 15.0
Metropolitan areas (pop. 50,000–499,999) 11 1 9.1 1 9.1 5 45.5 1 9.1 3 27.3
Nonmetropolitan areas (pop. <50,000) 12 0 0.0 3 25.0 3 25.0 3 25.0 3 25.0
Subtotal 43 1 2.3 14 32.6 12 27.9 7 16.3 9 20.9
Total 195 18 9.2 48 24.6 50 25.6 42 21.5 37 19.0
Asian
Gender
Male 515 26 5.0 118 22.9 190 36.9 134 26.0 47 9.1
Female 80 3 3.8 18 22.5 20 25.0 27 33.7 12 15.0
Transgender womanc 16 1 6.3 4 25.0 6 37.5 3 18.8 2 12.5
Transgender manc 0 0 0.0 0 0.0 0 0 0 0.0 0 0.0
Additional gender identityd 1 0 0.0 0 0.0 1 100 0 0.0 0 0.0
Male sex at birth (≥13 yrs at diagnosis)
Age at diagnosis (yr)
13–24 79 6 7.6 15 19.0 41 51.9 13 16.5 4 5.1
25–34 225 12 5.3 65 28.9 87 38.7 41 18.2 20 8.9
35–44 101 2 2.0 24 23.8 36 35.6 29 28.7 10 9.9
45–54 79 6 7.6 13 16.5 23 29.1 29 36.7 8 10.1
≥55 48 1 2.1 5 10.4 10 20.8 25 52.1 7 14.6
Transmission categorye
Male-to-male sexual contact 477 26 5.4 112 23.5 180 37.7 117 24.6 43 8.9
Injection drug use 13 0 0.0 2 18.6 4 28.7 5 38.0 2 13.2
Male-to-male sexual contact and injection drug use 12 0 0.0 3 28.8 6 47.5 2 18.6 1 4.2
Heterosexual contactf 28 1 3.9 4 14.8 8 27.6 12 41.0 4 12.7
Otherg 2 0 0.0 0 0.0 0 0.0 1 45.0 1 35.0
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 477 25 5.2 112 23.5 176 36.9 120 25.2 44 9.2
Metropolitan areas (pop. 50,000–499,999) 37 1 2.7 9 24.3 14 37.8 10 27.0 3 8.1
Nonmetropolitan areas (pop. <50,000) 17 1 5.9 1 5.9 7 41.2 7 41.2 1 5.9
Subtotal 532 27 5.1 122 22.9 197 37.0 137 25.8 49 9.2
Female sex at birth (≥13 yrs at diagnosis)
Age at diagnosis (yr)
13–24 3 0 0.0 0 0.0 1 33.3 1 33.3 1 33.3
25–34 22 2 9.1 6 27.3 6 27.3 4 18.2 4 18.2
35–44 20 1 5.0 5 25.0 5 25.0 9 45.0 0 0.0
45–54 18 0 0.0 4 22.2 3 16.7 7 38.9 4 22.2
≥55 17 0 0.0 3 17.6 5 29.4 6 35.3 3 17.6
Transmission categorye
Injection drug use 5 0 0.0 1 19.2 1 26.9 1 25.0 2 28.8
Heterosexual contactf 74 3 4.1 17 22.4 19 25.3 25 34.6 10 13.6
Otherg 1 0 0.0 1 38.5 0 0.0 0 0.0 1 38.5
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 72 3 4.2 14 19.4 20 27.8 23 31.9 12 16.7
Metropolitan areas (pop. 50,000–499,999) 4 0 0.0 2 50.0 0 0.0 2 50.0 0 0.0
Nonmetropolitan areas (pop. <50,000) 4 0 0.0 2 50.0 0 0.0 2 50.0 0 0.0
Subtotal 80 3 3.8 18 22.5 20 25.0 27 33.7 12 15.0
Total 612 30 4.9 140 22.9 217 35.5 164 26.8 61 10.0
Black/African American
Gender
Male 8,991 623 6.9 2,032 22.6 2,909 32.4 1,742 19.4 1,685 18.7
Female 2,771 156 5.6 783 28.3 769 27.8 645 23.3 418 15.1
Transgender womanc 288 26 9.0 92 31.9 80 27.8 32 11.1 58 20.1
Transgender manc 11 2 18.2 3 27.3 4 36.4 1 9.1 1 9.1
Additional gender identityd 8 0 0.0 2 25.0 4 50.0 1 12.5 1 12.5
Male sex at birth (≥13 yrs at diagnosis)
Age at diagnosis (yr)
13–24 2,724 276 10.1 649 23.8 1,028 37.7 252 9.3 519 19.1
25–34 3,705 256 6.9 923 24.9 1,192 32.2 654 17.7 680 18.4
35–44 1,375 64 4.7 295 21.5 397 28.9 360 26.2 259 18.8
45–54 775 25 3.2 146 18.8 190 24.5 272 35.1 142 18.3
≥55 708 28 4.0 113 16.0 186 26.3 237 33.5 144 20.3
Transmission categorye
Male-to-male sexual contact 7,634 570 7.5 1,796 23.5 2,557 33.5 1,309 17.1 1,403 18.4
Injection drug use 283 19 6.7 54 19.0 71 25.1 68 23.9 71 25.2
Male-to-male sexual contact and injection drug use 213 17 7.8 66 31.0 57 26.7 28 13.3 45 21.1
Heterosexual contactf 1,143 43 3.7 207 18.1 304 26.6 366 32.0 222 19.5
Otherg 14 1 3.7 3 23.5 4 26.5 4 29.4 2 16.9
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 7,533 548 7.3 1,748 23.2 2,459 32.6 1,375 18.3 1,403 18.6
Metropolitan areas (pop. 50,000–499,999) 1,111 71 6.4 247 22.2 349 31.4 246 22.1 198 17.8
Nonmetropolitan areas (pop. <50,000) 592 26 4.4 124 20.9 176 29.7 145 24.5 121 20.4
Subtotal 9,287 649 7.0 2,126 22.9 2,993 32.2 1,775 19.1 1,744 18.8
Female sex at birth (≥13 yrs at diagnosis)
Age at diagnosis (yr)
13–24 390 40 10.3 139 35.6 125 32.1 33 8.5 53 13.6
25–34 805 55 6.8 255 31.7 244 30.3 133 16.5 118 14.7
35–44 622 26 4.2 170 27.3 166 26.7 156 25.1 104 16.7
45–54 511 16 3.1 128 25.0 125 24.5 171 33.5 71 13.9
≥55 454 21 4.6 94 20.7 113 24.9 153 33.7 73 16.1
Transmission categorye
Injection drug use 232 18 7.6 61 26.2 55 23.8 58 25.0 41 17.4
Heterosexual contactf 2,511 137 5.4 715 28.5 708 28.2 578 23.0 374 14.9
Otherg 38 4 9.7 10 27.2 9 24.3 10 26.4 5 12.5
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 2,220 130 5.9 648 29.2 604 27.2 506 22.8 332 15.0
Metropolitan areas (pop. 50,000–499,999) 395 20 5.1 100 25.3 119 30.1 98 24.8 58 14.7
Nonmetropolitan areas (pop. <50,000) 156 8 5.1 35 22.4 48 30.8 40 25.6 25 16.0
Subtotal 2,782 158 5.7 786 28.3 773 27.8 646 23.2 419 15.1
Total 12,069 807 6.7 2,912 24.1 3,766 31.2 2,421 20.1 2,163 17.9
Hispanic/Latinoh
Gender
Male 6,475 457 7.1 1,655 25.6 2,142 33.1 1,469 22.7 752 11.6
Female 821 36 4.4 232 28.3 225 27.4 220 26.8 108 13.2
Transgender womanc 189 20 10.6 57 30.2 66 34.9 19 10.1 27 14.3
Transgender manc 10 4 40.0 5 50.0 1 10.0 0 0.0 0 0.0
Additional gender identityd 3 2 66.7 0 0.0 0 0.0 1 33.3 0 0.0
Male sex at birth (≥13 yrs at diagnosis)
Age at diagnosis (yr)
13–24 1,314 140 10.7 354 26.9 521 39.6 130 9.9 169 12.9
25–34 2,748 218 7.9 768 27.9 954 34.7 511 18.6 297 10.8
35–44 1,415 74 5.2 344 24.3 432 30.5 376 26.6 189 13.4
45–54 771 33 4.3 174 22.6 191 24.8 296 38.4 77 10.0
≥55 419 14 3.3 72 17.2 110 26.3 176 42.0 47 11.2
Transmission categorye
Male-to-male sexual contact 5,842 442 7.6 1,526 26.1 1,978 33.9 1,221 20.9 676 11.6
Injection drug use 232 11 4.5 51 22.0 63 26.9 75 32.1 33 14.4
Male-to-male sexual contact and injection drug use 245 17 7.0 75 30.8 69 28.0 49 20.0 35 14.3
Heterosexual contactf 345 10 2.8 59 17.2 98 28.4 143 41.7 34 9.9
Otherg 4 0 0.0 1 17.1 1 28.6 1 31.4 1 17.1
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 5,875 427 7.3 1,541 26.2 1,968 33.5 1,277 21.7 662 11.3
Metropolitan areas (pop. 50,000–499,999) 534 41 7.7 109 20.4 176 33.0 139 26.0 69 12.9
Nonmetropolitan areas (pop. <50,000) 221 10 4.5 58 26.2 55 24.9 67 30.3 31 14.0
Subtotal 6,667 479 7.2 1,712 25.7 2,208 33.1 1,489 22.3 779 11.7
Female sex at birth (≥13 yrs at diagnosis)
Age at diagnosis (yr)
13–24 130 10 7.7 48 36.9 45 34.6 10 7.7 17 13.1
25–34 225 9 4.0 84 37.3 62 27.6 43 19.1 27 12.0
35–44 216 14 6.5 44 20.4 61 28.2 66 30.6 31 14.4
45–54 141 5 3.5 31 22.0 37 26.2 50 35.5 18 12.8
≥55 119 2 1.7 30 25.2 21 17.6 51 42.9 15 12.6
Transmission categorye
Injection drug use 123 10 7.9 29 23.4 34 27.6 30 24.2 21 17.0
Heterosexual contactf 703 30 4.3 206 29.3 191 27.2 189 26.9 87 12.3
Otherg 5 0 0.0 2 40.7 1 14.8 2 27.8 1 9.3
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 721 37 5.1 201 27.9 193 26.8 194 26.9 96 13.3
Metropolitan areas (pop. 50,000–499,999) 69 1 1.4 28 40.6 21 30.4 12 17.4 7 10.1
Nonmetropolitan areas (pop. <50,000) 36 1 2.8 6 16.7 12 33.3 14 38.9 3 8.3
Subtotal 831 40 4.8 237 28.5 226 27.2 220 26.5 108 13.0
Total 7,498 519 6.9 1,949 26.0 2,434 32.5 1,709 22.8 887 11.8
Native Hawaiian/other Pacific Islander
Gender
Male 46 2 4.3 7 15.2 23 50.0 9 19.6 5 10.9
Female 14 0 0.0 5 35.7 6 42.9 3 21.4 0 0.0
Transgender womanc 3 0 0.0 1 33.3 0 0.0 1 33.3 1 33.3
Transgender manc 0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Additional gender identityd 0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Male sex at birth (≥13 yrs at diagnosis)
Age at diagnosis (yr)
13–24 9 0 0.0 2 22.2 6 66.7 0 0.0 1 11.1
25–34 22 0 0.0 4 18.2 11 50.0 4 18.2 3 13.6
35–44 13 1 7.7 2 15.4 6 46.2 3 23.1 1 7.7
45–54 4 1 25.0 0 0.0 0 0.0 2 50.0 1 25.0
≥55 1 0 0.0 0 0.0 0 0.0 1 100 0 0.0
Transmission categorye
Male-to-male sexual contact 41 0 0.0 7 17.1 21 50.4 9 21.0 5 11.5
Injection drug use 3 0 0.0 0 0.0 1 44.0 1 48.0 0 0.0
Male-to-male sexual contact and injection drug use 3 1 30.3 1 30.3 0 0,0 0 0.0 1 33.3
Heterosexual contactf 2 1 43.5 0 0.0 1 47.8 0 8.7 0 0.0
Otherg 0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 41 2 4.9 7 17.1 18 43.9 9 22.0 5 12.2
Metropolitan areas (pop. 50,000–499,999) 5 0 0.0 1 20.0 3 60.0 0 0.0 1 20.0
Nonmetropolitan areas (pop. <50,000) 3 0 0.0 0 0.0 2 66.7 1 33.3 0 0.0
Subtotal 49 2 4.1 8 16.3 23 46.9 10 20.4 6 12.2
Female sex at birth (≥13 yrs at diagnosis)
Age at diagnosis (yr)
13–24 3 0 0.0 3 100 0 0.0 0 0.0 0 0.0
25–34 2 0 0.0 1 50.0 1 50.0 0 0.0 0 0.0
35–44 2 0 0.0 0 0.0 1 50.0 1 50.0 0 0.0
45–54 3 0 0.0 0 0.0 2 66.7 1 33.3 0 0.0
≥55 4 0 0.0 1 25.0 2 50.0 1 25.0 0 0
Transmission categorye
Injection drug use 2 0 0.0 0 0.0 1 66.7 0 0.0 0 0.0
Heterosexual contactf 12 0 0.0 5 40.0 4 38.3 3 21.7 0 0.0
Otherg 0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 9 0 0.0 3 33.3 4 44.4 2 22.2 0 0.0
Metropolitan areas (pop. 50,000–499,999) 3 0 0.0 2 66.7 1 33.3 0 0.0 0 0.0
Nonmetropolitan areas (pop. <50,000) 2 0 0.0 0 0.0 1 50.0 1 50.0 0 0.0
Subtotal 14 0 0.0 5 35.7 6 42.9 3 21.4 0 0.0
Total 63 2 3.2 13 20.6 29 46.0 13 20.6 6 9.5
White
Gender
Male 5,981 442 7.4 1,684 28.2 1,609 26.9 1,357 22.7 889 14.9
Female 1,189 85 7.1 365 30.7 283 23.8 239 20.1 217 18.3
Transgender womanc 68 4 5.9 28 41.2 19 27.9 7 10.3 10 14.7
Transgender manc 14 2 14.3 3 21.4 6 42.9 1 7.1 2 14.3
Additional gender identityd 4 0 0.0 1 25.0 3 75.0 0 0.0 0 0.0
Male sex at birth (≥13 yrs at diagnosis)
Age at diagnosis (yr)
13–24 734 77 10.5 248 33.8 244 33.2 55 7.5 110 15.0
25–34 2,112 177 8.4 661 31.3 602 28.5 339 16.1 333 15.8
35–44 1,293 94 7.3 359 27.8 347 26.8 301 23.3 192 14.8
45–54 999 63 6.3 240 24.0 238 23.8 315 31.5 143 14.3
≥55 915 35 3.8 205 22.4 200 21.9 354 38.7 121 13.2
Transmission categorye
Male-to-male sexual contact 4,795 355 7.4 1,350 28.2 1,332 27.8 1,086 22.7 671 14.0
Injection drug use 475 40 8.4 137 28.9 104 22.0 89 18.7 104 22.0
Male-to-male sexual contact and injection drug use 492 40 8.2 158 32.2 131 26.7 77 15.6 86 17.4
Heterosexual contactf 284 10 3.6 65 22.7 63 22.0 110 38.8 37 12.9
Otherg 7 0 0.0 2 31.9 1 13.0 2 31.9 1 20.3
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 4,419 333 7.5 1,299 29.4 1,215 27.5 927 21.0 645 14.6
Metropolitan areas (pop. 50,000–499,999) 1,032 80 7.8 257 24.9 262 25.4 262 25.4 171 16.6
Nonmetropolitan areas (pop. <50,000) 574 31 5.4 150 26.1 146 25.4 170 29.6 77 13.4
Subtotal 6,053 446 7.4 1,713 28.3 1,631 26.9 1,364 22.5 899 14.9
Female sex at birth (≥13 yrs at diagnosis)
Age at diagnosis (yr)
13–24 129 13 10.1 59 45.7 30 23.3 7 5.4 20 15.5
25–34 364 32 8.8 124 34.1 91 25.0 44 12.1 73 20.1
35–44 290 20 6.9 93 32.1 71 24.5 45 15.5 61 21.0
45–54 236 11 4.7 52 22.0 55 23.3 81 34.3 37 15.7
≥55 184 11 6.0 40 21.7 42 22.8 63 34.2 28 15.2
Transmission categorye
Injection drug use 391 26 6.5 111 28.5 102 26.1 66 16.8 86 22.1
Heterosexual contactf 803 61 7.6 253 31.5 186 23.1 172 21.4 131 16.4
Otherg 9 0 0.0 4 43.0 1 16.3 2 25.6 1 14.0
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 781 56 7.2 251 32.1 172 22.0 163 20.9 139 17.8
Metropolitan areas (pop. 50,000–499,999) 285 25 8.8 82 28.8 75 26.3 47 16.5 56 19.6
Nonmetropolitan areas (pop. <50,000) 134 6 4.5 33 24.6 41 30.6 30 22.4 24 17.9
Subtotal 1,203 87 7.2 368 30.6 289 24.0 240 20.0 219 18.2
Total 7,256 533 7.3 2,081 28.7 1,920 26.5 1,604 22.1 1,118 15.4
Multiracial
Gender
Male 575 33 5.7 151 26.3 187 32.5 122 21.2 82 14.3
Female 124 8 6.5 34 27.4 34 27.4 20 16.1 28 22.6
Transgender womanc 27 2 7.4 9 33.3 6 22.2 10 37.0 0 0.0
Transgender manc 3 1 33.3 1 33.3 1 33.3 0 0.0 0 0.0
Additional gender identityd 0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Male sex at birth (≥13 yrs at diagnosis)
Age at diagnosis (yr)
13–24 154 11 7.1 51 33.1 57 37.0 16 10.4 19 12.3
25–34 226 15 6.6 54 23.9 78 34.5 47 20.8 32 14.2
35–44 123 6 4.9 33 26.8 31 25.2 31 25.2 22 17.9
45–54 63 1 1.6 14 22.2 19 30.2 25 39.7 4 6.3
≥55 36 2 5.6 8 22.2 8 22.2 13 36.1 5 13.9
Transmission categorye
Male-to-male sexual contact 505 32 6.2 139 27.5 169 33.6 103 20.5 62 12.2
Injection drug use 39 1 3.6 7 18.3 10 25.5 11 27.8 10 24.7
Male-to-male sexual contact and injection drug use 37 1 3.5 12 32.4 6 15.0 11 30.5 7 18.5
Heterosexual contactf 22 1 3.7 2 10.2 8 38.0 7 30.1 4 18.1
Otherg 0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 474 25 5.3 123 25.9 157 33.1 105 22.2 64 13.5
Metropolitan areas (pop. 50,000–499,999) 85 7 8.2 26 30.6 23 27.1 21 24.7 8 9.4
Nonmetropolitan areas (pop. <50,000) 41 3 7.3 10 24.4 13 31.7 6 14.6 9 22.0
Subtotal 602 35 5.8 160 26.6 193 32.1 132 21.9 82 13.6
Female sex at birth (≥13 yrs at diagnosis)
Age at diagnosis (yr)
13–24 26 2 7.7 9 34.6 8 30.8 1 3.8 6 23.1
25–34 44 2 4.5 13 29.5 11 25.0 5 11.4 13 29.5
35–44 24 1 4.2 7 29.2 6 25.0 5 20.8 5 20.8
45–54 17 1 5.9 4 23.5 7 41.2 4 23.5 1 5.9
≥55 16 3 18.8 2 12.5 3 18.8 5 31.3 3 18.8
Transmission categorye
Injection drug use 20 2 8.8 5 23.5 4 18.6 4 19.1 6 29.9
Heterosexual contactf 106 7 6.7 30 28.1 31 29.5 16 15.2 22 20.4
Otherg 1 0 0.0 1 55.6 0 0.0 0 0.0 0 0.0
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 87 7 8.0 25 28.7 25 28.7 12 13.8 18 20.7
Metropolitan areas (pop. 50,000–499,999) 28 1 3.6 6 21.4 8 28.6 5 17.9 8 28.6
Nonmetropolitan areas (pop. <50,000) 12 1 8.3 4 33.3 2 16.7 3 25.0 2 16.7
Subtotal 127 9 7.1 35 27.6 35 27.6 20 15.7 28 22.0
Total 729 44 6.0 195 26.7 228 31.3 152 20.9 110 15.1

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; OI, opportunistic infection (i.e., AIDS-defining condition); pop, population; CDC, Centers for Disease Control and Prevention [footnotes only].
Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Stage of disease at time of HIV diagnosis is based on first CD4 test performed or documentation of an AIDS-defining condition ≤3 months after a diagnosis of HIV infection. Data are based on residence at time of diagnosis. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to the CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kentucky, Pennsylvania, Vermont, and Puerto Rico.
a First positive HIV test result is within 6 months after a negative HIV test result. The diagnosis of an AIDS-defining condition or a low CD4 test result before the 6 months have elapsed does not change the stage from stage 0 to stage 3.
b Includes persons with no CD4 information.
c “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
d Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
e Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
f Sexual contact with a person known to have, or with a risk factor for, HIV infection.
g Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.
h Hispanic/Latino persons can be of any race.

Table 1d. Stage of Disease at Time of HIV Diagnosis During 2020 (COVID-19 Pandemic) Among Males (Sex Assigned at Birth) Aged ≥13 Years with Infection Attributed to Male-To-Male Sexual Contact, by Race/Ethnicity and Age at Diagnosis—45 States and the District of Columbia
Stage 0a Stage 1
(CD4 ≥ 500 cells/µL or ≥ 26%)		 Stage 2
(CD4 = 200–499 cells/µL or 14%–25%)		 Stage 3 (AIDS)
(OI or CD4 < 200 cells/µL or <14%)		 Stage unknownb
Total No. No. % No. % No. % No. % No. %
American Indian/Alaska Native
13–24 28 5 18.1 10 34.8 9 32.6 0 0.0 4 14.5
25–34 44 3 6.9 11 25.3 7 15.4 13 29.4 10 23.0
35–44 24 5 19.3 4 14.3 7 28.7 4 16.0 5 21.7
45–54 17 1 5.3 3 15.9 4 21.2 9 51.8 1 5.9
≥55 8 0 0.0 2 18.1 3 36.1 3 33.7 1 12.0
Subtotal 121 14 11.3 28 23.4 29 24.3 28 23.4 21 17.6
Asian
13–24 76 6 7.9 15 19.8 38 50.1 13 16.9 4 5.3
25–34 209 11 5.1 60 28.5 81 38.5 39 18.8 19 9.1
35–44 92 2 2.2 23 24.9 34 36.6 24 26.6 9 9.7
45–54 67 6 8.8 11 15.6 21 30.5 25 36.8 6 8.3
≥55 33 1 3.0 4 11.8 7 21.5 16 48.9 5 14.8
Subtotal 477 26 5.4 112 23.5 180 37.7 117 24.6 43 8.9
Black/African American
13–24 2,548 260 10.2 604 23.7 975 38.3 232 9.1 478 18.8
25–34 3,250 230 7.1 816 25.1 1,065 32.8 563 17.3 576 17.7
35–44 1,015 53 5.2 229 22.5 301 29.7 248 24.5 184 18.1
45–54 487 17 3.6 92 18.9 129 26.5 153 31.3 96 19.7
≥55 335 10 3.1 56 16.7 87 26.0 113 33.8 69 20.5
Subtotal 7,634 570 7.5 1,796 23.5 2,557 33.5 1,309 17.1 1,403 18.4
Hispanic/Latinoc
13–24 1,233 131 10.7 330 26.7 490 39.7 122 9.9 160 13.0
25–34 2,483 207 8.3 683 27.5 881 35.5 449 18.1 264 10.6
35–44 1,197 63 5.2 309 25.8 366 30.6 302 25.2 158 13.2
45–54 617 30 4.8 145 23.6 159 25.7 223 36.1 61 9.8
≥55 312 11 3.6 59 18.9 83 26.6 125 40.2 34 10.8
Subtotal 5,842 442 7.6 1,526 26.1 1,978 33.9 1,221 20.9 676 11.6
Native Hawaiian/other Pacific Islander
13–24 9 0 0.0 2 22.2 6 66.7 0 0.0 1 11.1
25–34 18 0 0.0 3 16.9 10 55.4 3 16.4 2 11.3
35–44 11 0 0.0 2 18.7 5 44.9 3 27.1 1 9.3
45–54 3 0 0.0 0 0.0 0 0.0 2 72.0 1 28.0
≥55 1 0 0.0 0 0.0 0 0.0 1 100 0 0.0
Subtotal 41 0 0.0 7 17.1 21 50.4 9 21.0 5 11.5
White
13–24 655 64 9.8 223 34.0 220 33.6 48 7.3 100 15.3
25–34 1,673 148 8.8 501 29.9 499 29.8 281 16.8 245 14.7
35–44 932 69 7.4 257 27.5 260 27.9 228 24.5 119 12.8
45–54 785 45 5.7 197 25.1 186 23.7 245 31.2 112 14.2
≥55 750 30 3.9 173 23.1 168 22.4 284 37.9 95 12.6
Subtotal 4,795 355 7.4 1,350 28.2 1,332 27.8 1,086 22.7 671 14.0
Multiracial
13–24 138 11 8.0 45 32.4 52 37.9 13 9.5 17 12.3
25–34 195 14 7.2 50 25.3 71 36.1 37 18.9 24 12.5
35–44 96 4 4.4 30 31.4 24 25.0 23 24.3 14 14.9
45–54 49 1 2.0 9 18.0 17 35.5 19 39.3 3 5.1
≥55 27 1 4.9 6 21.3 5 20.1 11 40.3 4 13.4
Subtotal 505 32 6.2 139 27.5 169 33.6 103 20.5 62 12.2
All
13–24 4,686 478 10.2 1,227 26.2 1,790 38.2 427 9.1 764 16.3
25–34 7,872 612 7.8 2,123 27.0 2,612 33.2 1,385 17.6 1,141 14.5
35–44 3,365 195 5.8 852 25.3 996 29.6 832 24.7 490 14.6
45–54 2,025 100 4.9 457 22.6 515 25.4 675 33.3 278 13.7
≥55 1,466 53 3.6 299 20.4 353 24.1 554 37.8 207 14.1
Total 19,414 1,438 7.4 4,958 25.5 6,265 32.3 3,873 20.0 2,880 14.8

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; OI, opportunistic infection (i.e., AIDS-defining condition); CDC, Centers for Disease Control and Prevention [footnotes only].
Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Stage of disease at time of HIV diagnosis is based on first CD4 test performed or documentation of an AIDS-defining condition ≤3 months after a diagnosis of HIV infection.
Data are based on residence at time of diagnosis. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to the CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kentucky, Pennsylvania, Vermont, and Puerto Rico.
Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total. Data presented based on sex at birth and includes transgender persons.
a First positive HIV test result is within 6 months after a negative HIV test result. The diagnosis of an AIDS-defining condition or a low CD4 test result before the 6 months have elapsed does not change the stage from stage 0 to stage 3.
b Includes persons with no CD4 information.
c Hispanic/Latino persons can be of any race.

Table 1e. Stage of Disease at Time of HIV Diagnosis During 2020 (COVID-19 Pandemic) Among Transgender and Additional Gender Identity Persons Aged ≥13 Years, by Selected Characteristics—45 States and the District of Columbia
Stage 0a Stage 1
(CD4 ≥ 500 cells/µL or ≥ 26%)		 Stage 2
(CD4 = 200–499 cells/µL or 14%–25%)		 Stage 3 (AIDS)
(OI or CD4 < 200 cells/µL or <14%)		 Stage unknownb
Total No. No. % No. % No. % No. % No. %
Transgender womanc
Age at diagnosis (yr)
13–24 161 27 16.8 48 29.8 48 29.8 13 8.1 25 15.5
25–34 301 20 6.6 98 32.6 92 30.6 42 14.0 49 16.3
35–44 79 3 3.8 30 38.0 20 25.3 9 11.4 17 21.5
45–54 45 3 6.7 13 28.9 12 26.7 9 20.0 8 17.8
≥55 13 0 0.0 5 38.5 5 38.5 1 7.7 2 15.4
Race/ethnicity
American Indian/Alaska Native 8 0 0.0 3 37.5 0 0.0 2 25.0 3 37.5
Asian 16 1 6.3 4 25.0 6 37.5 3 18.8 2 12.5
Black/African American 288 26 9.0 92 31.9 80 27.8 32 11.1 58 20.1
Hispanic/Latinod 189 20 10.6 57 30.2 66 34.9 19 10.1 27 14.3
Native Hawaiian/other Pacific Islander 3 0 0.0 1 33.3 0 0.0 1 33.3 1 33.3
White 68 4 5.9 28 41.2 19 27.9 7 10.3 10 14.7
Multiracial 27 2 7.4 9 33.3 6 22.2 10 37.0 0 0.0
Exposure categorye
Sexual contactf 543 47 8.7 178 32.8 166 30.6 65 12.0 87 16.0
Injection drug use 0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Sexual contactf and injection drug use 31 4 12.9 8 25.8 7 22.6 3 9.7 9 29.0
Otherg 25 2 8.0 8 32.0 4 16.0 6 24.0 5 20.0
Subtotal 599 53 8.8 194 32.4 177 29.5 74 12.4 101 16.9
Transgender manc
Age at diagnosis (yr)
13–24 12 3 25.0 5 41.7 3 25.0 1 8.3 0 0.0
25–34 17 4 23.5 5 29.4 5 29.4 0 0.0 3 17.6
35–44 7 2 28.6 2 28.6 2 28.6 1 14.3 0 0.0
45–54 2 0 0.0 0 0.0 2 100 0 0.0 0 0.0
≥55 0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Race/ethnicity
American Indian/Alaska Native 0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Asian 0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Black/African American 11 2 18.2 3 27.3 4 36.4 1 9.1 1 9.1
Hispanic/Latinod 10 4 40.0 5 50.0 1 10.0 0 0.0 0 0.0
Native Hawaiian/other Pacific Islander 0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
White 14 2 14.3 3 21.4 6 42.9 1 7.1 2 14.3
Multiracial 3 1 33.3 1 33.3 1 33.3 0 0.0 0 0.0
Exposure categorye
Sexual contactf 27 8 29.6 7 25.9 8 29.6 2 7.4 2 7.4
Injection drug use 1 0 0.0 0 0.0 0 0.0 0 0.0 1 100
Sexual contactf and injection drug use 5 1 20.0 3 60.0 1 20.0 0 0.0 0 0.0
Otherg 5 0 0.0 2 40.0 3 60.0 0 0.0 0 0.0
Subtotal 38 9 23.7 12 31.6 12 31.6 2 5.3 3 7.9
Additional gender identityh
Age at diagnosis (yr)
13–24 8 1 12.5 1 12.5 4 50.0 2 25.0 0 0.0
25–34 6 0 0.0 2 33.3 3 50.0 0 0.0 1 16.7
35–44 2 1 50.0 0 0.0 1 50.0 0 0.0 0 0.0
45–54 0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
≥55 0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Race/ethnicity
American Indian/Alaska Native 0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Asian 1 0 0.0 0 0.0 1 100 0 0.0 0 0.0
Black/African American 8 0 0.0 2 25.0 4 50.0 1 12.5 1 12.5
Hispanic/Latinod 3 2 66.7 0 0.0 0 0.0 1 33.3 0 0.0
Native Hawaiian/other Pacific Islander 0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
White 4 0 0.0 1 25.0 3 75.0 0 0.0 0 0.0
Multiracial 0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Exposure categorye
Sexual contactf 13 1 7.7 3 23.1 7 53.8 1 7.7 1 7.7
Injection drug use 0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Sexual contactf and injection drug use 1 0 0.0 0 0.0 1 100 0 0.0 0 0.0
Otherg 2 1 50.0 0 0.0 0 0.0 1 50.0 0 0.0
Subtotal 16 2 12.5 3 18.8 8 50.0 2 12.5 1 6.3
Total 653 64 9.8 209 32.0 197 30.2 78 11.9 105 16.1

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; OI, opportunistic infection (i.e., AIDS-defining condition); CDC, Centers for Disease Control and Prevention [footnotes only].
Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Stage of disease at diagnosis of HIV infection is based on first CD4 test performed or documentation of an AIDS-defining condition ≤3 months after a diagnosis of HIV infection. Data are based on residence at time of diagnosis. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to the CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kentucky, Pennsylvania, Vermont, and Puerto Rico.
a First positive HIV test result is within 6 months after a negative HIV test result. The diagnosis of an AIDS-defining condition or a low CD4 test result before the 6 months have elapsed does not change the stage from stage 0 to stage 3.
b Includes persons with no CD4 information.
c “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
d Hispanic/Latino persons can be of any race.
e Risk factor data for transgender and additional gender identity persons are presented using the exposure category classification, which is meant to convey all the known ways the person could have been exposed to HIV. Exposure categories are mutually exclusive and have no presumed hierarchical order of probability, except for rare circumstances where route of transmission has been confirmed through investigation. See Technical Notes for more information on exposure categories.
f For persons assigned “male” sex at birth, sexual contact with any person. For persons assigned “female” sex at birth, sexual contact with a person assigned “male” sex at birth.
g Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.. Data not displayed because the numbers were too small to be meaningful.
hAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

Table 2a. Linkage to HIV Medical Care Within 1 Month and Viral Suppression Within 6 Months of HIV Diagnosis During 2020 (COVID-19 Pandemic) Among Persons Aged ≥13 Years, by Selected Characteristics—45 States and the District of Columbia
Linkage to Care
≤1 month		 Viral Suppression
Total diagnoses ≥1 CD4 or VL tests No CD4 or VL test VL <200 copies/mL ≤6 months
No. No. % No. % No. %
Gender
Male 22,727 18,739 82.5 3,988 17.5 15,449 68.0
Female 5,042 4,146 82.2 896 17.8 3,392 67.3
Transgender womana 599 484 80.8 115 19.2 385 64.3
Transgender mana 38 35 92.1 3 7.9 30 78.9
Additional gender identityb 16 15 93.8 1 6.3 12 75.0
Age at diagnosis (yr)
13–24 5,728 4,585 80.0 1,143 20.0 3,973 69.4
25–34 10,570 8,701 82.3 1,869 17.7 7,194 68.1
35–44 5,545 4,573 82.5 972 17.5 3,719 67.1
45–54 3,644 3,081 84.5 563 15.5 2,485 68.2
≥55 2,935 2,479 84.5 456 15.5 1,897 64.6
Race/ethnicity
American Indian/Alaska Native 195 156 80.0 39 20.0 117 60.0
Asian 612 538 87.9 74 12.1 484 79.1
Black/African American 12,069 9,615 79.7 2,454 20.3 7,816 64.8
Hispanic/Latinoc 7,498 6,380 85.1 1,118 14.9 5,354 71.4
Native Hawaiian/other Pacific Islander 63 54 85.7 9 14.3 42 66.7
White 7,256 6,066 83.6 1,190 16.4 4,953 68.3
Multiracial 729 610 83.7 119 16.3 502 68.9
Transmission categoryd
Male-to-male sexual contact 19,414 16,097 82.9 3,317 17.1 13,507 69.6
Injection drug use 1,846 1,439 77.9 407 22.1 1,002 54.3
Male 1,052 819 77.8 234 22.2 562 53.4
Female 794 620 78.1 174 21.9 440 55.4
Male-to-male sexual contact and injection drug use 1,023 821 80.3 202 19.7 608 59.4
Heterosexual contacte 6,058 4,994 82.4 1,064 17.6 4,094 67.6
Male 1,826 1,479 81.0 347 19.0 1,152 63.1
Female 4,231 3,515 83.1 717 16.9 2,942 69.5
Otherf 82 68 83.1 14 16.9 57 70.1
Male 27 22 80.5 5 19.5 18 66.3
Female 55 46 84.3 9 15.7 40 71.9
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 22,809 18,905 82.9 3,904 17.1 15,638 68.6
Metropolitan areas (pop. 50,000–499,999) 3,629 2,945 81.2 684 18.8 2,358 65.0
Nonmetropolitan areas (pop. <50,000) 1,846 1,484 80.4 362 19.6 1,207 65.4
Total 28,422 23,419 82.4 5,003 17.6 19,268 67.8

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, Centers for Disease Control and Prevention [footnotes only].
Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Data are based on residence at time of diagnosis. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are within 6 months of diagnosis of HIV infection during 2020. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to the CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kentucky, Pennsylvania, Vermont, and Puerto Rico.
a “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
b Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
c Hispanic/Latino persons can be of any race.
d Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
e Sexual contact with a person known to have, or with a risk factor for, HIV infection.
f Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

Table 2b. Linkage to HIV Medical Care Within 1 Month and Viral Suppression Within 6 Months of HIV Diagnosis During 2020 (COVID-19 Pandemic) Among Persons Aged ≥13 Years, by Area of Residence—45 States and the District of Columbia
Linkage to Care
≤1 month		 Viral Suppression
Total ≥1 CD4 or VL tests No CD4 or VL test VL <200 copies/mL ≤6 months
No. No. % No. % No. %
Alabama 585 466 79.7 119 20.3 387 66.2
Alaska 29 28 96.6 1 3.4 22 75.9
Arizona 662 561 84.7 101 15.3 458 69.2
Arkansas 242 193 79.8 49 20.2 142 58.7
California 3,924 3,269 83.3 655 16.7 2,614 66.6
Colorado 324 284 87.7 40 12.3 231 71.3
Connecticut 171 143 83.6 28 16.4 120 70.2
Delaware 93 75 80.6 18 19.4 67 72.0
District of Columbia 197 172 87.3 25 12.7 142 72.1
Florida 3,408 2,863 84.0 545 16.0 2,331 68.4
Georgia 1,977 1,605 81.2 372 18.8 1,306 66.1
Hawaii 51 44 86.3 7 13.7 38 74.5
Illinois 1,096 921 84.0 175 16.0 721 65.8
Indiana 433 323 74.6 110 25.4 291 67.2
Iowa 100 90 90.0 10 10.0 76 76.0
Kansas 138 118 85.5 20 14.5 110 79.7
Louisiana 722 549 76.0 173 24.0 489 67.7
Maine 16 15 93.8 1 6.3 12 75.0
Marylanda 706 617 87.4 89 12.6 508 72.0
Massachusetts 434 382 88.0 52 12.0 334 77.0
Michigan 519 438 84.4 81 15.6 373 71.9
Minnesota 229 206 90.0 23 10.0 167 72.9
Mississippi 402 294 73.1 108 26.9 256 63.7
Missouri 359 285 79.4 74 20.6 236 65.7
Montana 14 13 92.9 1 7.1 10 71.4
Nebraska 73 65 89.0 8 11.0 45 61.6
Nevada 392 338 86.2 54 13.8 271 69.1
New Hampshire 33 26 78.8 7 21.2 22 66.7
New Mexico 131 111 84.7 20 15.3 83 63.4
New York 1,963 1,685 85.8 278 14.2 1,472 75.0
North Carolina 1,079 887 82.2 192 17.8 757 70.2
North Dakota 36 31 86.1 5 13.9 25 69.4
Ohio 888 761 85.7 127 14.3 629 70.8
Oklahoma 333 253 76.0 80 24.0 181 54.4
Oregon 180 150 83.3 30 16.7 147 81.7
Rhode Island 53 48 90.6 5 9.4 40 75.5
South Carolina 655 576 87.9 79 12.1 491 75.0
South Dakota 34 29 85.3 5 14.7 15 44.1
Tennessee 647 481 74.3 166 25.7 406 62.8
Texas 3,548 2,731 77.0 817 23.0 2,149 60.6
Utah 131 111 84.7 20 15.3 102 77.9
Virginia 628 512 81.5 116 18.5 441 70.2
Washington 421 373 88.6 48 11.4 328 77.9
West Virginia 139 99 71.2 40 28.8 55 39.6
Wisconsin 213 185 86.9 28 13.1 158 74.2
Wyoming 14 13 92.9 1 7.1 10 71.4
Region of residenceb
Northeast (excluding NJ, PA, VT) 2,670 2,299 86.1 371 13.9 2000 74.9
Midwest 4,118 3,452 83.8 666 16.2 2846 69.1
South (excluding KY) 15,361 12,373 80.5 2,988 19.5 10108 65.8
West (excluding ID) 6,273 5,295 84.4 978 15.6 4314 68.8

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, Centers for Disease Control and Prevention [footnotes only].
“Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Data are based on residence at time of diagnosis. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are within 6 months of diagnosis of HIV infection during 2020. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to the CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kentucky, Pennsylvania, Vermont, and Puerto Rico.
a Data should be interpreted with caution due to incomplete reporting of case information to CDC during December 2021.
b Data should be interpreted with caution and are based on areas with laws and complete reporting to CDC.

Table 2c. Linkage to HIV Medical Care Within 1 Month and Viral Suppression Within 6 Months of HIV Diagnosis During 2020 (COVID-19 Pandemic) Among Persons Aged ≥13 Years, by Race/Ethnicity and Selected Characteristics—45 States and the District of Columbia
Linkage to Care
≤1 month		 Viral Suppression
Total ≥1 CD4 or VL tests No CD4 or VL test VL <200 copies/mL ≤6 months
No. No. % No. % No. %
American Indian/Alaska Native
Gender
Male 144 118 81.9 26 18.1 90 62.5
Female 43 32 74.4 11 25.6 24 55.8
Transgender womana 8 6 75.0 2 25.0 3 37.5
Transgender mana 0 0 0.0 0 0.0 0 0.0
Additional gender identityb 0 0 0.0 0 0.0 0 0.0
Male sex at birth (≥13 yrs at diagnosis)
Age at diagnosis (yr)
13–24 33 28 84.8 5 15.2 21 63.6
25–34 54 41 75.9 13 24.1 33 61.1
35–44 33 26 78.8 7 21.2 17 51.5
45–54 22 21 95.5 1 4.5 15 68.2
≥55 10 8 80.0 2 20.0 7 70.0
Transmission categoryc
Male-to-male sexual contact 121 99 82.2 22 17.8 76 62.7
Injection drug use 8 5 57.5 3 42.5 3 37.5
Male-to-male sexual contact and injection drug use 20 18 87.6 3 12.4 14 67.2
Heterosexual contactd 3 3 89.3 0 0.0 1 28.6
Othere 0 0 0.0 0 0.0 0 0.0
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 80 66 82.5 14 17.5 46 57.5
Metropolitan areas (pop. 50,000–499,999) 30 24 80.0 6 20.0 22 73.3
Nonmetropolitan areas (pop. <50,000) 42 34 81.0 8 19.0 25 59.5
Subtotal 152 124 81.6 28 18.4 93 61.2
Female sex at birth (≥13 yrs at diagnosis)
Age at diagnosis (yr)
13–24 0 0 0.0 0 0.0 0 0.0
25–34 16 10 62.5 6 37.5 7 43.8
35–44 18 16 88.9 2 11.1 14 77.8
45–54 5 4 80.0 1 20.0 2 40.0
≥55 4 2 50.0 2 50.0 1 25.0
Transmission categoryc
Injection drug use 20 14 69.0 6 31.0 9 43.7
Heterosexual contactd 23 18 79.0 5 21.0 15 66.1
Othere 0 0 0.0 0 0.0 0 0.0
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 20 18 90.0 2 10.0 15 75.0
Metropolitan areas (pop. 50,000–499,999) 11 6 54.5 5 45.5 4 36.4
Nonmetropolitan areas (pop. <50,000) 12 8 66.7 4 33.3 5 41.7
Subtotal 43 32 74.4 11 25.6 24 55.8
Total 195 156 80.0 39 20.0 117 60.0
Asian
Gender
Male 515 455 88.3 60 11.7 408 79.2
Female 80 68 85.0 12 15.0 62 77.5
Transgender womana 16 14 87.5 2 12.5 13 81.3
Transgender mana 0 0 0.0 0 0.0 0 0.0
Additional gender identityb 1 1 100 0 0.0 1 100
Male sex at birth (≥13 yrs at diagnosis)
Age at diagnosis (yr)
13–24 79 72 91.1 7 8.9 63 79.7
25–34 225 203 90.2 22 9.8 181 80.4
35–44 101 86 85.1 15 14.9 83 82.2
45–54 79 69 87.3 10 12.7 65 82.3
≥55 48 40 83.3 8 16.7 30 62.5
Transmission categoryc
Male-to-male sexual contact 477 422 88.5 55 11.5 385 80.7
Injection drug use 13 11 86.0 2 14.0 7 57.4
Male-to-male sexual contact and injection drug use 12 11 94.9 1 5.1 8 72.0
Heterosexual contactd 28 24 85.5 4 14.5 21 73.1
Othere 2 1 65.0 1 35.0 1 30.0
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 477 421 88.3 56 11.7 383 80.3
Metropolitan areas (pop. 50,000–499,999) 37 32 86.5 5 13.5 26 70.3
Nonmetropolitan areas (pop. <50,000) 17 17 100 0 0.0 13 76.5
Subtotal 532 470 88.3 62 11.7 422 79.3
Female sex at birth (≥13 yrs at diagnosis)
Age at diagnosis (yr)
13–24 3 2 66.7 1 33.3 2 66.7
25–34 22 18 81.8 4 18.2 17 77.3
35–44 20 18 90.0 2 10.0 18 90.0
45–54 18 15 83.3 3 16.7 14 77.8
≥55 17 15 88.2 2 11.8 11 64.7
Transmission categoryc
Injection drug use 5 4 80.8 1 19.2 4 82.7
Heterosexual contactd 74 63 85.4 11 14.6 57 77.6
Othere 1 1 76.9 0 0.0 1 53.8
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 72 60 83.3 12 16.7 56 77.8
Metropolitan areas (pop. 50,000–499,999) 4 4 100 0 0.0 3 75.0
Nonmetropolitan areas (pop. <50,000) 4 4 100 0 0.0 3 75.0
Subtotal 80 68 85.0 12 15.0 62 77.5
Total 612 538 87.9 74 12.1 484 79.1
Black/African American
Gender
Male 8,991 7,092 78.9 1,899 21.1 5,746 63.9
Female 2,771 2,276 82.1 495 17.9 1,878 67.8
Transgender womana 288 230 79.9 58 20.1 177 61.5
Transgender mana 11 10 90.9 1 9.1 9 81.8
Additional gender identityb 8 7 87.5 1 12.5 6 75.0
Male sex at birth (≥13 yrs at diagnosis)
Age at diagnosis (yr)
13–24 2,724 2,129 78.2 595 21.8 1,782 65.4
25–34 3,705 2,927 79.0 778 21.0 2,390 64.5
35–44 1,375 1,086 79.0 289 21.0 859 62.5
45–54 775 624 80.5 151 19.5 490 63.2
≥55 708 563 79.5 145 20.5 408 57.6
Transmission categoryc
Male-to-male sexual contact 7,634 6,060 79.4 1,575 20.6 4,942 64.7
Injection drug use 283 205 72.4 78 27.6 159 56.2
Male-to-male sexual contact and injection drug use 213 161 75.6 52 24.4 130 60.7
Heterosexual contactd 1,143 891 78.0 251 22.0 689 60.3
Othere 14 11 83.8 2 16.2 10 71.3
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 7,533 5,981 79.4 1,552 20.6 4,824 64.0
Metropolitan areas (pop. 50,000–499,999) 1,111 878 79.0 233 21.0 733 66.0
Nonmetropolitan areas (pop. <50,000) 592 440 74.3 152 25.7 353 59.6
Subtotal 9,287 7,329 78.9 1,958 21.1 5,929 63.8
Female sex at birth (≥13 yrs at diagnosis)
Age at diagnosis (yr)
13–24 390 309 79.2 81 20.8 280 71.8
25–34 805 662 82.2 143 17.8 546 67.8
35–44 622 511 82.2 111 17.8 414 66.6
45–54 511 428 83.8 83 16.2 343 67.1
≥55 454 376 82.8 78 17.2 304 67.0
Transmission categoryc
Injection drug use 232 186 80.0 47 20.0 134 57.6
Heterosexual contactd 2,511 2,068 82.3 444 17.7 1,725 68.7
Othere 38 32 84.3 6 15.7 28 74.2
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 2,220 1,839 82.8 381 17.2 1,517 68.3
Metropolitan areas (pop. 50,000–499,999) 395 315 79.7 80 20.3 261 66.1
Nonmetropolitan areas (pop. <50,000) 156 125 80.1 31 19.9 103 66.0
Subtotal 2,782 2,286 82.2 496 17.8 1,887 67.8
Total 12,069 9,615 79.7 2,454 20.3 7,816 64.8
Hispanic/Latinof
Gender
Male 6,475 5,524 85.3 951 14.7 4,620 71.4
Female 821 693 84.4 128 15.6 597 72.7
Transgender womana 189 152 80.4 37 19.6 129 68.3
Transgender mana 10 8 80.0 2 20.0 6 60.0
Additional gender identityb 3 3 100 0 0.0 2 66.7
Male sex at birth (≥13 yrs at diagnosis)
Age at diagnosis (yr)
13–24 1,314 1,069 81.4 245 18.6 958 72.9
25–34 2,748 2,378 86.5 370 13.5 1,979 72.0
35–44 1,415 1,197 84.6 218 15.4 1,000 70.7
45–54 771 670 86.9 101 13.1 537 69.6
≥55 419 365 87.1 54 12.9 277 66.1
Transmission categoryc
Male-to-male sexual contact 5,842 4,975 85.2 867 14.8 4,263 73.0
Injection drug use 232 194 83.7 38 16.3 116 50.1
Male-to-male sexual contact and injection drug use 245 205 83.8 40 16.2 144 58.7
Heterosexual contactd 345 301 87.4 43 12.6 226 65.5
Othere 4 3 85.7 1 14.3 3 71.4
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 5,875 5,041 85.8 834 14.2 4,255 72.4
Metropolitan areas (pop. 50,000–499,999) 534 439 82.2 95 17.8 334 62.5
Nonmetropolitan areas (pop. <50,000) 221 181 81.9 40 18.1 144 65.2
Subtotal 6,667 5,679 85.2 988 14.8 4,751 71.3
Female sex at birth (≥13 yrs at diagnosis)
Age at diagnosis (yr)
13–24 130 114 87.7 16 12.3 103 79.2
25–34 225 190 84.4 35 15.6 165 73.3
35–44 216 177 81.9 39 18.1 151 69.9
45–54 141 122 86.5 19 13.5 103 73.0
≥55 119 98 82.4 21 17.6 81 68.1
Transmission categoryc
Injection drug use 123 99 81.0 23 19.0 71 57.8
Heterosexual contactd 703 598 85.1 105 14.9 529 75.3
Othere 5 4 70.4 2 29.6 3 57.4
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 721 601 83.4 120 16.6 520 72.1
Metropolitan areas (pop. 50,000–499,999) 69 64 92.8 5 7.2 52 75.4
Nonmetropolitan areas (pop. <50,000) 36 34 94.4 2 5.6 29 80.6
Subtotal 831 701 84.4 130 15.6 603 72.6
Total 7,498 6,380 85.1 1,118 14.9 5,354 71.4
Native Hawaiian/other Pacific Islander
Gender
Male 46 39 84.8 7 15.2 28 60.9
Female 14 13 92.9 1 7.1 12 85.7
Transgender womana 3 2 66.7 1 33.3 2 66.7
Transgender mana 0 0 0.0 0 0.0 0 0.0
Additional gender identityb 0 0 0.0 0 0.0 0 0.0
Male sex at birth (≥13 yrs at diagnosis)
Age at diagnosis (yr)
13–24 9 7 77.8 2 22.2 8 88.9
25–34 22 17 77.3 5 22.7 12 54.5
35–44 13 12 92.3 1 7.7 7 53.8
45–54 4 4 100 0 0.0 2 50.0
≥55 1 1 100 0 0.0 1 100
Transmission categoryc
Male-to-male sexual contact 41 35 85.3 6 14.7 26 62.6
Injection drug use 3 2 60.0 1 40.0 0 0.0
Male-to-male sexual contact and injection drug use 3 2 69.7 1 30.3 2 66.7
Heterosexual contactd 2 2 100 0 0.0 2 87.0
Othere 0 0 0.0 0 0.0 0 0.0
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 41 34 82.9 7 17.1 25 61.0
Metropolitan areas (pop. 50,000–499,999) 5 4 80.0 1 20.0 3 60.0
Nonmetropolitan areas (pop. <50,000) 3 3 100 0 0.0 2 66.7
Subtotal 49 41 83.7 8 16.3 30 61.2
Female sex at birth (≥13 yrs at diagnosis)
Age at diagnosis (yr)
13–24 3 2 66.7 1 33.3 3 100
25–34 2 2 100 0 0.0 1 50.0
35–44 2 2 100 0 0.0 2 100
45–54 3 3 100 0 0.0 3 100
≥55 4 4 100 0 0.0 3 75.0
Transmission categoryc
Injection drug use 2 2 90.5 0 0.0 2 85.7
Heterosexual contactd 12 11 93.0 1 7.0 10 86.1
Othere 0 0 0.0 0 0.0 0 0.0
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 9 8 88.9 1 11.1 7 77.8
Metropolitan areas (pop. 50,000–499,999) 3 3 100 0 0.0 3 100
Nonmetropolitan areas (pop. <50,000) 2 2 100 0 0.0 2 100
Subtotal 14 13 92.9 1 7.1 12 85.7
Total 63 54 85.7 9 14.3 42 66.7
White
Gender
Male 5,981 5,030 84.1 951 15.9 4,162 69.6
Female 1,189 961 80.8 228 19.2 730 61.4
Transgender womana 68 57 83.8 11 16.2 46 67.6
Transgender mana 14 14 100 0 0.0 12 85.7
Additional gender identityb 4 4 100 0 0.0 3 75.0
Male sex at birth (≥13 yrs at diagnosis)
Age at diagnosis (yr)
13–24 734 597 81.3 137 18.7 534 72.8
25–34 2,112 1,741 82.4 371 17.6 1,466 69.4
35–44 1,293 1,091 84.4 202 15.6 880 68.1
45–54 999 858 85.9 141 14.1 710 71.1
≥55 915 804 87.9 111 12.1 621 67.9
Transmission categoryc
Male-to-male sexual contact 4,795 4,075 85.0 719 15.0 3,456 72.1
Injection drug use 475 374 78.7 101 21.3 256 54.0
Male-to-male sexual contact and injection drug use 492 395 80.3 97 19.7 294 59.7
Heterosexual contactd 284 241 84.8 43 15.2 201 70.6
Othere 7 5 79.7 1 20.3 5 65.2
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 4,419 3,732 84.5 687 15.5 3,107 70.3
Metropolitan areas (pop. 50,000–499,999) 1,032 852 82.6 180 17.4 682 66.1
Nonmetropolitan areas (pop. <50,000) 574 484 84.3 90 15.7 406 70.7
Subtotal 6,053 5,091 84.1 962 15.9 4,211 69.6
Female sex at birth (≥13 yrs at diagnosis)
Age at diagnosis (yr)
13–24 129 106 82.2 23 17.8 93 72.1
25–34 364 290 79.7 74 20.3 214 58.8
35–44 290 227 78.3 63 21.7 175 60.3
45–54 236 194 82.2 42 17.8 142 60.2
≥55 184 158 85.9 26 14.1 118 64.1
Transmission categoryc
Injection drug use 391 299 76.4 93 23.6 207 52.9
Heterosexual contactd 803 668 83.2 135 16.8 529 65.9
Othere 9 8 91.9 1 8.1 6 70.9
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 781 631 80.8 150 19.2 487 62.4
Metropolitan areas (pop. 50,000–499,999) 285 230 80.7 55 19.3 169 59.3
Nonmetropolitan areas (pop. <50,000) 134 111 82.8 23 17.2 83 61.9
Subtotal 1,203 975 81.0 228 19.0 742 61.7
Total 7,256 6,066 83.6 1,190 16.4 4,953 68.3
Multiracial
Gender
Male 575 481 83.7 94 16.3 395 68.7
Female 124 103 83.1 21 16.9 89 71.8
Transgender womana 27 23 85.2 4 14.8 15 55.6
Transgender mana 3 3 100 0 0.0 3 100
Additional gender identityb 0 0 0.0 0 0.0 0 0.0
Male sex at birth (≥13 yrs at diagnosis)
Age at diagnosis (yr)
13–24 154 127 82.5 27 17.5 104 67.5
25–34 226 186 82.3 40 17.7 154 68.1
35–44 123 104 84.6 19 15.4 83 67.5
45–54 63 56 88.9 7 11.1 47 74.6
≥55 36 31 86.1 5 13.9 22 61.1
Transmission categoryc
Male-to-male sexual contact 505 431 85.4 74 14.6 361 71.5
Injection drug use 39 29 73.5 10 26.5 19 49.0
Male-to-male sexual contact and injection drug use 37 28 75.2 9 24.8 16 44.4
Heterosexual contactd 22 17 77.8 5 22.2 14 63.4
Othere 0 0 0.0 0 0.0 0 0.0
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 474 399 84.2 75 15.8 327 69.0
Metropolitan areas (pop. 50,000–499,999) 85 72 84.7 13 15.3 52 61.2
Nonmetropolitan areas (pop. <50,000) 41 31 75.6 10 24.4 30 73.2
Subtotal 602 504 83.7 98 16.3 410 68.1
Female sex at birth (≥13 yrs at diagnosis)
Age at diagnosis (yr)
13–24 26 23 88.5 3 11.5 22 84.6
25–34 44 36 81.8 8 18.2 29 65.9
35–44 24 20 83.3 4 16.7 16 66.7
45–54 17 13 76.5 4 23.5 12 70.6
≥55 16 14 87.5 2 12.5 13 81.3
Transmission categoryc
Injection drug use 20 16 80.9 4 19.1 14 67.2
Heterosexual contactd 106 89 83.8 17 16.2 77 73.2
Othere 1 1 100 0 0.0 1 100
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 87 74 85.1 13 14.9 69 79.3
Metropolitan areas (pop. 50,000–499,999) 28 22 78.6 6 21.4 14 50.0
Nonmetropolitan areas (pop. <50,000) 12 10 83.3 2 16.7 9 75.0
Subtotal 127 106 83.5 21 16.5 92 72.4
Total 729 610 83.7 119 16.3 502 68.9

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); pop, population; CDC, Centers for Disease Control and Prevention [footnotes only].
Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Data are based on residence at time of diagnosis. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are within 6 months of diagnosis of HIV infection during 2020. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to the CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kentucky, Pennsylvania, Vermont, and Puerto Rico.
a “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
b Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
c Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
d Sexual contact with a person known to have, or with a risk factor for, HIV infection.
e Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.
f Hispanic/Latino persons can be of any race.

Table 2d. Linkage to HIV Medical Care Within 1 Month and Viral Suppression Within 6 Months of HIV Diagnosis During 2020 (COVID-19 Pandemic) Among Males (Sex Assigned at Birth) Aged ≥13 Years with Infection Attributed to Male-to-Male Sexual Contact, by Race/Ethnicity and Age a Diagnosis—45 States and the District of Columbia
Linkage to Care
≤1 month		 Viral Suppression
Total diagnoses ≥1 CD4 or VL tests No CD4 or VL test VL <200 copies/mL ≤6 months
No. No. % No. % No. %
American Indian/Alaska Native
13–24 28 23 81.9 5 18.1 17 61.6
25–34 44 36 81.6 8 18.4 28 63.4
35–44 24 18 75.0 6 25.0 13 51.6
45–54 17 16 94.1 1 5.9 12 70.6
≥55 8 7 83.1 1 16.9 7 78.3
Subtotal 121 99 82.2 22 17.8 76 62.7
Asian
13–24 76 69 90.8 7 9.2 61 80.4
25–34 209 189 90.4 20 9.6 171 81.5
35–44 92 78 85.0 14 15.0 75 81.7
45–54 67 59 88.1 8 11.9 57 84.8
≥55 33 27 82.2 6 17.8 21 64.4
Subtotal 477 422 88.5 55 11.5 385 80.7
Black/African American
13–24 2,548 2,001 78.6 546 21.4 1,688 66.3
25–34 3,250 2,588 79.6 663 20.4 2,118 65.2
35–44 1,015 811 80.0 203 20.0 638 62.9
45–54 487 391 80.3 96 19.7 309 63.5
≥55 335 269 80.2 66 19.8 189 56.5
Subtotal 7,634 6,060 79.4 1,575 20.6 4,942 64.7
Hispanic/Latinoa
13–24 1,233 1,005 81.5 228 18.5 912 74.0
25–34 2,483 2,149 86.5 334 13.5 1,827 73.6
35–44 1,197 1,012 84.6 185 15.4 876 73.2
45–54 617 538 87.2 79 12.8 431 69.9
≥55 312 271 86.9 41 13.1 216 69.3
Subtotal 5,842 4,975 85.2 867 14.8 4,263 73.0
Native Hawaiian/other Pacific Islander
13–24 9 7 77.8 2 22.2 8 88.9
25–34 18 15 83.1 3 16.9 10 55.4
35–44 11 10 90.7 1 9.3 6 54.2
45–54 3 3 100 0 0.0 1 40.0
≥55 1 1 100 0 0.0 1 100
Subtotal 41 35 85.3 6 14.7 26 62.6
White
13–24 655 536 81.9 119 18.1 487 74.3
25–34 1,673 1,408 84.2 265 15.8 1,211 72.4
35–44 932 800 85.9 131 14.1 673 72.2
45–54 785 672 85.5 114 14.5 567 72.1
≥55 750 659 87.9 90 12.1 519 69.2
Subtotal 4,795 4,075 85.0 719 15.0 3,456 72.1
Multiracial
13–24 138 117 84.9 21 15.1 98 70.7
25–34 195 163 83.4 32 16.6 138 70.8
35–44 96 84 88.2 11 11.8 70 72.8
45–54 49 43 87.9 6 12.1 40 80.9
≥55 27 24 88.1 3 11.9 16 59.0
Subtotal 505 431 85.4 74 14.6 361 71.5
All
13–24 4,686 3,758 80.2 928 19.8 3,270 69.8
25–34 7,872 6,546 83.2 1,325 16.8 5,502 69.9
35–44 3,365 2,814 83.6 551 16.4 2,350 69.8
45–54 2,025 1,721 85.0 304 15.0 1,416 69.9
≥55 1,466 1,257 85.8 208 14.2 969 66.1
Total 19,414 16,097 82.9 3,317 17.1 13,507 69.6

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, Centers for Disease Control and Prevention [footnotes only].
Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Data presented based on sex at birth and include transgender persons. Data are based on residence at time of diagnosis. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are within 6 months of diagnosis of HIV infection during 2020. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to the CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kentucky, Pennsylvania, Vermont, and Puerto Rico.
a Hispanic/Latino persons can be of any race.

Table 2e. Linkage to HIV Medical Care Within 1 Month and Viral Suppression Within 6 Months of HIV Diagnosis During 2020 (COVID-19 Pandemic) Among Transgender and Additional Gender Identity Persons Aged ≥13 Years, by Selected Characteristics—45 States and the District of Columbia
Linkage to Care
≤1 month		 Viral Suppression
Total diagnoses ≥1 CD4 or VL tests No CD4 or VL test VL <200 copies/mL ≤6 months
No. No. % No. % No. %
Transgender womana
Age at diagnosis (yr)
13–24 161 125 77.6 36 22.4 102 63.4
25–34 301 249 82.7 52 17.3 193 64.1
35–44 79 64 81.0 15 19.0 47 59.5
45–54 45 35 77.8 10 22.2 35 77.8
≥55 13 11 84.6 2 15.4 8 61.5
Race/ethnicity
American Indian/Alaska Native 8 6 75.0 2 25.0 3 37.5
Asian 16 14 87.5 2 12.5 13 81.3
Black/African American 288 230 79.9 58 20.1 177 61.5
Hispanic/Latinob 189 152 80.4 37 19.6 129 68.3
Native Hawaiian/other Pacific Islander 3 2 66.7 1 33.3 2 66.7
White 68 57 83.8 11 16.2 46 67.6
Multiracial 27 23 85.2 4 14.8 15 55.6
Exposure categoryc
Sexual contactd 543 441 81.2 102 18.8 354 65.2
Injection drug use 0 0 0.0 0 0.0 0 0.0
Sexual contactd and injection drug use 31 24 77.4 7 22.6 19 61.3
Othere 25 19 76.0 6 24.0 12 48.0
Subtotal 599 484 80.8 115 19.2 385 64.3
Transgender mana
Age at diagnosis (yr)
13–24 12 11 91.7 1 8.3 10 83.3
25–34 17 15 88.2 2 11.8 12 70.6
35–44 7 7 100 0 0.0 7 100
45–54 2 2 100 0 0.0 1 50.0
≥55 0 0 0.0 0 0.0 0 0.0
Race/ethnicity
American Indian/Alaska Native 0 0 0.0 0 0.0 0 0.0
Asian 0 0 0.0 0 0.0 0 0.0
Black/African American 11 10 90.9 1 9.1 9 81.8
Hispanic/Latinob 10 8 80.0 2 20.0 6 60.0
Native Hawaiian/other Pacific Islander 0 0 0.0 0 0.0 0 0.0
White 14 14 100 0 0.0 12 85.7
Multiracial 3 3 100 0 0.0 3 100
Exposure categoryc
Sexual contactd 27 24 88.9 3 11.1 22 81.5
Injection drug use 1 1 100 0 0.0 1 100
Sexual contactd and injection drug use 5 5 100 0 0.0 2 40.0
Othere 5 5 100 0 0.0 5 100
Subtotal 38 35 92.1 3 7.9 30 78.9
Additional gender identityf
Age at diagnosis (yr)
13–24 8 8 100 0 0.0 7 87.5
25–34 6 5 83.3 1 16.7 5 83.3
35–44 2 2 100 0 0.0 0 0.0
45–54 0 0 0.0 0 0.0 0 0.0
≥55 0 0 0.0 0 0.0 0 0.0
Race/ethnicity
American Indian/Alaska Native 0 0 0.0 0 0.0 0 0.0
Asian 1 1 100 0 0.0 1 100
Black/African American 8 7 87.5 1 12.5 6 75
Hispanic/Latinob 3 3 100 0 0.0 2 66.7
Native Hawaiian/other Pacific Islander 0 0 0.0 0 0.0 0 0.0
White 4 4 100 0 0.0 3 75.0
Multiracial 0 0 0.0 0 0.0 0 0.0
Exposure categoryc
Sexual contactd 13 12 92.3 1 7.7 9 69.2
Injection drug use 0 0 0.0 0 0.0 0 0.0
Sexual contactd and injection drug use 1 1 100 0 0.0 1 100
Othere 2 2 100 0 0.0 2 100
Subtotal 16 15 93.8 1 6.3 12 75.0
Total 653 534 81.8 119 18.2 427 65.4

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, Centers for Disease Control and Prevention [footnotes only].</br >
Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Data are based on residence at time of diagnosis. Linkage to HIV medical care was measured by documentation of ≥1 CD4 or VL tests ≤1 month after HIV diagnosis. A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are within 6 months of diagnosis of HIV infection during 2020. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to the CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kentucky, Pennsylvania, Vermont, and Puerto Rico. </br >
a “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender. </br >
b Hispanic/Latino persons can be of any race.</br >
c Risk factor data for transgender and additional gender identity adults and adolescents are presented using the exposure category classification, which is meant to convey all the known ways the person could have been exposed to HIV. Exposure categories are mutually exclusive and have no presumed hierarchical order of probability, except for rare circumstances where route of transmission has been confirmed through investigation. See Technical Notes for more information on exposure categories.</br >
d For persons assigned “male” sex at birth, sexual contact with any person. For persons assigned “female” sex at birth, sexual contact with a person assigned “male” sex at birth.</br >
e Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.</br >
f Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

Table 3a. Receipt of HIV Medical Care and Viral Suppression During 2020 (COVID-19 Pandemic) Among Persons Aged ≥13 Years with HIV Infection Diagnosed by Year-End 2019 and Alive at Year-End 2020, by Selected Characteristics—45 States and the District of Columbia
Persons alive at year-end 2019 ≥1 CD4 or VL tests ≥2 CD4 or VL testsa VL <200 copies/mLb
Total No. No. % No. % No. %
Gender
Male 717,879 531,998 74.1 363,048 50.6 466,295 65.0
Female 215,092 158,356 73.6 107,874 50.2 135,941 63.2
Transgender womanc 10,625 8,691 81.8 6,093 57.3 6,967 65.6
Transgender manc 444 362 81.5 235 52.9 303 68.2
Additional gender identityd 207 180 87.0 138 66.7 148 71.5
Age at year-end 2019 (yr)
13–24 28,697 22,402 78.1 15,136 52.7 18,236 63.5
25–34 150,764 113,838 75.5 73,880 49.0 93,549 62.0
35–44 178,445 131,102 73.5 86,484 48.5 111,292 62.4
45–54 243,064 180,910 74.4 123,290 50.7 159,138 65.5
≥55 343,277 251,335 73.2 178,598 52.0 227,439 66.3
Race/ethnicity
American Indian/Alaska Native 2,988 2,207 73.9 1,433 48.0 1,844 61.7
Asiane 14,655 10,716 73.1 7,259 49.5 9,987 68.1
Black/African American 382,521 275,796 72.1 187,003 48.9 230,853 60.4
Hispanic/Latinof 220,065 157,172 71.4 112,478 51.1 139,001 63.2
Native Hawaiian/other Pacific Islander 845 602 71.2 400 47.3 545 64.5
White 275,950 213,956 77.5 142,009 51.5 193,780 70.2
Multiracial 46,546 39,089 84.0 26,772 57.5 33,597 72.2
Transmission categoryg
Male-to-male sexual contact 544,758 413,448 75.9 280,673 51.5 366,068 67.2
Injection drug use 97,081 63,656 65.6 43,945 45.3 53,638 55.3
Male 55,700 34,257 61.5 23,936 43.0 28,955 52.0
Female 41,380 29,398 71.0 20,009 48.4 24,683 59.6
Male-to-male sexual contact and injection drug use 51,989 40,159 77.2 27,948 53.8 33,361 64.2
Heterosexual contacth 236,672 172,527 72.9 118,191 49.9 148,910 62.9
Male 69,303 48,196 69.5 33,558 48.4 41,204 59.5
Female 167,368 124,331 74.3 84,633 50.6 107,706 64.4
Otheri 13,748 9,798 71.3 6,631 48.2 7,677 55.8
Male 6,932 4,786 69.0 3,146 45.4 3,804 54.9
Female 6,817 5,012 73.5 3,485 51.1 3,874 56.8
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 774,569 574,276 74.1 391,927 50.6 501,543 64.8
Metropolitan areas (pop. 50,000–499,999) 94,638 71,812 75.9 49,285 52.1 62,264 65.8
Nonmetropolitan areas (pop. <50,000) 53,978 40,042 74.2 27,727 51.4 34,306 63.6
Totalj 944,247 699,587 74.1 477,388 50.6 609,654 64.6

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); pop, population; CDC, Centers for Disease Control and Prevention [footnotes only].
Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Data are based on address of residence as of December 31, 2020 (i.e., most recent known address). A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are from the most recent test during 2020. Data for the year 2020 are preliminary and based on death data received by CDC as of December 2021. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to the CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kentucky, Pennsylvania, Vermont, and Puerto Rico.
a Performed ≥3 months apart during 2020.
b A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are from the most recent test during 2020.
c “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
d Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
e Includes Asian/Pacific Islander legacy cases (see Technical Notes).
f Hispanic/Latino persons can be of any race.
g Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
h Sexual contact with a person known to have, or with a risk factor for, HIV infection.
I Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
j Includes 677 persons of unknown race/ethnicity.

Table 3b. Receipt of HIV Medical Care and Viral Suppression During 2020 (COVID-19 Pandemic) Among Persons Aged ≥13 Years with HIV Infection Diagnosed by Year-End 2019 and Alive at Year-End 2020, by Area of Residence—45 States and the District of Columbia
Persons alive at year-end 2020 ≥1 CD4 or VL tests ≥2 CD4 or VL testsa VL <200 copies/mLb
Total No. No. % No. % No. %
Alabama 13,579 10,272 75.6 7,046 51.9 8,875 65.4
Alaska 701 611 87.2 358 51.1 550 78.5
Arizona 17,060 12,624 74.0 9,413 55.2 11,242 65.9
Arkansas 5,821 3,783 65.0 2,592 44.5 2,885 49.6
California 130,455 95,969 73.6 65,152 49.9 85,115 65.2
Colorado 12,928 8,430 65.2 5,048 39.0 7,512 58.1
Connecticut 10,402 8,074 77.6 5,365 51.6 7,418 71.3
Delaware 3,349 2,681 80.1 1,656 49.4 2,405 71.8
District of Columbia 13,596 8,787 64.6 5,473 40.3 7,444 54.8
Florida 111,231 85,400 76.8 66,418 59.7 74,884 67.3
Georgia 55,634 39,747 71.4 27,990 50.3 33,659 60.5
Hawaii 2,330 1,930 82.8 1,423 61.1 1,776 76.2
Illinois 34,712 25,822 74.4 15,728 45.3 22,449 64.7
Indiana 11,440 8,668 75.8 5,133 44.9 7,493 65.5
Iowa 2,836 2,432 85.8 1,547 54.5 2,248 79.3
Kansasc 3,213 2,584 80.4 1,848 57.5 2,324 72.3
Louisiana 20,676 15,905 76.9 11,618 56.2 13,895 67.2
Maine 1,635 1,351 82.6 869 53.1 1,266 77.4
Marylandd 32,715 22,914 70.0 14,660 44.8 20,335 62.2
Massachusetts 20,602 15,169 73.6 8,761 42.5 13,685 66.4
Michigan 16,352 12,820 78.4 7,864 48.1 11,342 69.4
Minnesota 8,771 6,494 74.0 3,464 39.5 5,858 66.8
Mississippi 9,326 6,594 70.7 4,434 47.5 5,156 55.3
Missouri 12,511 9,497 75.9 6,399 51.1 8,108 64.8
Montana 671 573 85.4 385 57.4 517 77.0
Nebraska 2,248 1,670 74.3 918 40.8 1,357 60.4
Nevada 10,656 7,823 73.4 5,467 51.3 6,818 64.0
New Hampshire 1,296 1,021 78.8 647 49.9 951 73.4
New Mexico 3,811 2,942 77.2 1,848 48.5 2,176 57.1
New York 123,315 87,926 71.3 64,098 52.0 77,805 63.1
North Carolinac 32,498 24,493 75.4 15,330 47.2 21,291 65.5
North Dakota 490 389 79.4 250 51.0 330 67.3
Ohio 22,818 16,823 73.7 9,869 43.3 14,775 64.8
Oklahoma 6,281 4,421 70.4 3,057 48.7 3,696 58.8
Oregon 7,164 6,147 85.8 3,455 48.2 5,597 78.1
Rhode Island 2,615 2,050 78.4 1,019 39.0 1,812 69.3
South Carolinac 17,283 14,018 81.1 10,739 62.1 12,434 71.9
South Dakota 660 555 84.1 310 47.0 313 47.4
Tennessee 17,572 14,176 80.7 9,881 56.2 11,841 67.4
Texas 93,839 68,963 73.5 46,181 49.2 56,378 60.1
Utah 3,132 2,321 74.1 1,368 43.7 2,142 68.4
Virginia 23,425 16,399 70.0 11,275 48.1 14,683 62.7
Washington 13,877 11,541 83.2 6,776 48.8 10,697 77.1
West Virginia 1,951 1,377 70.6 800 41.0 1,175 60.2
Wisconsin 6,428 5,125 79.7 3,269 50.9 4,718 73.4
Wyoming 342 276 80.7 187 54.7 224 65.5
Region of residencee
Northeast (excluding NJ, PA, VT) 159,865 115,591 72.3 80,759 50.5 102,937 64.4
Midwest 122,479 92,879 75.8 56,599 46.2 81,315 66.4
South (excluding KY) 458,776 339,930 74.1 239,150 52.1 291,036 63.4
West (excluding ID) 203,127 151,187 74.4 100,880 49.7 134,366 66.1

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, Centers for Disease Control and Prevention [footnotes only].
Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Data are based on address of residence as of December 31, 2020 (i.e., most recent known address). Data for the year 2020 are preliminary and based on death data received by CDC as of December 2021. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to the CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kentucky, Pennsylvania, Vermont, and Puerto Rico.
a Performed ≥3 months apart during 2020.
b A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are from the most recent test during 2020.
c Data should be interpreted with caution due to incomplete ascertainment of deaths that occurred during the year 2020.
d Data should be interpreted with caution due to incomplete reporting of case information to CDC during December 2021.
e Data should be interpreted with caution and are based on areas with laws and complete reporting to CDC.

Table 3c. Receipt of HIV Medical Care and Viral Suppression During 2020 (COVID-19 Pandemic) Among Persons Aged ≥13 Years with HIV Infection Diagnosed by Year-End 2019 and Alive at Year-End 2020, by Race/Ethnicity and Selected Characteristics—45 States and the District of Columbia
Persons alive at year-end 2020 ≥1 CD4 or VL tests ≥2 CD4 or VL testsa VL <200 copies/mLb
Total No. No. % No. % No. %
American Indian/Alaska Native
Gender
Male 2,201 1,624 73.8 1,043 47.4 1,378 62.6
Female 735 540 73.5 358 48.7 432 58.8
Transgender womanc 47 39 83.0 30 63.8 32 68.1
Transgender manc 4 3 75.0 2 50.0 1 25.0
Additional gender identityd 1 1 100 0 0.0 1 100
Male sex at birth (≥13 yrs at diagnosis)
Age at year-end 2019 (yr)
13–24 105 83 79.0 48 45.7 70 66.7
25–34 498 377 75.7 225 45.2 302 60.6
35–44 498 381 76.5 243 48.8 320 64.3
45–54 569 424 74.5 282 49.6 362 63.6
≥55 579 399 68.9 275 47.5 357 61.7
Transmission categorye
Male-to-male sexual contact 1,598 1,198 75.0 774 48.5 1,034 64.7
Injection drug use 215 141 65.6 90 41.7 109 50.7
Male-to-male sexual contact and injection drug use 278 204 73.6 133 47.9 166 59.9
Heterosexual contactf 142 108 75.8 68 47.6 91 63.8
Otherg 16 13 78.1 8 51.9 11 65.6
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 1,227 885 72.1 590 48.1 770 62.8
Metropolitan areas (pop. 50,000–499,999) 382 307 80.4 203 53.1 265 69.4
Nonmetropolitan areas (pop. <50,000) 594 444 74.7 263 44.3 352 59.3
Subtotal 2,249 1,664 74.0 1,073 47.7 1,411 62.7
Female sex at birth (≥13 yrs at diagnosis)
Age at year-end 2019 (yr)
13–24 15 10 66.7 8 53.3 9 60.0
25–34 94 64 68.1 44 46.8 41 43.6
35–44 191 139 72.8 82 42.9 101 52.9
45–54 204 147 72.1 98 48.0 123 60.3
≥55 235 183 77.9 128 54.5 159 67.7
Transmission categorye
Injection drug use 244 170 69.6 115 47.3 129 52.8
Heterosexual contactf 476 361 75.9 238 50.1 296 62.1
Otherg 19 12 61.9 6 33.9 9 45.5
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 350 235 67.1 157 44.9 192 54.9
Metropolitan areas (pop. 50,000–499,999) 148 121 81.8 91 61.5 105 70.9
Nonmetropolitan areas (pop. <50,000) 222 172 77.5 104 46.8 130 58.6
Subtotal 739 543 73.5 360 48.7 433 58.6
Total 2,988 2,207 73.9 1,433 48.0 1,844 61.7
Asianh
Gender
Male 11,977 8,807 73.5 6,005 50.1 8,230 68.7
Female 2,495 1,766 70.8 1,167 46.8 1,629 65.3
Transgender womanc 172 134 77.9 80 46.5 119 69.2
Transgender manc 8 7 87.5 5 62.5 7 87.5
Additional gender identityd 3 2 66.7 2 66.7 2 66.7
Male sex at birth (≥13 yrs at diagnosis)
Age at year-end 2019 (yr)
13–24 436 351 80.5 244 56.0 330 75.7
25–34 2,487 1,873 75.3 1,244 50.0 1,755 70.6
35–44 2,873 2,116 73.7 1,418 49.4 1,946 67.7
45–54 3,556 2,668 75.0 1,835 51.6 2,506 70.5
≥55 2,800 1,935 69.1 1,346 48.1 1,814 64.8
Transmission categorye
Male-to-male sexual contact 10,314 7,657 74.2 5,193 50.4 7,156 69.4
Injection drug use 398 250 62.8 162 40.7 228 57.4
Male-to-male sexual contact and injection drug use 391 292 74.5 213 54.4 274 69.9
Heterosexual contactf 936 664 70.9 462 49.4 618 66.0
Otherg 113 80 71.3 57 50.5 75 66.5
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 11,093 8,198 73.9 5,581 50.3 7,670 69.1
Metropolitan areas (pop. 50,000–499,999) 683 493 72.2 329 48.2 451 66.0
Nonmetropolitan areas (pop. <50,000) 158 112 70.9 88 55.7 106 67.1
Subtotal 12,152 8,943 73.6 6,087 50.1 8,351 68.7
Female sex at birth (≥13 yrs at diagnosis)
Age at year-end 2019 (yr)
13–24 84 70 83.3 59 70.2 69 82.1
25–34 306 236 77.1 167 54.6 213 69.6
35–44 736 533 72.4 331 45.0 498 67.7
45–54 686 474 69.1 286 41.7 436 63.6
≥55 691 460 66.6 329 47.6 420 60.8
Transmission categorye
Injection drug use 165 104 62.9 74 45.0 93 56.1
Heterosexual contactf 2,228 1,588 71.3 1,033 46.4 1,465 65.8
Otherg 110 81 73.6 65 58.5 78 70.7
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 2,144 1,526 71.2 1,017 47.4 1,409 65.7
Metropolitan areas (pop. 50,000–499,999) 223 154 69.1 98 43.9 141 63.2
Nonmetropolitan areas (pop. <50,000) 73 54 74.0 36 49.3 49 67.1
Subtotal 2,503 1,773 70.8 1,172 46.8 1,636 65.4
Total 14,655 10,716 73.1 7,259 49.5 9,987 68.1
Black/African American
Gender
Male 250,370 178,921 71.5 121,255 48.4 148,977 59.5
Female 126,989 92,682 73.0 62,924 49.6 78,662 61.9
Transgender womanc 4,894 3,976 81.2 2,679 54.7 3,043 62.2
Transgender manc 193 156 80.8 101 52.3 123 63.7
Additional gender identityd 75 61 81.3 44 58.7 48 64.0
Male sex at birth (≥13 yrs at diagnosis)
Age at year-end 2019 (yr)
13–24 12,418 9,555 76.9 6,280 50.6 7,528 60.6
25–34 58,449 43,294 74.1 27,689 47.4 34,123 58.4
35–44 46,101 33,789 73.3 22,438 48.7 27,643 60.0
45–54 55,344 40,085 72.4 27,642 49.9 34,021 61.5
≥55 83,018 56,228 67.7 39,923 48.1 48,748 58.7
Transmission categorye
Male-to-male sexual contact 169,016 124,690 73.8 83,257 49.3 103,721 61.4
Injection drug use 25,743 15,651 60.8 10,955 42.6 13,149 51.1
Male-to-male sexual contact and injection drug use 13,889 10,300 74.2 7,313 52.6 8,302 59.8
Heterosexual contactf 43,464 30,179 69.4 21,006 48.3 25,324 58.3
Otherg 3,217 2,131 66.2 1,442 44.8 1,568 48.7
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 210,280 150,938 71.8 101,387 48.2 125,608 59.7
Metropolitan areas (pop. 50,000–499,999) 24,502 17,771 72.5 12,376 50.5 14,697 60.0
Nonmetropolitan areas (pop. <50,000) 14,160 10,326 72.9 7,672 54.2 8,520 60.2
Subtotal 255,330 182,951 71.7 123,972 48.6 152,063 59.6
Female sex at birth (≥13 yrs at diagnosis)
Age at year-end 2019 (yr)
13–24 3,581 2,716 75.8 1,916 53.5 2,040 57.0
25–34 14,707 10,523 71.6 6,864 46.7 8,007 54.4
35–44 27,356 19,477 71.2 12,579 46.0 15,940 58.3
45–54 36,619 26,913 73.5 18,234 49.8 23,142 63.2
≥55 44,928 33,216 73.9 23,438 52.2 29,661 66.0
Transmission categorye
Injection drug use 19,599 13,647 69.6 9,323 47.6 11,470 58.5
Heterosexual contactf 103,750 76,418 73.7 51,761 49.9 65,253 62.9
Otherg 3,842 2,780 72.4 1,947 50.7 2,067 53.8
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 104,910 76,410 72.8 51,565 49.2 64,867 61.8
Metropolitan areas (pop. 50,000–499,999) 12,801 9,708 75.8 6,821 53.3 8,243 64.4
Nonmetropolitan areas (pop. <50,000) 6,424 4,734 73.7 3,390 52.8 3,971 61.8
Subtotal 127,191 92,845 73.0 63,031 49.6 78,790 61.9
Total 382,521 275,796 72.1 187,003 48.9 230,853 60.4
Hispanic/Latinoi
Gender
Male 177,143 124,946 70.5 89,209 50.4 110,956 62.6
Female 39,204 29,197 74.5 21,038 53.7 25,539 65.1
Transgender womanc 3,562 2,893 81.2 2,136 60.0 2,391 67.1
Transgender manc 95 80 84.2 51 53.7 70 73.7
Additional gender identityd 61 56 91.8 44 72.1 45 73.8
Male sex at birth (≥13 yrs at diagnosis)
Age at year-end 2019 (yr)
13–24 5,786 4,635 80.1 3,203 55.4 3,980 68.8
25–34 34,085 26,287 77.1 17,854 52.4 22,652 66.5
35–44 41,631 29,285 70.3 20,336 48.8 25,597 61.5
45–54 48,820 33,803 69.2 24,489 50.2 30,233 61.9
≥55 50,436 33,878 67.2 25,501 50.6 30,924 61.3
Transmission categorye
Male-to-male sexual contact 137,515 100,252 72.9 71,419 51.9 90,015 65.5
Injection drug use 15,765 8,740 55.4 6,374 40.4 7,424 47.1
Male-to-male sexual contact and injection drug use 12,156 9,031 74.3 6,522 53.7 7,372 60.6
Heterosexual contactf 13,847 8,835 63.8 6,376 46.0 7,761 56.0
Otherg 1,476 1,030 69.8 692 46.9 814 55.2
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 160,056 114,849 71.8 82,373 51.5 102,132 63.8
Metropolitan areas (pop. 50,000–499,999) 11,864 8,019 67.6 5,593 47.1 6,984 58.9
Nonmetropolitan areas (pop. <50,000) 6,212 3,461 55.7 2,435 39.2 2,922 47.0
Subtotal 180,758 127,888 70.8 91,383 50.6 113,386 62.7
Female sex at birth (≥13 yrs at diagnosis)
Age at year-end 2019 (yr)
13–24 1,068 818 76.6 585 54.8 638 59.7
25–34 4,282 3,186 74.4 2,163 50.5 2,577 60.2
35–44 8,164 5,857 71.7 3,988 48.8 4,938 60.5
45–54 11,181 8,450 75.6 6,083 54.4 7,428 66.4
≥55 14,612 10,973 75.1 8,276 56.6 10,034 68.7
Transmission categoryc
Injection drug use 8,029 5,833 72.6 4,157 51.8 4,916 61.2
Heterosexual contactf 29,840 22,349 74.9 16,148 54.1 19,848 66.5
Otherg 1,438 1,103 76.6 790 54.9 852 59.2
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 34,670 25,971 74.9 18,814 54.3 22,726 65.5
Metropolitan areas (pop. 50,000–499,999) 2,665 1,988 74.6 1,425 53.5 1,764 66.2
Nonmetropolitan areas (pop. <50,000) 1,269 890 70.1 582 45.9 745 58.7
Subtotal 39,307 29,284 74.5 21,095 53.7 25,615 65.2
Total 220,065 157,172 71.4 112,478 51.1 139,001 63.2
Native Hawaiian/other Pacific Islander
Gender
Male 684 495 72.4 325 47.5 445 65.1
Female 129 82 63.6 57 44.2 77 59.7
Transgender womanc 32 25 78.1 18 56.3 23 71.9
Transgender manc 0 0 0.0 0 0.0 0 0.0
Additional gender identityd 0 0 0.0 0 0.0 0 0.0
Male sex at birth (≥13 yrs at diagnosis)
Age at year-end 2019 (yr)
13–24 28 23 82.1 13 46.4 19 67.9
25–34 168 122 72.6 79 47.0 103 61.3
35–44 182 126 69.2 73 40.1 111 61.0
45–54 172 126 73.3 94 54.7 118 68.6
≥55 166 123 74.1 84 50.6 117 70.5
Transmission categorye
Male-to-male sexual contact 619 445 71.9 291 47.0 401 64.8
Injection drug use 20 13 65.7 10 49.0 10 50.5
Male-to-male sexual contact and injection drug use 43 35 80.1 21 48.8 32 72.9
Heterosexual contactf 30 23 76.9 19 64.9 21 70.2
Otherg 5 4 97.8 2 51.1 4 97.8
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 583 422 72.4 284 48.7 381 65.4
Metropolitan areas (pop. 50,000–499,999) 79 57 72.2 39 49.4 51 64.6
Nonmetropolitan areas (pop. <50,000) 39 32 82.1 17 43.6 27 69.2
Subtotal 716 520 72.6 343 47.9 468 65.4
Female sex at birth (≥13 yrs at diagnosis)
Age at year-end 2019 (yr)
13–24 3 2 66.7 2 66.7 2 66.7
25–34 21 14 66.7 9 42.9 14 66.7
35–44 32 23 71.9 14 43.8 20 62.5
45–54 30 17 56.7 13 43.3 16 53.3
≥55 43 26 60.5 19 44.2 25 58.1
Transmission categorye
Injection drug use 22 13 60.6 8 37.2 12 56.0
Heterosexual contactf 106 68 64.4 49 46.0 64 60.7
Otherg 1 1 41.7 0 0.0 1 41.7
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 92 60 65.2 43 46.7 55 59.8
Metropolitan areas (pop. 50,000–499,999) 21 15 71.4 8 38.1 15 71.4
Nonmetropolitan areas (pop. <50,000) 12 6 50.0 5 41.7 6 50.0
Subtotal 129 82 63.6 57 44.2 77 59.7
Total 845 602 71.2 400 47.3 545 64.5
White
Gender
Male 239,835 187,591 78.2 124,923 52.1 170,680 71.2
Female 34,875 25,338 72.7 16,373 46.9 22,203 63.7
Transgender womanc 1,096 909 82.9 634 57.8 791 72.2
Transgender manc 104 83 79.8 51 49.0 75 72.1
Additional gender identityd 40 35 87.5 28 70.0 31 77.5
Male sex at birth (≥13 yrs at diagnosis)
Age at year-end 2019 (yr)
13–24 3,092 2,472 79.9 1,644 53.2 2,199 71.1
25–34 23,616 18,540 78.5 11,610 49.2 16,226 68.7
35–44 34,342 26,764 77.9 16,902 49.2 23,660 68.9
45–54 63,626 50,312 79.1 32,631 51.3 45,529 71.6
≥55 116,287 90,442 77.8 62,795 54.0 83,884 72.1
Transmission categoryc
Male-to-male sexual contact 198,553 156,634 78.9 104,506 52.6 144,001 72.5
Injection drug use 11,326 7,633 67.4 5,003 44.2 6,486 57.3
Male-to-male sexual contact and injection drug use 21,188 16,859 79.6 11,252 53.1 14,403 68.0
Heterosexual contactf 8,242 6,227 75.5 4,109 49.9 5,556 67.4
Otherg 1,653 1,177 71.2 712 43.1 1,052 63.6
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 186,920 145,629 77.9 97,127 52.0 133,120 71.2
Metropolitan areas (pop. 50,000–499,999) 30,484 24,625 80.8 16,511 54.2 22,130 72.6
Nonmetropolitan areas (pop. <50,000) 17,796 14,338 80.6 9,512 53.5 12,763 71.7
Subtotal 240,963 188,530 78.2 125,582 52.1 171,498 71.2
Female sex at birth (≥13 yrs at diagnosis)
Age at year-end 2019 (yr)
13–24 758 597 78.8 394 52.0 506 66.8
25–34 3,906 2,780 71.2 1,704 43.6 2,219 56.8
35–44 6,852 4,886 71.3 3,001 43.8 4,063 59.3
45–54 9,959 7,223 72.5 4,593 46.1 6,345 63.7
≥55 13,512 9,940 73.6 6,735 49.8 9,149 67.7
Transmission categoryc
Injection drug use 10,757 7,485 69.6 4,846 45.1 6,306 58.6
Heterosexual contactf 23,251 17,258 74.2 11,165 48.0 15,387 66.2
Otherg 980 683 69.7 416 42.4 588 60.1
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 23,493 16,892 71.9 10,926 46.5 14,822 63.1
Metropolitan areas (pop. 50,000–499,999) 6,194 4,698 75.8 3,120 50.4 4,117 66.5
Nonmetropolitan areas (pop. <50,000) 4,237 3,167 74.7 2,000 47.2 2,768 65.3
Subtotal 34,987 25,426 72.7 16,427 47.0 22,282 63.7
Total 275,950 213,956 77.5 142,009 51.5 193,780 70.2
Multiracial
Gender
Male 35,173 29,573 84.1 20,260 57.6 25,590 72.8
Female 10,484 8,743 83.4 5,951 56.8 7,391 70.5
Transgender womanc 822 715 87.0 516 62.8 568 69.1
Transgender manc 40 33 82.5 25 62.5 27 67.5
Additional gender identityd 27 25 92.6 20 74.1 21 77.8
Male sex at birth (≥13 yrs at diagnosis)
Age at year-end 2018 (yr)
13–24 985 794 80.6 540 54.8 637 64.7
25–34 6,879 5,569 81.0 3,553 51.6 4,568 66.4
35–44 7,160 5,892 82.3 3,885 54.3 4,961 69.3
45–54 9,123 7,723 84.7 5,305 58.1 6,712 73.6
≥55 11,871 10,331 87.0 7,510 63.3 9,297 78.3
Transmission categorye
Male-to-male sexual contact 26,797 22,541 84.1 15,212 56.8 19,710 73.6
Injection drug use 2,173 1,826 84.0 1,340 61.6 1,545 71.1
Male-to-male sexual contact and injection drug use 3,997 3,436 86.0 2,494 62.4 2,811 70.3
Heterosexual contactf 2,613 2,156 82.5 1,516 58.0 1,830 70.0
Otherg 438 349 79.7 231 52.8 279 63.7
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 29,887 25,215 84.4 17,286 57.8 21,839 73.1
Metropolitan areas (pop. 50,000–499,999) 3,348 2,844 84.9 1,967 58.8 2,451 73.2
Nonmetropolitan areas (pop. <50,000) 2,010 1,701 84.6 1,199 59.7 1,429 71.1
Subtotal 36,018 30,309 84.1 20,793 57.7 26,175 72.7
Female sex at birth (≥13 yrs at diagnosis)
Age at year-end 2018 (yr)
13–24 333 276 82.9 200 60.1 209 62.8
25–34 1,251 972 77.7 675 54.0 748 59.8
35–44 2,302 1,832 79.6 1,192 51.8 1,492 64.8
45–54 3,016 2,536 84.1 1,698 56.3 2,159 71.6
≥55 3,626 3,164 87.3 2,214 61.1 2,814 77.6
Transmission categoryc
Injection drug use 2,509 2,144 85.5 1,484 59.1 1,755 70.0
Heterosexual contactf 7,606 6,283 82.6 4,234 55.7 5,388 70.8
Otherg 413 353 85.5 261 63.3 279 67.7
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 8,350 6,997 83.8 4,743 56.8 5,905 70.7
Metropolitan areas (pop. 50,000–499,999) 1,209 1,012 83.7 704 58.2 850 70.3
Nonmetropolitan areas (pop. <50,000) 731 605 82.8 424 58.0 518 70.9
Subtotal 10,528 8,780 83.4 5,979 56.8 7,422 70.5
Total 46,546 39,089 84.0 26,772 57.5 33,597 72.2

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, Centers for Disease Control and Prevention [footnotes only].
Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Data are based on address of residence as of December 31, 2020 (i.e., most recent known address). Data for the year 2020 are preliminary and based on death data received by CDC as of December 2021. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to the CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kentucky, Pennsylvania, Vermont, and Puerto Rico.
a Performed ≥3 months apart during 2020.
b A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are from the most recent test during 2020.
c “Transgender male-to-female” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender female-to-male” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
d Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
e Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
f Sexual contact with a person known to have, or with a risk factor for, HIV infection.
g Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
h Includes Asian/Pacific Islander legacy cases (see Technical Notes).
i Hispanic/Latino persons can be of any race.

Table 3d. Receipt of HIV Medical Care and Viral Suppression During 2020 (COVID-19 Pandemic) Among Males (Sex Assigned at Birth) Aged ≥13 Years with Infection Attributed to Male-to-Male Sexual Contact, by Race/Ethnicity and Age Group—45 States and the District of Columbia
Males alive at year-end 2020 ≥1 CD4 or VL tests ≥2 CD4 or VL testsa VL <200 copies/mLb
Total No. No. % No. % No. %
American Indian/Alaska Native
13–24 84 66 78.8 38 44.9 58 68.7
25–34 410 314 76.6 185 45.2 252 61.5
35–44 371 286 77.2 180 48.4 250 67.4
45–54 392 295 75.3 201 51.1 259 66.1
≥55 341 237 69.4 171 50.1 215 63.1
Subtotal 1,598 1,198 75.0 774 48.5 1,034 64.7
Asianc
13–24 366 295 80.7 200 54.6 281 76.7
25–34 2,326 1,754 75.4 1,163 50.0 1,641 70.5
35–44 2,482 1,830 73.7 1,221 49.2 1,682 67.8
45–54 2,942 2,222 75.5 1,522 51.7 2,083 70.8
≥55 2,199 1,557 70.8 1,087 49.4 1,470 66.8
Subtotal 10,314 7,657 74.2 5,193 50.4 7,156 69.4
Black/African American
13–24 10,435 8,142 78.0 5,306 50.8 6,477 62.1
25–34 51,382 38,536 75.0 24,627 47.9 30,563 59.5
35–44 35,582 26,494 74.5 17,538 49.3 21,869 61.5
45–54 34,240 25,189 73.6 17,251 50.4 21,646 63.2
≥55 37,378 26,330 70.4 18,535 49.6 23,165 62.0
Subtotal 169,016 124,690 73.8 83,257 49.3 103,721 61.4
Hispanic/Latinod
13–24 5,013 4,045 80.7 2,810 56.1 3,523 70.3
25–34 29,985 23,326 77.8 15,895 53.0 20,349 67.9
35–44 33,961 24,370 71.8 16,926 49.8 21,616 63.6
45–54 36,706 26,081 71.1 18,925 51.6 23,758 64.7
≥55 31,850 22,430 70.4 16,863 52.9 20,769 65.2
Subtotal 137,515 100,252 72.9 71,419 51.9 90,015 65.5
Native Hawaiian/other Pacific Islander
13–24 25 20 80.6 11 44.4 16 64.5
25–34 147 105 71.7 68 46.2 89 60.9
35–44 165 116 70.3 65 39.6 102 61.8
45–54 146 105 72.0 77 52.4 98 67.2
≥55 136 99 72.6 70 51.4 96 70.4
Subtotal 619 445 71.9 291 47.0 401 64.8
White
13–24 2,514 2,037 81.0 1,368 54.4 1,829 72.7
25–34 19,570 15,363 78.5 9,577 48.9 13,707 70.0
35–44 27,795 21,692 78.0 13,688 49.2 19,518 70.2
45–54 52,093 41,356 79.4 26,797 51.4 37,829 72.6
≥55 96,581 76,185 78.9 53,077 55.0 71,118 73.6
Subtotal 198,553 156,634 78.9 104,506 52.6 144,001 72.5
Multiracial
13–24 778 631 81.1 429 55.1 515 66.1
25–34 5,923 4,796 81.0 3,054 51.6 3,969 67.0
35–44 5,756 4,742 82.4 3,084 53.6 4,067 70.7
45–54 6,673 5,662 84.8 3,836 57.5 5,001 74.9
≥55 7,666 6,711 87.5 4,809 62.7 6,158 80.3
Subtotal 26,797 22,541 84.1 15,212 56.8 19,710 73.6
All races
13–24 19,214 15,236 79.3 10,161 52.9 12,699 66.1
25–34 109,742 84,194 76.7 54,570 49.7 70,571 64.3
35–44 106,123 79,531 74.9 52,703 49.7 69,104 65.1
45–54 133,272 100,917 75.7 68,614 51.5 90,681 68.0
≥55 176,405 133,569 75.7 94,626 53.6 123,013 69.7
Total 544,758 413,448 75.9 280,673 51.5 366,068 67.2

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, Centers for Disease Control and Prevention [footnotes only].
Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Data presented based on sex at birth and include transgender persons. Data are based on address of residence as of December 31, 2020 (i.e., most recent known address). Data for the year 2020 are preliminary and based on death data received by CDC as of December 2021. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to the CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kentucky, Pennsylvania, Vermont, and Puerto Rico.
a Performed ≥3 months apart during 2020.
b A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are from the most recent test during 2020.
c Includes Asian/Pacific Islander legacy cases (see Technical Notes).
d Hispanic/Latino persons can be of any race.

Table 3e. Receipt of HIV Medical Care and Viral Suppression During 2020 (COVID-19 Pandemic) Among Transgender and Additional Gender Identity Persons Aged ≥13 Years with HIV Infection Diagnosed by Year-End 2019 and Alive at Year-End 2020, by Selected Characteristics—45 States and the District of Columbia
Persons alive at year-end 2020 ≥1 CD4 or VL tests ≥2 CD4 or VL testsa VL <200 copies/mLb
Total No. No. % No. % No. %
Transgender womanc
Age at year-end 2019 (yr)
13–24 757 596 78.7 361 47.7 427 56.4
25–34 3,785 3,075 81.2 2,052 54.2 2,329 61.5
35–44 2,771 2,250 81.2 1,615 58.3 1,793 64.7
45–54 2,032 1,694 83.4 1,249 61.5 1,470 72.3
≥55 1,280 1,076 84.1 816 63.8 948 74.1
Race/ethnicity
American Indian/Alaska Native 47 39 83.0 30 63.8 32 68.1
Asiand 172 134 77.9 80 46.5 119 69.2
Black/African American 4,894 3,976 81.2 2,679 54.7 3,043 62.2
Hispanic/Latinoe 3,562 2,893 81.2 2,136 60.0 2,391 67.1
Native Hawaiian/other Pacific Islander 32 25 78.1 18 56.3 23 71.9
White 1,096 909 82.9 634 57.8 791 72.2
Multiracial 822 715 87.0 516 62.8 568 69.1
Exposure categoryf
Sexual contactg 8,962 7,328 81.8 5,077 56.7 5,937 66.2
Injection drug use 21 15 71.4 11 52.4 10 47.6
Sexual contactg and injection drug use 1,451 1,223 84.3 912 62.9 927 63.9
Otherh 191 125 65.4 93 48.7 93 48.7
Subtotal 10,625 8,691 81.8 6,093 57.3 6,967 65.6
Transgender manc
Age at year-end 2019 (yr)
13–24 33 25 75.8 18 54.5 23 69.7
25–34 144 121 84.0 83 57.6 102 70.8
35–44 111 89 80.2 57 51.4 77 69.4
45–54 94 76 80.9 47 50.0 58 61.7
≥55 62 51 82.3 30 48.4 43 69.4
Race/ethnicity
American Indian/Alaska Native 4 3 75.0 2 50.0 1 25.0
Asiand 8 7 87.5 5 62.5 7 87.5
Black/African American 193 156 80.8 101 52.3 123 63.7
Hispanic/Latinoe 95 80 84.2 51 53.7 70 73.7
Native Hawaiian/other Pacific Islander 0 0 0.0 0 0.0 0 0.0
White 104 83 79.8 51 49.0 75 72.1
Multiracial 40 33 82.5 25 62.5 27 67.5
Exposure categoryf
Sexual contactg 334 272 81.4 176 52.7 238 71.3
Injection drug use 9 8 88.9 4 44.4 7 77.8
Sexual contactg and injection drug use 54 42 77.8 25 46.3 24 44.4
Otherh 47 40 85.1 30 63.8 34 72.3
Subtotal 444 362 81.5 235 52.9 303 68.2
Additional gender identityi
Age at year-end 2019 (yr)
13–24 27 24 88.9 18 66.7 22 81.5
25–34 75 66 88.0 52 69.3 56 74.7
35–44 42 37 88.1 29 69.0 24 57.1
45–54 33 29 87.9 23 69.7 25 75.8
≥55 30 24 80.0 16 53.3 21 70.0
Race/ethnicity
American Indian/Alaska Native 1 1 100 0 0.0 1 100
Asiand 3 2 66.7 2 66.7 2 66.7
Black/African American 75 61 81.3 44 58.7 48 64.0
Hispanic/Latinoe 61 56 91.8 44 72.1 45 73.8
Native Hawaiian/other Pacific Islander 0 0 0.0 0 0.0 0 0.0
White 40 35 87.5 28 70.0 31 77.5
Multiracial 27 25 92.6 20 74.1 21 77.8
Exposure categoryf
Sexual contactg 182 160 87.9 125 68.7 133 73.1
Injection drug use 1 0 0.0 0 0.0 0 0.0
Sexual contactg and injection drug use 19 17 89.5 11 57.9 12 63.2
Otherh 5 3 60.0 2 40.0 3 60.0
Subtotal 207 180 87.0 138 66.7 148 71.5
Total 11,276 9,233 81.9 6,466 57.3 7,418 65.8

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, Centers for Disease Control and Prevention [footnotes only].
Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Data are based on address of residence as of December 31, 2020 (i.e., most recent known address). Data for the year 2020 are preliminary and based on death data received by CDC as of December 2021. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to the CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kentucky, Pennsylvania, Vermont, and Puerto Rico.
a Performed ≥3 months apart during 2020.
b A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are from the most recent test during 2020.
c “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
d Includes Asian/Pacific Islander legacy cases (see Technical Notes).
e Hispanic/Latino persons can be of any race.
f Risk factor data for transgender and additional gender identity persons are presented using the exposure category classification, which is meant to convey all the known ways the person could have been exposed to HIV. Exposure categories are mutually exclusive and have no presumed hierarchical order of probability, except for rare circumstances where route of transmission has been confirmed through investigation. See Technical Notes for more information on exposure categories.
g For persons assigned “male” sex at birth, sexual contact with any person. For persons assigned “female” sex at birth, sexual contact with a person assigned “male” sex at birth.
h Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.
i Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

Table 4a. HIV Viral Suppression During 2020 (COVID-19 Pandemic) Among Persons Aged ≥13 Years with HIV Infection Diagnosed by Year-End 2019 and Alive at Year-End 2020, by Selected Characteristics—45 States and the District of Columbia
VL <200 copies/mL
Persons alive at year-end 2020 Persons with ≥1 CD4 or VL tests Persons with ≥1 VL tests Among persons alive at year-end 2020 Among persons with ≥1 CD4 or VL tests Among persons with ≥1 VL tests
No. %a No. % No. % No. % % %
Gender
Male 717,879 76.0 531,998 74.1 511,888 71.3 466,295 65.0 87.6 91.1
Female 215,092 22.8 158,356 73.6 153,093 71.2 135,941 63.2 85.8 88.8
Transgender womanb 10,625 1.1 8,691 81.8 8,440 79.4 6,967 65.6 80.2 82.5
Transgender manb 444 0.0 362 81.5 350 78.8 303 68.2 83.7 86.6
Additional gender identityc 207 0.0 180 87.0 178 86.0 148 71.5 82.2 83.1
Age at year-end 2019 (yr)
13–24 28,697 3.0 22,402 78.1 21,762 75.8 18,236 63.5 81.4 83.8
25–34 150,764 16.0 113,838 75.5 110,025 73.0 93,549 62.0 82.2 85.0
35–44 178,445 18.9 131,102 73.5 126,344 70.8 111,292 62.4 84.9 88.1
45–54 243,064 25.7 180,910 74.4 174,454 71.8 159,138 65.5 88.0 91.2
≥55 343,277 36.4 251,335 73.2 241,364 70.3 227,439 66.3 90.5 94.2
Race/ethnicity
American Indian/Alaska Native 2,988 0.3 2,207 73.9 2,098 70.2 1,844 61.7 83.6 87.9
Asiand 14,655 1.6 10,716 73.1 10,358 70.7 9,987 68.1 93.2 96.4
Black/African American 382,521 40.5 275,796 72.1 265,694 69.5 230,853 60.4 83.7 86.9
Hispanic/Latinoe 220,065 23.3 157,172 71.4 152,271 69.2 139,001 63.2 88.4 91.3
Native Hawaiian/other Pacific Islander 845 0.1 602 71.2 578 68.4 545 64.5 90.5 94.3
White 275,950 29.2 213,956 77.5 205,166 74.3 193,780 70.2 90.6 94.5
Multiracial 46,546 4.9 39,089 84.0 37,736 81.1 33,597 72.2 86.0 89.0
Transmission categoryf
Male-to-male sexual contact 544,758 57.7 413,448 75.9 398,417 73.1 366,068 67.2 88.5 91.9
Injection drug use 97,081 10.3 63,656 65.6 61,096 62.9 53,638 55.3 84.3 87.8
Male 55,700 5.9 34,257 61.5 32,737 58.8 28,955 52.0 84.5 88.4
Female 41,380 4.4 29,398 71.0 28,359 68.5 24,683 59.6 84.0 87.0
Male-to-male sexual contact and injection drug use 51,989 5.5 40,159 77.2 38,457 74.0 33,360 64.2 83.1 86.7
Heterosexual contactg 236,672 25.1 172,527 72.9 166,477 70.3 148,910 62.9 86.3 89.4
Male 69,303 7.3 48,196 69.5 46,245 66.7 41,204 59.5 85.5 89.1
Female 167,368 17.7 124,331 74.3 120,232 71.8 107,706 64.4 86.6 89.6
Otherh 13,748 1.5 9,798 71.3 9,501 69.1 7,677 55.8 78.4 80.8
Male 6,932 0.7 4,786 69.0 4,626 66.7 3,803 54.9 79.5 82.2
Female 6,817 0.7 5,012 73.5 4,875 71.5 3,874 56.8 77.3 79.5
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 774,569 82.0 574,276 74.1 554,367 71.6 501,543 64.8 87.3 90.5
Metropolitan areas (pop. 50,000–499,999) 94,638 10.0 71,812 75.9 68,843 72.7 62,264 65.8 86.7 90.4
Nonmetropolitan areas (pop. <50,000) 53,978 5.7 40,042 74.2 37,957 70.3 34,306 63.6 85.7 90.4
Totali 944,247 100 699,587 74.1 673,949 71.4 609,654 64.6 87.1 90.5

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); pop, population; CDC, Centers for Disease Control and Prevention [footnotes only].
Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Data are based on address of residence as of December 31, 2020 (i.e., most recent known address). A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are from the most recent test during 2020. Data for the year 2020 are preliminary and based on death data received by CDC as of December 2021. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to the CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kentucky, Pennsylvania, Vermont, and Puerto Rico.
a Represents percentage of the total number for the column.
b “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
c Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
d Includes Asian/Pacific Islander legacy cases (see Technical Notes).
e Hispanic/Latino persons can be of any race.
f Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
g Sexual contact with a person known to have, or with a risk factor for, HIV infection.
h Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
I Includes 677 persons of unknown race/ethnicity.

Table 4b. HIV Viral Suppression During 2020 (COVID-19 Pandemic) Among Persons Aged ≥13 Years with HIV Infection Diagnosed by Year-End 2019 and Alive at Year-End 2020, by Area of Residence—45 States and the District of Columbia
VL <200 copies/mL
Persons alive at year-end 2020 Persons with ≥1 CD4 or VL tests Persons with ≥1 VL tests Among persons alive at year-end 2020 Among persons with ≥1 CD4 or VL tests Among persons with ≥1 VL tests
No. No. % No. % No. % % %
Alabama 13,579 10,272 75.6 9,942 73.2 8,875 65.4 86.4 89.3
Alaska 701 611 87.2 592 84.5 550 78.5 90.0 92.9
Arizona 17,060 12,624 74.0 12,090 70.9 11,242 65.9 89.1 93.0
Arkansas 5,821 3,783 65.0 3,313 56.9 2,885 49.6 76.3 87.1
California 130,455 95,969 73.6 91,662 70.3 85,115 65.2 88.7 92.9
Colorado 12,928 8,430 65.2 8,089 62.6 7,512 58.1 89.1 92.9
Connecticut 10,402 8,074 77.6 7,959 76.5 7,418 71.3 91.9 93.2
Delaware 3,349 2,681 80.1 2,627 78.4 2,405 71.8 89.7 91.5
District of Columbia 13,596 8,787 64.6 8,386 61.7 7,444 54.8 84.7 88.8
Florida 111,231 85,400 76.8 82,794 74.4 74,884 67.3 87.7 90.4
Georgia 55,634 39,747 71.4 38,158 68.6 33,659 60.5 84.7 88.2
Hawaii 2,330 1,930 82.8 1,896 81.4 1,776 76.2 92.0 93.7
Illinois 34,712 25,822 74.4 24,910 71.8 22,449 64.7 86.9 90.1
Indiana 11,440 8,668 75.8 8,198 71.7 7,493 65.5 86.4 91.4
Iowa 2,836 2,432 85.8 2,399 84.6 2,248 79.3 92.4 93.7
Kansasa 3,213 2,584 80.4 2,537 79.0 2,324 72.3 89.9 91.6
Louisiana 20,676 15,905 76.9 15,646 75.7 13,895 67.2 87.4 88.8
Maine 1,635 1,351 82.6 1,322 80.9 1,266 77.4 93.7 95.8
Marylandb 32,715 22,914 70.0 22,407 68.5 20,335 62.2 88.7 90.8
Massachusetts 20,602 15,169 73.6 14,506 70.4 13,685 66.4 90.2 94.3
Michigan 16,352 12,820 78.4 12,426 76.0 11,342 69.4 88.5 91.3
Minnesota 8,771 6,494 74.0 6,276 71.6 5,858 66.8 90.2 93.3
Mississippi 9,326 6,594 70.7 6,047 64.8 5,156 55.3 78.2 85.3
Missouri 12,511 9,497 75.9 9,006 72.0 8,108 64.8 85.4 90.0
Montana 671 573 85.4 559 83.3 517 77.0 90.2 92.5
Nebraska 2,248 1,670 74.3 1,503 66.9 1,357 60.4 81.3 90.3
Nevada 10,656 7,823 73.4 7,415 69.6 6,818 64.0 87.2 91.9
New Hampshire 1,296 1,021 78.8 1,001 77.2 951 73.4 93.1 95.0
New Mexico 3,811 2,942 77.2 2,395 62.8 2,176 57.1 74.0 90.9
New York 123,315 87,926 71.3 86,794 70.4 77,805 63.1 88.5 89.6
North Carolinaa 32,498 24,493 75.4 23,730 73.0 21,291 65.5 86.9 89.7
North Dakota 490 389 79.4 364 74.3 330 67.3 84.8 90.7
Ohio 22,818 16,823 73.7 16,302 71.4 14,775 64.8 87.8 90.6
Oklahoma 6,281 4,421 70.4 4,218 67.2 3,696 58.8 83.6 87.6
Oregon 7,164 6,147 85.8 5,912 82.5 5,597 78.1 91.1 94.7
Rhode Island 2,615 2,050 78.4 1,934 74.0 1,812 69.3 88.4 93.7
South Carolinaa 17,283 14,018 81.1 13,675 79.1 12,434 71.9 88.7 90.9
South Dakota 660 555 84.1 362 54.8 313 47.4 56.4 86.5
Tennessee 17,572 14,176 80.7 13,459 76.6 11,841 67.4 83.5 88.0
Texas 93,839 68,963 73.5 64,872 69.1 56,378 60.1 81.8 86.9
Utah 3,132 2,321 74.1 2,267 72.4 2,142 68.4 92.3 94.5
Virginia 23,425 16,399 70.0 16,035 68.5 14,683 62.7 89.5 91.6
Washington 13,877 11,541 83.2 11,345 81.8 10,697 77.1 92.7 94.3
West Virginia 1,951 1,377 70.6 1,329 68.1 1,175 60.2 85.3 88.4
Wisconsin 6,428 5,125 79.7 5,051 78.6 4,718 73.4 92.1 93.4
Wyoming 342 276 80.7 239 69.9 224 65.5 81.2 93.7
Region of residencec
Northeast (excluding NJ, PA, VT) 159,865 115,591 72.3 113,516 71.0 102,937 64.4 89.1 90.7
Midwest 122,479 92,879 75.8 89,334 72.9 81,315 66.4 87.5 91.0
South (excluding KY) 458,776 339,930 74.1 326,638 71.2 291,036 63.4 85.6 89.1
West (excluding ID) 203,127 151,187 74.4 144,461 71.1 134,366 66.1 88.9 93.0

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage; VL, viral load (copies/mL); CDC, Centers for Disease Control and Prevention [footnotes only].
Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Data are based on address of residence as of December 31, 2020 (i.e., most recent known address). A VL test result of <200 copies/mL indicates HIV viral suppression. VL test results are from the most recent test during 2020. Data for the year 2020 are preliminary and based on death data received by CDC as of December 2021. Data not provided for states and associated counties that do not have laws requiring reporting of all CD4 and viral loads, or that have incomplete reporting of laboratory data to the CDC. Areas without laws: Idaho and New Jersey. Areas with incomplete reporting: Kentucky, Pennsylvania, Vermont, and Puerto Rico.
a Data should be interpreted with caution due to incomplete ascertainment of deaths that occurred during the year 2020.
b Data should be interpreted with caution due to incomplete reporting of case information to CDC during December 2021.
c Data should be interpreted with caution and are based on areas with laws and complete reporting to CDC.

Table 5a. Stage 3 (AIDS) at Time of HIV Diagnosis Among Persons Aged ≥13 Years, by Year of Diagnosis and Selected Characteristics, 2016–2020—United States
2016 2017 2018 2019 2020 (COVID-19 pandemic)
Stage 3 (AIDS) at diagnosisa Stage 3 (AIDS) at diagnosisa Stage 3 (AIDS) at diagnosisa Stage 3 (AIDS) at diagnosisa Stage 3 (AIDS) at diagnosisa
Total No. No. % Total No. No. % Total No. No. % Total No. No. % Total No. No. %
Gender
Male 31,268 6,599 21.1 30,414 6,319 20.8 29,690 6,139 20.7 28,918 5,925 20.5 24,242 5,208 21.5
Female 7,447 1,657 22.3 7,242 1,603 22.1 7,037 1,530 21.7 6,890 1,419 20.6 5,409 1,256 23.2
Transgender womanb 674 92 13.6 612 83 13.6 627 82 13.1 652 90 13.8 638 77 12.1
Transgender manb 22 4 18.2 33 5 15.2 48 2 4.2 45 5 11.1 40 2 5.0
Additional gender identityc 11 3 27.3 15 3 20.0 15 1 6.7 23 0 0.0 17 2 11.8
Age at diagnosis (yr)
13–24 8,656 751 8.7 8,277 742 9.0 7,848 715 9.1 7,638 633 8.3 6,082 553 9.1
25–34 13,588 2,219 16.3 13,395 2,155 16.1 13,384 2,125 15.9 13,075 2,139 16.4 11,258 1,959 17.4
35–44 7,455 2,019 27.1 7,240 1,875 25.9 7,180 1,847 25.7 7,114 1,790 25.2 5,924 1,491 25.2
45–54 5,902 1,965 33.3 5,567 1,880 33.8 5,235 1,744 33.3 4,887 1,553 31.8 3,929 1,372 34.9
≥55 3,821 1,401 36.7 3,837 1,361 35.5 3,770 1,323 35.1 3,814 1,324 34.7 3,153 1,170 37.1
Race/ethnicity
American Indian/Alaska Native 216 50 23.1 200 45 22.5 173 28 16.2 204 27 13.2 200 43 21.5
Asian 923 216 23.4 923 234 25.4 862 225 26.1 733 178 24.3 635 176 27.7
Black/African American 16,723 3,393 20.3 16,223 3,251 20.0 15,736 3,102 19.7 15,471 2,993 19.3 12,824 2,569 20.0
Hispanic/Latinod 10,083 2,195 21.8 9,925 2,098 21.1 9,945 2,143 21.5 9,889 2,093 21.2 7,999 1,821 22.8
Native Hawaiian/other Pacific Islander 38 8 21.1 50 13 26.0 61 13 21.3 66 11 16.7 65 13 20.0
White 9,865 2,188 22.2 9,628 2,099 21.8 9,433 2,023 21.4 9,063 1,913 21.1 7,831 1,758 22.4
Multiracial 1,574 305 19.4 1,367 273 20.0 1,207 220 18.2 1,102 224 20.3 792 165 20.8
Transmission categorye
Male-to-male sexual contact 25,948 4,972 19.2 25,346 4,823 19.0 24,545 4,720 19.2 23,975 4,514 18.8 20,572 4,096 19.9
Injection drug use 2,223 542 24.4 2,378 559 23.5 2,512 545 21.7 2,536 548 21.6 2,033 454 22.3
Male 1,189 328 27.6 1,292 342 26.5 1,407 325 23.1 1,381 343 24.8 1,178 280 23.8
Female 1,034 215 20.8 1,086 217 20.0 1,105 220 19.9 1,154 205 17.8 855 174 20.3
Male-to-male sexual contact and injection drug use 1,539 259 16.8 1,470 215 14.6 1,465 207 14.2 1,524 248 16.3 1,105 187 16.9
Heterosexual contactf 9,631 2,558 26.6 9,033 2,393 26.5 8,805 2,259 25.7 8,400 2,102 25.0 6,549 1,784 27.2
Male 3,251 1,125 34.6 2,902 1,015 35.0 2,877 961 33.4 2,669 895 33.5 2,012 715 35.5
Female 6,380 1,433 22.5 6,131 1,378 22.5 5,928 1,297 21.9 5,730 1,207 21.1 4,536 1,069 23.6
Otherg 80 25 30.4 89 23 25.6 89 23 26.1 94 26 28.2 88 25 28.2
Male 25 11 45.7 31 9 30.2 37 9 24.3 39 15 37.4 29 10 34.0
Female 56 13 23.7 58 13 23.2 53 14 27.5 54 12 21.5 59 15 25.3
Region of residence
Northeast 6,198 1,355 21.9 5,977 1,290 21.6 5,557 1,256 22.6 5,305 1,164 21.9 4,262 961 22.5
Midwest 5,141 1,161 22.6 5,096 1,080 21.2 4,927 1,111 22.5 4,740 992 20.9 4,118 873 21.2
South 20,209 4,278 21.2 19,662 4,160 21.2 19,364 3,899 20.1 19,149 3,848 20.1 15,661 3,365 21.5
West 7,874 1,561 19.8 7,581 1,483 19.6 7,569 1,488 19.7 7,334 1,435 19.6 6,305 1,346 21.3
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 32,145 6,576 20.5 31,220 6,299 20.2 30,428 6,090 20 29,649 5,886 19.9 24,464 5,101 20.9
Metropolitan areas (pop. 50,000–499,999) 4,640 1,104 23.8 4,604 1,069 23.2 4,557 1,046 23.0 4,449 974 21.9 3,799 900 23.7
Nonmetropolitan areas (pop. <50,000) 2,321 630 27.1 2,245 596 26.5 2,324 605 26 2,274 570 25.1 1,939 522 26.9
Total 39,422 8,355 21.2 38,316 8,013 20.9 37,417 7,754 20.7 36,528 7,439 20.4 30,346 6,545 21.6

Abbreviations: pop, population; CD4, CD4+ T-lymphocyte count (cells/µL) or percentage [footnotes only].
Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Data are based on residence at time of diagnosis.
a Based on first CD4 test performed or documentation of an AIDS-defining condition ≤3 months after a diagnosis of HIV infection.
b “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
c Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
d Hispanic/Latino persons can be of any race.
e Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
f Sexual contact with a person known to have, or with a risk factor for, HIV infection.
g Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.

Table 5b. Stage 3 (AIDS) at Time of HIV Diagnosis Among Persons Aged ≥13 Years, by Year of Diagnosis and Selected Characteristics, 2016–2020—United States and 6 Dependent Areas
2016 2017 2018 2019 2020 (COVID-19 pandemic)
Stage 3 (AIDS) at diagnosisa Stage 3 (AIDS) at diagnosisa Stage 3 (AIDS) at diagnosisa Stage 3 (AIDS) at diagnosisa Stage 3 (AIDS) at diagnosisa
Total No. No. % Total No. No. % Total No. No. % Total No. No. % Total No. No. %
Gender
Male 31,710 6,712 21.2 30,778 6,382 20.7 30,058 6,222 20.7 29,247 6,000 20.5 24,488 5,261 21.5
Female 7,552 1,679 22.2 7,336 1,627 22.2 7,117 1,547 21.7 6,971 1,446 20.7 5,450 1,269 23.3
Transgender womanb 677 92 13.6 614 83 13.5 629 82 13.0 654 90 13.8 640 78 12.2
Transgender manb 22 4 18.2 33 5 15.2 49 3 6.1 45 5 11.1 40 2 5.0
Additional gender identityc 11 3 27.3 15 3 20.0 15 1 6.7 23 0 0.0 17 2 11.8
Age at diagnosis (yr)
13–24 8,739 759 8.7 8,355 747 8.9 7,927 720 9.1 7,701 639 8.3 6,135 556 9.1
25–34 13,724 2,237 16.3 13,520 2,173 16.1 13,519 2,143 15.9 13,191 2,162 16.4 11,336 1,968 17.4
35–44 7,582 2,055 27.1 7,327 1,899 25.9 7,255 1,868 25.7 7,192 1,807 25.1 5,985 1,508 25.2
45–54 6,006 2,002 33.3 5,658 1,902 33.6 5,328 1,773 33.3 4,954 1,582 31.9 3,977 1,391 35.0
≥55 3,921 1,437 36.6 3,916 1,379 35.2 3,839 1,351 35.2 3,902 1,351 34.6 3,202 1,189 37.1
Race/ethnicity
American Indian/Alaska Native 216 50 23.1 200 45 22.5 173 28 16.2 204 27 13.2 200 43 21.5
Asian 924 216 23.4 926 236 25.5 866 225 26.0 740 181 24.5 635 176 27.7
Black/African American 16,729 3,395 20.3 16,227 3,252 20.0 15,744 3,103 19.7 15,476 2,996 19.4 12,827 2,569 20.0
Hispanic/Latinod 10,618 2,325 21.9 10,371 2,181 21.0 10,377 2,240 21.6 10,280 2,187 21.3 8,285 1,888 22.8
Native Hawaiian/other Pacific Islander 43 9 20.9 51 13 25.5 63 15 23.8 70 12 17.1 65 13 20.0
White 9,867 2,189 22.2 9,633 2,100 21.8 9,436 2,024 21.4 9,068 1,914 21.1 7,831 1,758 22.4
Multiracial 1,575 306 19.4 1,368 273 20.0 1,209 220 18.2 1,102 224 20.3 792 165 20.8
Transmission categorye
Male-to-male sexual contact 26,244 5,024 19.1 25,580 4,859 19.0 24,810 4,766 19.2 24,204 4,557 18.8 20,758 4,123 19.9
Injection drug use 2,271 561 24.7 2,421 565 23.4 2,537 554 21.8 2,566 559 21.8 2,055 461 22.5
Male 1,225 344 28.1 1,326 349 26.3 1,431 334 23.3 1,406 351 24.9 1,198 288 24.0
Female 1,046 217 20.7 1,095 217 19.8 1,107 220 19.9 1,160 208 18.0 857 174 20.3
Male-to-male sexual contact and injection drug use 1,551 264 17.0 1,483 216 14.6 1,477 214 14.5 1,536 252 16.4 1,109 188 16.9
Heterosexual contactf 9,826 2616 26.6 9,203 2,436 26.5 8,954 2,298 25.7 8,539 2,147 25.1 6,626 1,815 27.4
Male 3,353 1,164 34.7 2,987 1,035 34.6 2,947 983 33.4 2,734 916 33.5 2,051 733 35.7
Female 6,473 1,453 22.4 6,216 1,402 22.6 6,008 1,315 21.9 5,805 1,231 21.2 4,575 1,082 23.7
Otherg 81 25 30.4 89 23 25.5 90 24 26.2 94 27 28.3 88 25.0 28.2
Male 25 11 45.6 31 9 30.1 37 9 24.5 40 15 37.9 29 10 34.0
Female 56 13 23.7 58 13 23.1 53 14 27.5 55 12 21.4 59 15 25.3
Region of residence
Northeast 6,198 1,355 21.9 5,977 1,290 21.6 5,557 1,256 22.6 5,305 1,164 21.9 4,262 961 22.5
Midwest 5,141 1,161 22.6 5,096 1,080 21.2 4,927 1,111 22.5 4,740 992 20.9 4,118 873 21.2
South 20,209 4,278 21.2 19,662 4,160 21.2 19,364 3,899 20.1 19,149 3,848 20.1 15,661 3,365 21.5
West 7,874 1,561 19.8 7,581 1,483 19.6 7,569 1,488 19.7 7,334 1,435 19.6 6,305 1,346 21.3
U.S. dependent areas 550 135 24.5 460 87 18.9 451 101 22.4 412 102 24.8 289 67 23.2
Total 39,972 8,490 21.2 38,776 8,100 20.9 37,868 7,855 20.7 36,940 7,541 20.4 30,635 6,612 21.6

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage [footnotes only].
Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Data are based on residence at time of diagnosis.
a Based on first CD4 test performed or documentation of an AIDS-defining condition ≤3 months after a diagnosis of HIV infection.
b “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
c Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
d Hispanic/Latino persons can be of any race.
e Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
f Sexual contact with a person known to have, or with a risk factor for, HIV infection.
g Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.

Table 5c. Stage 3 (AIDS) at Time of HIV Diagnosis Among Persons Aged ≥13 Years, by Year of Diagnosis and Area of Residence, 2016–2020—United States and 6 Dependent Areas
2016 2017 2018 2019 2020 (COVID-19 pandemic)
Stage 3 (AIDS) at diagnosisa Stage 3 (AIDS) at diagnosisa Stage 3 (AIDS) at diagnosisa Stage 3 (AIDS) at diagnosisa Stage 3 (AIDS) at diagnosisa
Total No. No. % Total No. No. % Total No. No. % Total No. No. % Total No. No. %
Alabama 653 142 21.7 647 141 21.8 604 127 21.0 635 135 21.3 585 127 21.7
Alaska 37 6 16.2 30 7 23.3 23 4 17.4 27 2 7.4 29 3 10.3
Arizona 714 143 20.0 720 135 18.7 752 159 21.1 747 135 18.1 662 148 22.4
Arkansas 314 68 21.7 287 50 17.4 286 60 21.0 289 72 24.9 242 59 24.4
California 5,092 973 19.1 4,839 924 19.1 4,749 883 18.6 4,454 834 18.7 3,924 839 21.4
Colorado 421 84 20.0 434 79 18.2 403 96 23.8 465 101 21.7 324 77 23.8
Connecticut 256 66 25.8 274 65 23.7 259 64 24.7 212 60 28.3 171 42 24.6
Delaware 111 35 31.5 125 32 25.6 91 22 24.2 94 20 21.3 93 25 26.9
District of Columbia 351 58 16.5 316 40 12.7 280 43 15.4 250 37 14.8 197 41 20.8
Florida 4,659 985 21.1 4,558 973 21.3 4,515 926 20.5 4,361 914 21.0 3,408 714 21.0
Georgia 2,523 469 18.6 2,606 569 21.8 2,486 495 19.9 2,407 490 20.4 1,977 433 21.9
Hawaii 76 11 14.5 76 13 17.1 72 15 20.8 64 13 20.3 51 18 35.3
Idaho 46 7 15.2 45 11 24.4 37 15 40.5 33 14 42.4 32 13 40.6
Illinois 1,476 308 20.9 1,372 291 21.2 1,369 275 20.1 1,257 241 19.2 1,096 225 20.5
Indiana 486 108 22.2 515 126 24.5 511 128 25.0 486 100 20.6 433 104 24.0
Iowa 132 32 24.2 125 31 24.8 114 26 22.8 100 22 22.0 100 25 25.0
Kansas 149 34 22.8 120 25 20.8 157 42 26.8 132 26 19.7 138 35 25.4
Kentucky 338 109 32.2 367 88 24.0 378 76 20.1 328 70 21.3 300 63 21.0
Louisiana 1,106 256 23.1 989 226 22.9 957 183 19.1 880 186 21.1 722 162 22.4
Maine 53 12 22.6 29 11 37.9 31 10 32.3 30 11 36.7 16 8 50.0
Marylandb 1,093 227 20.8 1,020 248 24.3 990 202 20.4 915 206 22.5 706 153 21.7
Massachusetts 640 138 21.6 602 124 20.6 648 150 23.1 538 111 20.6 434 100 23.0
Michigan 745 177 23.8 773 154 19.9 719 168 23.4 674 148 22.0 519 96 18.5
Minnesota 297 67 22.6 278 75 27.0 286 68 23.8 273 63 23.1 229 48 21.0
Mississippi 424 119 28.1 429 115 26.8 475 129 27.2 471 120 25.5 402 90 22.4
Missouri 511 119 23.3 505 84 16.6 450 96 21.3 487 89 18.3 359 65 18.1
Montana 20 3 15.0 31 6 19.4 24 5 20.8 25 5 20.0 14 5 35.7
Nebraska 74 18 24.3 87 13 14.9 77 25 32.5 81 21 25.9 73 18 24.7
Nevada 508 114 22.4 497 107 21.5 497 95 19.1 518 120 23.2 392 70 17.9
New Hampshire 39 11 28.2 32 5 15.6 38 10 26.3 31 5 16.1 33 8 24.2
New Jersey 1,184 275 23.2 1,105 240 21.7 1,020 235 23.0 1,083 238 22.0 805 177 22.0
New Mexico 149 32 21.5 148 30 20.3 155 38 24.5 174 28 16.1 131 25 19.1
New York 2,822 567 20.1 2,736 568 20.8 2,449 539 22.0 2,336 494 21.1 1,963 430 21.9
North Carolina 1,384 274 19.8 1,291 264 20.4 1,180 205 17.4 1,365 213 15.6 1,079 225 20.9
North Dakota 46 12 26.1 38 10 26.3 36 5 13.9 40 9 22.5 36 15 41.7
Ohio 954 228 23.9 982 212 21.6 973 225 23.1 965 213 22.1 888 190 21.4
Oklahoma 293 74 25.3 300 63 21.0 278 61 21.9 336 54 16.1 333 72 21.6
Oregon 228 54 23.7 203 49 24.1 229 52 22.7 199 49 24.6 180 28 15.6
Pennsylvania 1,127 264 23.4 1,093 244 22.3 1,018 218 21.4 993 229 23.1 775 184 23.7
Rhode Island 72 19 26.4 86 24 27.9 76 22 28.9 71 14 19.7 53 9 17.0
South Carolina 744 179 24.1 708 179 25.3 725 174 24.0 722 165 22.9 655 162 24.7
South Dakota 42 12 28.6 41 8 19.5 29 7 24.1 33 8 24.2 34 4 11.8
Tennessee 712 115 16.2 721 123 17.1 742 145 19.5 773 134 17.3 647 110 17.0
Texas 4,532 957 21.1 4,356 857 19.7 4,425 859 19.4 4,342 839 19.3 3,548 740 20.9
Utah 139 24 17.3 113 22 19.5 120 17 14.2 135 27 20.0 131 30 22.9
Vermont 5 3 60.0 20 9 45.0 18 8 44.4 11 2 18.2 12 3 25.0
Virginia 904 191 21.1 865 170 19.7 866 171 19.7 833 170 20.4 628 165 26.3
Washington 423 102 24.1 435 96 22.1 496 108 21.8 480 105 21.9 421 88 20.9
West Virginia 68 20 29.4 77 22 28.6 86 21 24.4 148 23 15.5 139 24 17.3
Wisconsin 229 46 20.1 260 51 19.6 206 46 22.3 212 52 24.5 213 48 22.5
Wyoming 21 8 38.1 10 4 40.0 12 1 8.3 13 2 15.4 14 2 14.3
Subtotal 39,422 8,355 21.2 38,316 8,013 20.9 37,417 7,754 20.7 36,528 7,439 20.4 30,346 6,545 21.6
U.S. dependent areas
American Samoa 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
Guam 4 2 50.0 4 2 50.0 7 3 42.9 11 3 27.3 0 0 0.0
Northern Mariana Islands 0 0 0.0 1 0 0.0 1 0 0.0 2 1 50.0 0 0 0.0
Puerto Rico 532 128 24.1 447 84 18.8 431 96 22.3 391 94 24.0 286 67 23.4
Republic of Palau 2 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0 0 0 0.0
U.S. Virgin Islands 12 5 41.7 8 1 12.5 12 2 16.7 8 4 50.0 3 0 0.0
Subtotal 550 135 24.5 460 87 18.9 451 101 22.4 412 102 24.8 289 67 23.2
Total 39,972 8,490 21.2 38,776 8,100 20.9 37,868 7,855 20.7 36,940 7,541 20.4 30,635 6,612 21.6

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage [footnotes only].
Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Data are based on residence at time of diagnosis.
a Based on first CD4 test performed or documentation of an AIDS-defining condition ≤3 months after a diagnosis of HIV infection.
bData should be interpreted with caution due to incomplete reporting of 2020 case information to CDC during December 2021.

Table 5d. Stage 3 (AIDS) at time of HIV diagnosis among persons aged ≥13 years, by race/ethnicity and area of residence, 2020 (COVID-19 pandemic)—United States
Black/African American Hispanic/Latinoa White Otherb
Stage 3 (AIDS) at diagnosisc Stage 3 (AIDS) at diagnosisc Stage 3 (AIDS) at diagnosisc Stage 3 (AIDS) at diagnosisc
Total No. No. % Total No. No. % Total No. No. % Total No. No. %
Alabama 402 80 19.9 28 7 25.0 140 36 25.7 15 4 26.7
Alaska 1 0 0.0 4 2 50.0 9 1 11.1 15 0 0.0
Arizona 96 18 18.8 265 61 23.0 236 51 21.6 65 18 27.7
Arkansas 113 29 25.7 24 4 16.7 101 26 25.7 4 0 0.0
California 682 121 17.7 1,966 451 22.9 946 176 18.6 330 91 27.6
Colorado 62 15 24.2 103 28 27.2 146 32 21.9 13 2 15.4
Connecticut 55 16 29.1 59 7 11.9 52 17 32.7 5 2 40.0
Delaware 50 15 30.0 13 3 23.1 27 7 25.9 3 0 0.0
District of Columbia 141 28 19.9 22 3 13.6 27 6 22.2 7 4 57.1
Florida 1,367 293 21.4 1,171 241 20.6 783 162 20.7 87 18 20.7
Georgia 1,438 304 21.1 178 41 23.0 319 75 23.5 42 13 31.0
Hawaii 1 1 100 7 2 28.6 12 5 41.7 31 10 32.3
Idaho 2 0 0.0 8 7 87.5 20 5 25.0 2 1 50.0
Illinois 571 104 18.2 235 56 23.8 220 49 22.3 70 16 22.9
Indiana 177 33 18.6 51 19 37.3 185 47 25.4 20 5 25.0
Iowa 25 8 32.0 5 1 20.0 56 16 28.6 14 0 0.0
Kansas 41 14 34.1 21 3 14.3 70 17 24.3 6 1 16.7
Kentucky 66 13 19.7 28 6 21.4 183 38 20.8 23 6 26.1
Louisiana 505 98 19.4 62 21 33.9 144 41 28.5 11 2 18.2
Maine 4 2 50.0 0 0 0.0 12 6 50.0 0 0 0.0
Marylandd 501 98 19.6 86 23 26.7 85 24 28.2 34 8 23.5
Massachusetts 136 38 27.9 115 22 19.1 168 36 21.4 15 4 26.7
Michigan 320 48 15.0 38 10 26.3 141 35 24.8 20 3 15.0
Minnesota 97 24 24.7 34 7 20.6 72 14 19.4 26 3 11.5
Mississippi 303 66 21.8 11 3 27.3 78 20 25.6 10 1 10.0
Missouri 157 23 14.6 29 7 24.1 158 33 20.9 15 2 13.3
Montana 0 0 0.0 1 1 100 13 4 30.8 0 0 0.0
Nebraska 17 4 23.5 20 6 30.0 31 8 25.8 5 0 0.0
Nevada 122 17 13.9 122 22 18.0 121 23 19.0 27 8 29.6
New Hampshire 1 0 0.0 4 1 25.0 25 5 20.0 3 2 66.7
New Jersey 310 59 19.0 331 73 22.1 132 35 26.5 32 10 31.3
New Mexico 4 0 0.0 69 11 15.9 25 6 24.0 33 8 24.2
New York 824 177 21.5 675 147 21.8 319 73 22.9 145 33 22.8
North Carolina 626 113 18.1 142 45 31.7 256 61 23.8 55 6 10.9
North Dakota 12 5 41.7 4 0 0.0 12 6 50.0 8 4 50.0
Ohio 468 81 17.3 33 8 24.2 353 91 25.8 34 10 29.4
Oklahoma 81 19 23.5 51 11 21.6 140 32 22.9 61 10 16.4
Oregon 12 2 16.7 42 6 14.3 108 17 15.7 18 3 16.7
Pennsylvania 376 76 20.2 132 25 18.9 231 74 32.0 36 9 25.0
Rhode Island 9 1 11.1 19 3 15.8 23 4 17.4 2 1 50.0
South Carolina 405 96 23.7 52 21 40.4 158 35 22.2 40 10 25.0
South Dakota 7 1 14.3 4 2 50.0 15 1 6.7 8 0 0.0
Tennessee 378 59 15.6 46 14 30.4 199 36 18.1 24 1 4.2
Texas 1,265 214 16.9 1,448 334 23.1 676 144 21.3 159 48 30.2
Utah 5 2 40.0 49 13 26.5 62 13 21.0 15 2 13.3
Vermont 1 0 0.0 2 1 50.0 9 2 22.2 0 0 0.0
Virginia 413 109 26.4 68 18 26.5 124 36 29.0 23 2 8.7
Washington 82 19 23.2 75 13 17.3 202 42 20.8 62 14 22.6
West Virginia 10 3 30.0 5 2 40.0 116 17 14.7 8 2 25.0
Wisconsin 81 23 28.4 40 9 22.5 82 16 19.5 10 0 0.0
Wyoming 2 0 0.0 2 0 0.0 9 2 22.2 1 0 0.0
Total 12,824 2,569 20.0 7,999 1,821 22.8 7,831 1,758 22.4 1,692 397 23.5
Region of residence
Northeast 1,716 369 21.5 1,337 279 20.9 971 252 26.0 238 61 25.6
Midwest 1,973 368 18.7 514 128 24.9 1,395 333 23.9 236 44 18.6
South 8,064 1,637 20.3 3,435 797 23.2 3,556 796 22.4 606 135 22.3
West 1,071 195 18.2 2,713 617 22.7 1,909 377 19.7 612 157 25.7

Abbreviations: CD4, CD4+ T-lymphocyte count (cells/µL) or percentage [footnotes only].
Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Data are based on residence at time of diagnosis.
a Hispanic/Latino persons can be of any race.
b Includes American Indian/Alaska Native, Asian, Native Hawaiian/other Pacific Islander, and Multiracial persons.
c Based on first CD4 test performed or documentation of an AIDS-defining condition ≤3 months after a diagnosis of HIV infection.
d Data should be interpreted with caution due to incomplete reporting of case information to CDC during December 2021.

Table 6a. Deaths of Persons Aged ≥13 Years with Diagnosed HIV Infection, by Year of Death and Selected Characteristics, 2016–2020—United States
2016 2017 2018 2019 2020 (COVID-19 pandemic)
No. Rate per 100,000 population Rate per 1,000 PWDHa No. Rate per 100,000 population Rate per 1,000 PWDHa No. Rate per 100,000 population Rate per 1,000 PWDHa No. Rate per 100,000 population Rate per 1,000 PWDHa No. Rate per 100,000 population Rate per 1,000 PWDHa
Gender
Male 12,223 – 16.5 12,243 – 16.1 12,103 – 15.5 12,250 – 15.3 13,528 – 16.7
Female 4,025 – 17.2 3,994 – 16.8 3,983 – 16.5 3,830 – 15.6 4,435 – 17.9
Transgender womanb 120 – 12.0 106 – 10.1 117 – 10.6 144 – 12.4 188 – 15.5
Transgender manb 2 – 5.5 5 – 12.7 5 – 11.3 5 – 10.4 9 – 17.4
Additional gender identityc 1 – 6.0 2 – 10.8 1 – 4.9 1 – 4.4 – – –
Age at death (yr)
13–24 166 0.3 3.7 151 0.3 3.5 130 0.3 3.1 133 0.3 3.3 145 0.3 3.9
25–34 1,100 2.5 7.1 1,046 2.3 6.5 1,033 2.3 6.2 1,095 2.4 6.4 1,182 2.6 6.8
35–44 1,968 4.9 10.1 1,834 4.5 9.4 1,771 4.3 9.1 1,787 4.3 9.0 1,967 4.7 9.9
45–54 4,650 10.9 14.8 4,469 10.6 14.5 4,182 10.1 14.1 3,625 8.9 12.7 3,635 9.0 13.4
≥55 8,487 9.4 30.5 8,850 9.6 29.0 9,093 9.6 27.3 9,590 9.9 26.5 11,231 11.5 28.8
Race/ethnicity
American Indian/Alaska Native 47 2.4 17.2 47 2.4 16.3 48 2.4 15.9 58 2.9 18.3 78 3.9 23.5
Asiand 100 0.7 7.7 88 0.6 6.3 84 0.5 5.7 101 0.6 6.5 97 0.6 6.0
Black/African American 7,232 21.9 18.0 7,198 21.6 17.5 6,983 20.7 16.6 6,992 20.6 16.2 7,928 23.1 18.1
Hispanic/Latinoe 2,632 6.0 12.0 2,694 6.0 11.8 2,840 6.2 12.1 2,740 5.8 11.3 3,245 6.8 13.0
Native Hawaiian/other Pacific Islander 14 3.0 18.7 9 1.9 11.5 13 2.7 15.5 14 2.8 15.7 10 2.0 10.6
White 5,310 3.1 18.0 5,238 3.1 17.5 5,151 3.0 16.9 5,234 3.1 17.0 5,512 3.2 17.7
Multiracial 1,033 23.5 19.4 1,074 23.6 20.0 1,090 23.2 20.3 1,087 22.4 20.2 1,290 25.7 24.1
Transmission categoryf
Male-to-male sexual contact 6,889 – 12.8 6,992 – 12.6 6,892 – 12.0 7,177 – 12.1 7,801 – 12.8
Injection drug use 3,660 – 30.1 3,551 – 29.4 3,496 – 29.2 3,374 – 28.3 3,751 – 31.8
Male 2,270 – 31.9 2,170 – 30.9 2,173 – 31.2 2,071 – 30.0 2,327 – 34.1
Female 1,390 – 27.5 1,381 – 27.4 1,323 – 26.4 1,304 – 26.1 1,425 – 28.7
Male-to-male sexual contact and injection drug use 1,391 – 23.8 1,372 – 23.5 1,444 – 24.6 1,366 – 23.3 1,595 – 27.3
Heterosexual contactg 4,252 – 16.7 4,256 – 16.3 4,205 – 15.8 4,154 – 15.4 4,811 – 17.6
Male 1,690 – 21.7 1,709 – 21.6 1,602 – 19.9 1,685 – 20.7 1,873 – 22.9
Female 2,562 – 14.5 2,547 – 14.1 2,603 – 14.1 2,469 – 13.1 2,939 – 15.4
Otherh 178 – 12.4 179 – 12.2 171 – 11.4 158 – 10.4 201 – 12.9
Male 103 – 13.8 108 – 14.2 108 – 14.0 96 – 12.3 120 – 15.2
Female 75 – 10.8 71 – 10.0 63 – 8.7 62 – 8.3 81 – 10.5
Region of residence
Northeast 3,709 7.8 15.9 3,699 7.7 15.7 3,528 7.4 14.9 3,632 7.6 15.2 4,424 9.3 18.5
Midwest 1,857 3.3 15.9 1,915 3.4 15.9 2,004 3.5 16.2 1,938 3.4 15.3 2,230 3.9 17.3
South 8,049 7.9 18.2 7,996 7.8 17.5 7,870 7.6 16.8 7,893 7.5 16.4 8,607 8.1 17.6
West 2,756 4.3 14.2 2,740 4.3 13.8 2,807 4.3 13.7 2,767 4.2 13.2 2,899 4.4 13.6
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 10,289 5.6 12.9 10,400 5.6 12.6 10,159 5.4 12.1 10,639 5.6 12.3 12,411 6.5 14.2
Metropolitan areas (pop. 50,000–499,999) 1,350 2.9 14.2 1,521 3.2 15.5 1,494 3.1 14.7 1,601 3.3 15.1 1,671 3.5 15.4
Nonmetropolitan areas (pop. <50,000) 896 2.3 16.7 954 2.5 17.2 869 2.3 15.3 939 2.4 16.0 1,075 2.8 18.0
Totali 16,371 6.1 16.6 16,350 6.0 16.2 16,209 5.9 15.7 16,230 5.9 15.4 18,160 6.5 16.9

Abbreviations: pop, population; PWDH, persons with diagnosed HIV infection; CDC, Centers for Disease Control and Prevention [footnotes only].
Note. Deaths of persons with diagnosed HIV infection may be due to any cause. Data are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Data for the year 2020 are preliminary and based on death data received by CDC as of December 2021.
a Denominator was calculated as (No. PWDH at the end of [year X-1]) + (No. new diagnoses during year X).
b “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
c Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
d Includes Asian/Pacific Islander legacy cases (see Technical Notes).
e Hispanic/Latino persons can be of any race.
f Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
g Sexual contact with a person known to have, or with a risk factor for, HIV infection.
h Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
i Includes persons of unknown race/ethnicity.

Table 6b. Deaths of Persons Aged ≥13 Years with Diagnosed HIV Infection, by Year of Death and Selected Characteristics, 2016–2020—United States and 6 Dependent Areas
2016 2017 2018 2019 2020 (COVID-19 pandemic)
No. Rate per 100,000 population Rate per 1,000 PWDHa No. Rate per 100,000 population Rate per 1,000 PWDHa No. Rate per 100,000 population Rate per 1,000 PWDHa No. Rate per 100,000 population Rate per 1,000 PWDHa No. Rate per 100,000 population Rate per 1,000 PWDHa
Gender
Male 12,548 – 16.6 12,544 – 16.2 12,395 – 15.6 12,524 – 15.5 13,774 – 16.7
Female 4,121 – 17.2 4,102 – 16.9 4,059 – 16.4 3,913 – 15.6 4,517 – 17.9
Transgender womanb 120 – 12.0 108 – 10.3 118 – 10.7 146 – 12.5 189 – 15.5
Transgender manb 2 – 5.5 5 – 12.7 5 – 11.3 5 – 10.3 9 – 17.3
Additional gender identityc 1 – 6.0 2 – 10.8 1 – 4.9 1 – 4.4 0 – 0.0
Age at death (yr)
13–24 171 0.3 3.7 153 0.3 3.5 134 0.3 3.2 135 0.3 3.4 145 0.3 3.9
25–34 1,115 2.5 7.1 1,067 2.3 6.5 1,053 2.3 6.2 1,113 2.4 6.4 1,188 2.6 6.8
35–44 2,031 5.0 10.2 1,884 4.6 9.6 1,820 4.4 9.2 1,842 4.4 9.2 2,015 4.7 10.0
45–54 4,774 11.0 15.0 4,598 10.8 14.7 4,271 10.2 14.1 3,736 9.0 12.9 3,706 9.1 13.4
≥55 8,701 9.5 30.6 9,059 9.7 29.1 9,300 9.7 27.4 9,763 10.0 26.5 11,435 11.5 28.8
Race/ethnicity
American Indian/Alaska Native 47 – 17.2 47 – 16.3 48 – 15.9 58 – 18.3 78 – 23.5
Asiand 100 – 7.7 88 – 6.3 84 – 5.7 101 – 6.5 97 – 6.0
Black/African American 7,242 – 18.0 7,203 – 17.5 6,983 – 16.6 6,993 – 16.2 7,930 – 18.1
Hispanic/Latinoe 3,039 – 12.9 3,099 – 12.7 3,203 – 12.7 3,091 – 11.9 3,570 – 13.5
Native Hawaiian/other Pacific Islander 16 – 20.5 9 – 11.1 16 – 18.4 16 – 17.3 10 – 10.3
White 5,311 – 18.0 5,239 – 17.5 5,152 – 16.9 5,236 – 17.0 5,514 – 17.7
Multiracial 1,034 – 19.4 1,074 – 20.0 1,092 – 20.3 1,090 – 20.2 1,290 – 24.1
Transmission categoryf
Male-to-male sexual contact 6,968 – 12.8 7,063 – 12.6 6,972 – 12.0 7,250 – 12.1 7,874 – 12.9
Injection drug use 3,828 – 30.2 3,718 – 29.7 3,651 – 29.4 3,526 – 28.6 3,874 – 31.7
Male 2,403 – 32.1 2,302 – 31.1 2,295 – 31.4 2,191 – 30.3 2,424 – 33.9
Female 1,425 – 27.6 1,416 – 27.5 1,356 – 26.5 1,335 – 26.2 1,450 – 28.7
Male-to-male sexual contact and injection drug use 1,423 – 24.0 1,396 – 23.5 1,467 – 24.7 1,390 – 23.4 1,621 – 27.4
Heterosexual contactg 4,386 – 16.8 4,402 – 16.5 4,308 – 15.9 4,261 – 15.4 4,918 – 17.6
Male 1,766 – 22.0 1,783 – 21.9 1,664 – 20.1 1,742 – 20.8 1,922 – 22.8
Female 2,620 – 14.5 2,619 – 14.1 2,644 – 14.0 2,519 – 13.1 2,995 – 15.4
Otherh 187 – 12.7 181 – 12.1 180 – 11.8 163 – 10.5 202 – 12.7
Male 109 – 14.2 109 – 14.0 115 – 14.6 98 – 12.4 121 – 15.1
Female 78 – 11.1 72 – 10.0 65 – 8.8 64 – 8.5 81 – 10.4
Region of residence
Northeast 3,709 7.8 15.9 3,699 7.7 15.7 3,528 7.4 14.9 3,632 7.6 15.2 4,424 9.3 18.5
Midwest 1,857 3.3 15.9 1,915 3.4 15.9 2,004 3.5 16.2 1,938 3.4 15.3 2,230 3.9 17.3
South 8,049 7.9 18.2 7,996 7.8 17.5 7,870 7.6 16.8 7,893 7.5 16.4 8,607 8.1 17.6
West 2,756 4.3 14.2 2,740 4.3 13.8 2,807 4.3 13.7 2,767 4.2 13.2 2,899 4.4 13.6
U.S. dependent areas 421 13.0 24.4 411 12.9 24.3 369 11.9 22.0 359 11.5 21.3 329 10.6 19.6
Totali 16,792 6.1 16.7 16,761 6.1 16.3 16,578 6.0 15.8 16,589 5.9 15.5 18,489 6.6 17.0

Abbreviations: PWDH, persons with diagnosed HIV infection; CDC, Centers for Disease Control and Prevention [footnotes only].
Note. Deaths of persons with diagnosed HIV infection may be due to any cause. Data are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Data for the year 2020 are preliminary and based on death data received by CDC as of December 2021.
a Denominator was calculated as (No. PWDH at the end of [year X-1]) + (No. new diagnoses during year X).
b “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
c Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
d Includes Asian/Pacific Islander legacy cases (see Technical Notes).
e Hispanic/Latino persons can be of any race.
f Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
g Sexual contact with a person known to have, or with a risk factor for, HIV infection.
h Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
i Includes persons of unknown race/ethnicity.

Table 6c. Deaths of Persons Aged ≥13 Years with Diagnosed HIV Infection, by Year of Death and Area of Residence, 2016–2020—United States and 6 Dependent Areas
2016 2017 2018 2019 2020 (COVID-19 pandemic)
No. Rate per 100,000 population Age-adjusted rate per 100,000 pop Rate per 1,000 PWDHa Age-adjusted rate per 1,000 PWDH No. Rate per 100,000 population Age-adjusted rate per 100,000 pop Rate per 1,000 PWDHa Age-adjusted rate per 1,000 PWDH No. Rate per 100,000 population Age-adjusted rate per 100,000 pop Rate per 1,000 PWDHa Age-adjusted rate per 1,000 PWDH No. Rate per 100,000 population Age-adjusted rate per 100,000 pop Rate per 1,000 PWDHa Age-adjusted rate per 1,000 PWDH No. Rate per 100,000 population Age-adjusted rate per 100,000 pop Rate per 1,000 PWDHa Age-adjusted rate per 1,000 PWDH
Alabama 258 6.3 6.0 20.3 19.3 261 6.4 6.3 19.7 18.1 234 5.7 5.4 17.1 15.3 272 6.6 6.2 19.3 16.8 268 6.5 6.1 18.6 16.7
Alaska 12 2.0 1.9 17.1 16.2 7 1.2 1.2 9.7 8.5 9 1.5 1.4 12.6 9.3 12 2.0 2.0 16.3 13.3 17 2.8 2.7 22.8 18.1
Arizona 243 4.2 4.1 15.7 13.6 248 4.2 4.0 15.5 13.7 251 4.2 4.0 15.1 12.7 234 3.8 3.7 13.5 11.4 280 4.5 4.2 15.6 13.0
Arkansas 98 3.9 3.8 18.0 16.3 105 4.2 4.1 18.6 16.8 83 3.3 3.4 14.4 12.8 107 4.2 4.1 17.8 16.8 106 4.2 3.9 17.2 15.8
California 1,771 5.4 5.2 14.0 11.8 1,726 5.3 5.0 13.3 11.1 1,732 5.3 4.9 13.1 10.6 1,764 5.3 5.0 13.1 10.8 1,783 5.4 4.9 13.1 10.3
Colorado 128 2.8 2.7 10.7 8.5 132 2.8 2.7 10.7 8.4 143 3.0 2.9 11.2 8.5 130 2.7 2.6 9.9 8.4 166 3.4 3.2 12.4 9.7
Connecticut 199 6.5 5.7 19.3 13.8 199 6.5 5.4 18.9 15.1 182 5.9 5.0 17.1 11.7 204 6.7 5.5 18.9 12.8 212 6.9 5.8 19.7 13.0
Delaware 56 7.0 6.1 17.6 16.6 67 8.3 7.0 20.1 13.8 68 8.3 7.1 20.3 14.9 77 9.3 8.6 22.4 17.7 62 7.4 6.2 17.7 14.5
District of Columbia 234 39.5 43.1 16.2 13.5 233 38.9 41.1 16.2 13.2 202 33.5 36.6 14.2 11.5 201 33.1 35.3 14.1 10.9 272 44.6 46.2 19.3 13.8
Florida 2,127 12.0 11.0 19.6 16.8 2,045 11.4 10.1 18.4 15.0 1,938 10.6 9.4 17.2 13.6 1,989 10.8 9.3 17.3 13.7 2,207 11.8 10.2 18.9 14.7
Georgia 850 10.0 9.7 16.5 15.8 840 9.7 9.4 15.7 14.8 862 9.9 9.5 15.5 14.3 837 9.5 9.0 14.6 13.2 895 10.0 9.5 15.3 13.7
Hawaii 38 3.2 2.9 15.5 11.1 37 3.1 2.9 15.2 15.6 36 3.0 2.6 15.1 10.4 44 3.7 3.1 18.3 13.0 35 2.9 2.5 14.5 14.4
Idaho 12 0.9 0.8 11.1 10.3 20 1.4 1.4 17.6 13.8 15 1.0 1.1 12.7 8.8 11 0.7 0.7 8.8 6.2 19 1.3 1.1 14.8 10.0
Illinois 529 4.9 4.7 15.2 13.9 507 4.7 4.4 14.4 13.2 558 5.2 4.8 15.5 13.7 548 5.1 4.7 15.1 13.2 699 6.6 5.9 19.2 16.3
Indiana 200 3.6 3.5 18.4 17.0 210 3.8 3.7 18.7 16.8 195 3.5 3.4 16.9 15.0 164 2.9 2.8 14.0 11.8 206 3.7 3.4 17.1 14.1
Iowa 33 1.3 1.2 12.9 11.0 44 1.7 1.7 16.3 13.2 50 1.9 1.8 17.7 14.1 61 2.3 2.0 20.8 17.0 59 2.2 2.1 19.7 16.1
Kansasb 51 2.1 2.1 17.2 14.9 47 2.0 1.9 15.5 14.3 51 2.1 2.0 16.3 14.8 38 1.6 1.5 11.9 10.8 32 1.3 1.2 9.5 7.5
Kentucky 122 3.3 3.2 17.7 15.7 139 3.7 3.5 19.4 16.7 136 3.6 3.5 18.3 15.9 110 2.9 2.7 14.3 12.8 158 4.2 4.1 19.6 17.3
Louisiana 417 10.8 10.8 20.7 19.4 411 10.6 10.5 19.9 18.7 429 11.1 10.8 20.3 18.3 379 9.8 9.7 17.6 15.9 457 11.8 11.5 20.9 19.1
Maine 23 2.0 1.8 15.0 10.1 34 2.9 2.3 21.3 14.9 20 1.7 1.5 12.3 8.4 41 3.5 3.0 24.3 17.8 26 2.2 1.8 15.4 9.5
Marylandc 649 12.9 11.8 19.8 16.9 601 11.9 10.8 18.1 14.9 632 12.4 11.1 18.7 15.2 608 11.9 10.6 17.9 14.2 642 12.6 11.2 18.9 15.0
Massachusetts 293 5.0 4.4 14.5 10.5 306 5.2 4.6 14.8 11.6 306 5.2 4.6 14.6 10.9 299 5.0 4.5 14.1 10.8 311 5.2 4.5 14.6 10.2
Michigan 288 3.4 3.2 18.6 17.3 277 3.3 3.1 17.4 15.8 313 3.7 3.3 19.2 17.2 278 3.3 3.0 16.5 14.5 350 4.1 3.7 20.3 17.4
Minnesota 74 1.6 1.5 9.2 9.1 91 2.0 1.9 10.9 9.4 87 1.9 1.8 10.1 8.0 83 1.8 1.7 9.4 8.3 94 2.0 1.7 10.3 8.9
Mississippi 208 8.4 8.2 22.5 21.6 219 8.8 8.8 23.2 21.4 228 9.2 9.1 23.7 21.1 190 7.7 7.6 19.2 17.3 240 9.7 9.0 24.1 21.1
Missouri 196 3.8 3.6 16.2 14.7 214 4.2 4.1 17.2 14.7 234 4.6 4.3 18.3 15.6 230 4.5 4.2 17.7 16.2 243 4.7 4.3 18.6 15.7
Montana 17 1.9 1.9 28.7 20.5 15 1.7 1.7 23.8 21.1 13 1.5 1.4 20.0 16.3 13 1.4 1.4 19.3 15.1 9 1.0 1.1 12.9 9.1
Nebraska 29 1.9 1.8 14.0 13.9 33 2.1 2.0 15.4 14.5 31 2.0 1.8 14.2 12.9 33 2.1 2.1 14.7 11.6 25 1.6 1.6 10.7 8.6
Nevada 150 6.2 5.9 16.7 15.5 175 7.1 6.6 18.1 16.3 160 6.3 5.9 15.6 13.6 155 6.0 5.8 14.3 13.5 172 6.5 6.0 15.3 13.0
New Hampshire 20 1.7 1.8 17.1 13.8 21 1.8 1.6 17.6 13.8 18 1.5 1.4 14.3 15.5 17 1.4 1.3 12.9 8.3 12 1.0 0.9 9.0 7.1
New Jersey 645 8.6 7.6 18.6 14.5 645 8.6 7.5 18.4 13.9 637 8.5 7.3 18.1 13.7 624 8.3 7.0 17.5 12.6 717 9.5 8.1 20.0 14.6
New Mexico 48 2.8 2.5 14.4 12.4 62 3.6 3.3 17.8 13.5 75 4.3 4.2 20.2 16.0 56 3.2 3.0 14.5 11.3 78 4.4 4.0 19.5 14.8
New York 1,868 11.2 10.1 14.8 11.8 1,802 10.8 9.6 14.2 10.8 1,738 10.5 9.2 13.6 10.1 1,795 10.8 9.4 14.0 10.3 2,397 14.6 12.4 18.8 13.6
North Carolinab 523 6.1 5.8 17.3 15.8 553 6.4 5.9 17.7 15.4 533 6.1 5.5 16.6 13.8 509 5.7 5.3 15.2 12.5 563 6.3 5.6 16.5 13.8
North Dakota 5 0.8 0.9 13.3 9.0 3 0.5 0.4 7.3 8.7 8 1.3 1.3 17.5 24.1 5 0.8 0.8 10.0 10.1 5 0.8 0.8 9.5 8.4
Ohio 354 3.6 3.5 16.6 14.9 379 3.9 3.7 17.1 15.6 373 3.8 3.6 16.4 14.1 399 4.0 3.8 16.9 15.0 414 4.2 3.9 17.2 14.7
Oklahoma 119 3.7 3.6 20.0 18.4 108 3.3 3.4 17.7 16.8 117 3.6 3.4 18.7 17.2 142 4.3 4.2 21.8 19.4 155 4.7 4.4 22.9 19.7
Oregon 104 3.0 2.8 15.4 12.8 116 3.3 3.0 16.7 12.5 106 3.0 2.7 14.8 12.6 127 3.5 3.3 17.2 13.3 120 3.3 2.9 16.1 12.2
Pennsylvania 611 5.6 5.1 17.0 14.4 646 5.9 5.4 18.0 14.6 575 5.3 4.7 15.8 12.5 602 5.5 4.9 16.3 12.7 690 6.3 5.5 18.5 14.7
Rhode Island 39 4.3 3.7 16.0 11.8 34 3.7 3.3 13.2 9.8 41 4.5 4.0 15.6 10.9 40 4.4 3.5 14.8 10.9 48 5.2 4.4 17.7 11.6
South Carolinab 342 8.2 7.7 21.0 18.6 338 8.0 7.2 20.2 17.7 316 7.4 6.9 18.4 15.6 314 7.2 6.5 17.7 15.2 234 5.3 4.7 12.9 10.5
South Dakota 11 1.6 1.5 20.1 19.4 9 1.3 1.3 15.4 12.5 13 1.8 1.9 20.8 16.3 11 1.5 1.7 16.7 13.7 5 0.7 0.8 7.2 5.4
Tennessee 330 5.9 5.6 20.1 19.0 334 5.9 5.6 19.8 18.4 359 6.3 6.0 20.5 18.3 314 5.5 5.2 17.5 15.0 423 7.3 6.9 22.7 20.4
Texas 1,359 6.0 6.1 15.8 15.5 1,414 6.2 6.2 15.8 15.1 1,379 5.9 5.9 14.8 14.0 1,467 6.2 6.2 15.2 13.9 1,540 6.4 6.3 15.6 14.0
Utah 50 2.1 2.3 18.2 17.3 22 0.9 1.0 7.9 8.4 46 1.9 2.1 15.4 13.6 37 1.5 1.5 11.9 9.9 29 1.1 1.2 8.8 7.0
Vermontb 11 2.0 1.5 16.7 10.7 12 2.2 1.9 17.3 11.5 11 2.0 1.5 15.4 9.4 10 1.8 1.6 13.8 9.0 11 2.0 1.9 15.1 12.8
Virginia 317 4.5 4.2 14.5 12.7 297 4.2 3.8 13.2 10.9 307 4.3 4.0 13.2 11.3 330 4.6 4.1 13.8 11.1 334 4.6 4.2 13.7 10.9
Washington 178 2.9 2.7 13.9 12.9 175 2.8 2.6 13.2 10.4 214 3.4 3.1 15.6 12.1 179 2.8 2.6 12.7 10.3 184 2.8 2.7 12.7 11.3
West Virginia 40 2.6 2.4 22.5 21.1 31 2.0 1.8 17.0 13.9 47 3.0 2.8 24.3 21.1 47 3.1 2.8 23.1 18.0 51 3.3 3.3 23.8 20.2
Wisconsin 87 1.8 1.6 14.5 11.9 101 2.1 1.9 16.2 12.8 91 1.9 1.7 14.3 12.1 88 1.8 1.6 13.4 10.7 98 2.0 1.8 14.5 10.9
Wyoming 5 1.0 1.1 16.0 12.0 5 1.0 0.9 15.2 25.3 7 1.5 1.4 19.7 15.6 5 1.0 0.8 14.3 10.5 7 1.4 1.3 19.3 15.2
Subtotal 16,371 6.1 5.7 16.6 14.4 16,350 6.0 5.6 16.2 13.7 16,209 5.9 5.5 15.7 13.0 16,230 5.9 5.4 15.4 12.6 18,160 6.5 5.9 16.9 13.7
U.S. dependent area
American Samoa 0 0.0 0.0 0.0 0.0 0 0.0 0.0 0.0 0.0 0 0.0 0.0 0.0 0.0 2 5.5 6.6 666.7 365.5 0 0.0 0.0 0.0 0.0
Guamb 3 2.4 2.9 32.3 31.9 0 0.0 0.0 0.0 0.0 4 3.1 3.7 38.5 39.2 4 3.1 3.2 35.7 25.7 0 0.0 0.0 0.0 0.0
Northern Mariana Islands 0 0.0 0.0 0.0 0.0 0 0.0 0.0 0.0 0.0 0 0.0 0.0 0.0 0.0 0 0.0 0.0 0.0 0.0 0 0.0 0.0 0.0 0.0
Puerto Ricob 406 13.8 13.1 24.5 19.8 405 14.0 13.1 24.9 19.4 361 12.9 11.7 22.4 18.7 353 12.6 12.0 21.8 17.4 323 11.5 10.3 20.0 14.2
Republic of Palau 0 0.0 0.0 0.0 0.0 0 0.0 0.0 0.0 0.0 0 0.0 0.0 0.0 0.0 0 0.0 0.0 0.0 0.0 1 5.5 6.0 100 87.5
U.S. Virgin Islands 12 13.6 11.0 21.9 49.5 6 6.8 6.5 11.4 8.7 4 4.5 3.1 7.5 4.8 0 0.0 0.0 0.0 0.0 5 5.7 4.5 9.4 6.7
Subtotal 421 13.0 12.3 24.4 20.4 411 12.9 12.0 24.3 18.9 369 11.9 10.8 22.0 18.4 359 11.5 11.0 21.3 17.0 329 10.6 9.4 19.6 13.9
Total 16,792 6.1 5.8 16.7 14.5 16,761 6.1 5.7 16.3 13.8 16,578 6.0 5.5 15.8 13.1 16,589 5.9 5.4 15.5 12.7 18,489 6.6 6.0 17.0 13.7

Abbreviations: PWDH, persons with diagnosed HIV infection; pop, population; CDC, Centers for Disease Control and Prevention [footnotes only].
Note. Deaths of persons with diagnosed HIV infection may be due to any cause. Data are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Data for the year 2020 are preliminary and based on death data received by CDC as of December 2021.
a Denominator was calculated as (No. PWDH at the end of [year X-1]) + (No. new diagnoses during year X).
b Data should be interpreted with caution due to incomplete ascertainment of deaths that occurred during the year 2020.
c Data should be interpreted with caution due to incomplete reporting of case information to CDC during December 2021.

Table 6d. Deaths of Persons Aged ≥13 Years with Diagnosed HIV Infection Ever Classified as Stage 3 (AIDS), by Year of Death and Selected Characteristics, 2016–2020—United States
2016 2017 2018 2019 2020 (COVID-19 pandemic)
No. Rate per 100,000 population Rate per 1,000 PWAa No. Rate per 100,000 population Rate per 1,000 PWAa No. Rate per 100,000 population Rate per 1,000 PWAa No. Rate per 100,000 population Rate per 1,000 PWAa No. Rate per 100,000 population Rate per 1,000 PWAa
Gender
Male 9,703 – 24.3 9,659 – 24.0 9,445 – 23.3 9,413 – 23.0 10,386 – 25.3
Female 3,167 – 25.2 3,093 – 24.4 3,113 – 24.3 2,919 – 22.7 3,345 – 25.9
Transgender womanb 99 – 20.8 75 – 15.3 88 – 17.3 104 – 19.9 139 – 26.1
Transgender manb 1 – 6.2 4 – 23.8 2 – 11.6 3 – 16.6 5 – 27.5
Additional gender identityc 1 – 15.9 2 – 28.2 1 – 13.7 1 – 13.9 0 – 0.0
Age at death (yr)
13–24 95 0.2 10.2 89 0.2 10.8 77 0.2 10.5 70 0.1 10.9 70 0.1 12.5
25–34 771 1.7 15.4 709 1.6 14.2 719 1.6 14.5 710 1.5 14.4 721 1.6 15.0
35–44 1,540 3.8 16.1 1,403 3.4 15.3 1,340 3.2 15.0 1,294 3.1 14.8 1,413 3.4 16.6
45–54 3,823 9.0 20.0 3,616 8.6 19.6 3,369 8.1 19.1 2,876 7.0 17.4 2,873 7.1 18.6
≥55 6,742 7.4 36.7 7,016 7.6 35.0 7,144 7.6 32.9 7,490 7.8 31.9 8,798 9.0 35.0
Race/ethnicity
American Indian/Alaska Native 37 1.9 26.7 36 1.8 25.3 34 1.7 23.5 45 2.3 30.5 54 2.7 35.7
Asiand 82 0.5 13.5 67 0.4 10.5 64 0.4 9.7 77 0.5 11.3 74 0.4 10.5
Black/African American 5,722 17.3 26.7 5,648 16.9 26.1 5,450 16.2 24.9 5,350 15.7 24.2 6,018 17.6 27.1
Hispanic/Latinoe 2,177 5.0 17.8 2,239 5.0 18.0 2,309 5.0 18.3 2,212 4.7 17.3 2,587 5.4 20.0
Native Hawaiian/other Pacific Islander 10 2.2 26.2 8 1.7 20.5 9 1.9 22.3 12 2.4 28.9 9 1.8 21.6
White 4,080 2.4 26.4 3,942 2.3 25.5 3,882 2.3 25.1 3,849 2.2 24.8 4,079 2.4 26.4
Multiracial 863 19.6 27.9 893 19.6 28.9 901 19.2 29.2 894 18.4 29.2 1,054 21.0 34.6
Transmission categoryf
Male-to-male sexual contact 5,366 – 20.1 5,420 – 19.9 5,245 – 19.0 5,401 – 19.3 5,890 – 20.8
Injection drug use 2,974 – 37.6 2,861 – 36.8 2,764 – 36.1 2,628 – 34.8 2,918 – 39.3
Male 1,850 – 38.6 1,764 – 37.5 1,724 – 37.3 1,622 – 35.8 1,816 – 40.8
Female 1,124 – 36.1 1,097 – 35.6 1,040 – 34.1 1,006 – 33.3 1,102 – 37.0
Male-to-male sexual contact and injection drug use 1,156 – 31.7 1,135 – 31.4 1,221 – 34.1 1,103 – 31.2 1,282 – 36.7
Heterosexual contactg 3,323 – 24.0 3,267 – 23.3 3,273 – 23.0 3,169 – 22.0 3,607 – 24.9
Male 1,347 – 28.3 1,331 – 27.6 1,250 – 25.7 1,307 – 26.6 1,433 – 29.1
Female 1,976 – 21.8 1,936 – 21.0 2,024 – 21.6 1,862 – 19.7 2,175 – 22.8
Otherh 152 – 17.9 151 – 17.6 145 – 16.8 138 – 15.9 178 – 20.4
Male 85 – 18.6 87 – 19.0 93 – 20.3 84 – 18.3 104 – 22.8
Female 68 – 17.2 64 – 16.0 52 – 12.9 54 – 13.2 73 – 17.8
Region of residence
Northeast 2,924 6.1 21.8 2,882 6.0 21.6 2,753 5.8 20.7 2,843 5.9 21.5 3,419 7.2 26.1
Midwest 1,443 2.5 24.3 1,448 2.5 24.0 1,531 2.7 25.0 1,430 2.5 23.2 1,679 2.9 27.0
South 6,369 6.2 27.5 6,265 6.1 26.6 6,085 5.8 25.5 6,006 5.7 24.9 6,510 6.1 26.7
West 2,235 3.5 21.3 2,238 3.5 21.1 2,280 3.5 21.3 2,161 3.3 20.0 2,267 3.4 21.0
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 8,321 4.5 19.4 8,320 4.5 19.1 8,081 4.3 18.5 8,330 4.4 18.8 9,570 5.0 21.5
Metropolitan areas (pop. 50,000–499,999) 1,086 2.3 21.5 1,186 2.5 22.9 1,179 2.5 22.4 1,225 2.5 22.5 1,282 2.7 23.4
Nonmetropolitan areas (pop. <50,000) 693 1.8 23.9 759 2.0 25.4 668 1.7 22.1 732 1.9 23.8 817 2.1 26.3
Totali 12,971 4.8 24.5 12,833 4.7 24.0 12,649 4.6 23.4 12,440 4.5 22.9 13,875 5.0 25.4

Abbreviations: pop, population; PWA, persons with diagnosed HIV infection ever classified as stage 3 (AIDS); CDC, Centers for Disease Control and Prevention [footnotes only].
Note. Deaths of persons with diagnosed HIV infection ever classified as stage 3 (AIDS) may be due to any cause. Data are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Data for the year 2020 are preliminary and based on death data received by CDC as of December 2021.
a Denominator was calculated as (No. PWA at the end of [year X-1]) + (No. new diagnoses during year X).
b “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
c Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
d Includes Asian/Pacific Islander legacy cases (see Technical Notes).
e Hispanic/Latino persons can be of any race.
f Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
g Sexual contact with a person known to have, or with a risk factor for, HIV infection.
h Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
i Includes persons of unknown race/ethnicity.

Table 6e. Deaths of Persons Aged ≥13 Years with Diagnosed HIV Infection Ever Classified as Stage 3 (AIDS), by Year of Death and Selected Characteristics, 2016–2020—United States and 6 Dependent Areas
2016 2017 2018 2019 2020 (COVID-19 pandemic)
No. Rate per 100,000 population Rate per 1,000 PWAa No. Rate per 100,000 population Rate per 1,000 PWAa No. Rate per 100,000 population Rate per 1,000 PWAa No. Rate per 100,000 population Rate per 1,000 PWAa No. Rate per 100,000 population Rate per 1,000 PWAa
Gender
Male 9,933 – 24.5 9,864 – 24.1 9,642 – 23.4 9,601 – 23.1 10,563 – 25.3
Female 3,231 – 25.1 3,166 – 24.4 3,161 – 24.2 2,977 – 22.7 3,393 – 25.8
Transgender womanb 99 – 20.7 77 – 15.7 89 – 17.5 106 – 20.3 140 – 26.2
Transgender manb 1 – 6.2 4 – 23.8 2 – 11.6 3 – 16.5 5 – 27.2
Additional gender identityc 1 – 15.9 2 – 28.2 1 – 13.7 1 – 13.9 0 – 0.0
Age at death (yr)
13-24 100 0.2 10.6 91 0.2 10.9 81 0.2 10.9 71 0.1 10.9 70 0.1 12.3
25-34 779 1.7 15.4 723 1.6 14.3 732 1.6 14.6 719 1.5 14.4 725 1.6 14.9
35-44 1,582 3.9 16.3 1,438 3.5 15.5 1,373 3.3 15.2 1,322 3.1 15.0 1,442 3.4 16.7
45-54 3,914 9.1 20.1 3,702 8.7 19.7 3,428 8.2 19.1 2,959 7.2 17.6 2,921 7.2 18.6
≥55 6,890 7.5 36.7 7,159 7.6 35.0 7,281 7.6 32.8 7,617 7.8 31.8 8,943 9.0 34.9
Race/ethnicity
American Indian/Alaska Native 37 – 26.7 36 – 25.3 34 – 23.5 45 – 30.4 54 – 35.7
Asiand 82 – 13.4 67 – 10.5 64 – 9.6 77 – 11.2 74 – 10.5
Black/African American 5,732 – 26.7 5,651 – 26.1 5,450 – 24.9 5,350 – 24.2 6,019 – 27.1
Hispanic/Latinoe 2,457 – 18.7 2,516 – 18.9 2,551 – 18.9 2,454 – 18.0 2,811 – 20.4
Native Hawaiian/other Pacific Islander 12 – 30.2 8 – 19.6 11 – 26.0 14 – 32.3 9 – 20.8
White 4,081 – 26.4 3,942 – 25.5 3,883 – 25.1 3,850 – 24.8 4,080 – 26.4
Multiracial 864 – 28.0 893 – 28.9 902 – 29.3 897 – 29.2 1,054 – 34.6
Transmission categoryf
Male-to-male sexual contact 5,420 – 20.1 5,470 – 19.9 5,296 – 19.0 5,457 – 19.3 5,943 – 20.8
Injection drug use 3,093 – 37.7 2,970 – 36.8 2,868 – 36.1 2,729 – 34.9 3,001 – 39.0
Male 1,944 – 38.7 1,852 – 37.6 1,806 – 37.4 1,702 – 35.9 1,884 – 40.5
Female 1,149 – 36.1 1,117 – 35.6 1,062 – 34.2 1,027 – 33.4 1,116 – 36.8
Male-to-male sexual contact and injection drug use 1,185 – 32.0 1,153 – 31.5 1,238 – 34.1 1,120 – 31.2 1,301 – 36.7
Heterosexual contactg 3,408 – 24.0 3,367 – 23.4 3,339 – 22.9 3,242 – 22.0 3,677 – 24.9
Male 1,395 – 28.5 1,379 – 27.8 1,291 – 25.8 1,344 – 26.6 1,469 – 29.0
Female 2,013 – 21.7 1,988 – 21.1 2,048 – 21.4 1,898 – 19.6 2,208 – 22.7
Otherh 158 – 18.2 153 – 17.5 153 – 17.4 141 – 16.0 179 – 20.2
Male 89 – 19.0 88 – 18.9 99 – 21.2 86 – 18.4 106 – 22.6
Female 70 – 17.3 65 – 15.9 54 – 13.2 55 – 13.2 73 – 17.5
Region of residence
Northeast 2,924 6.1 21.8 2,882 6.0 21.6 2,753 5.8 20.7 2,843 5.9 21.5 3,419 7.2 26.1
Midwest 1,443 2.5 24.3 1,448 2.5 24.0 1,531 2.7 25.0 1,430 2.5 23.2 1,679 2.9 27.0
South 6,369 6.2 27.5 6,265 6.1 26.6 6,085 5.8 25.5 6,006 5.7 24.9 6,510 6.1 26.7
West 2,235 3.5 21.3 2,238 3.5 21.1 2,280 3.5 21.3 2,161 3.3 20.0 2,267 3.4 21.0
U.S. dependent areas 294 9.1 31.5 280 8.8 30.7 246 7.9 27.3 248 7.9 27.6 226 7.3 25.3
Totali 13,265 4.8 24.6 13,113 4.8 24.1 12,895 4.6 23.5 12,688 4.5 23.0 14,101 5.0 25.4

Abbreviations: PWA, persons with diagnosed HIV infection ever classified as stage 3 (AIDS); pop, population; CDC, Centers for Disease Control and Prevention [footnotes only].
Note. Deaths of persons with diagnosed HIV infection ever classified as stage 3 (AIDS) may be due to any cause. Data are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Data for the year 2020 are preliminary and based on death data received by CDC as of December 2021.
a Denominator was calculated as (No. PWA at the end of [year X-1]) + (No. new diagnoses during year X).
b “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
c Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
d Includes Asian/Pacific Islander legacy cases (see Technical Notes).
e Hispanic/Latino persons can be of any race.
f Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
g Sexual contact with a person known to have, or with a risk factor for, HIV infection.
h Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified.
i Includes persons of unknown race/ethnicity.

Table 6f. Deaths of Persons Aged ≥13 Years with Diagnosed HIV Infection Ever Classified as Stage 3 (AIDS), by Year of Death and Area of Residence, 2016–2020—United States and 6 Dependent Areas
2016 2017 2018 2019 2020 (COVID-19 pandemic)
No. Rate per 100,000 population Age-adjusted rate per 100,000 pop Rate per 1,000 PWDHa Age-adjusted rate per 1,000 PWDH No. Rate per 100,000 population Age-adjusted rate per 100,000 pop Rate per 1,000 PWDHa Age-adjusted rate per 1,000 PWDH No. Rate per 100,000 population Age-adjusted rate per 100,000 pop Rate per 1,000 PWDHa Age-adjusted rate per 1,000 PWDH No. Rate per 100,000 population Age-adjusted rate per 100,000 pop Rate per 1,000 PWDHa Age-adjusted rate per 1,000 PWDH No. Rate per 100,000 population Age-adjusted rate per 100,000 pop Rate per 1,000 PWDHa Age-adjusted rate per 1,000 PWDH
Alabama 192 4.7 4.5 33.5 31.7 199 4.9 4.8 33.6 28.4 166 4.0 3.9 27.4 24.1 172 4.2 4.1 27.7 22.0 171 4.1 3.9 27.0 23.6
Alaska 7 1.2 1.1 18.0 14.2 4 0.7 0.7 10.2 7.6 8 1.3 1.2 20.8 13.4 9 1.5 1.4 23.7 18.2 12 2.0 2.0 31.5 23.5
Arizona 196 3.4 3.3 25.9 20.4 195 3.3 3.1 25.3 25.7 200 3.3 3.2 25.3 22.8 171 2.8 2.7 21.2 16.0 200 3.2 2.9 24.3 20.9
Arkansas 69 2.8 2.7 27.3 21.6 79 3.2 3.1 30.2 25.3 62 2.5 2.5 23.6 20.6 77 3.1 3.0 28.3 30.4 74 2.9 2.7 26.5 24.0
California 1,458 4.5 4.3 20.6 17.7 1,435 4.4 4.2 20.2 17.2 1,412 4.3 4.0 19.9 17.3 1,381 4.2 3.9 19.4 19.2 1,426 4.3 4.0 20.0 16.7
Colorado 99 2.1 2.1 18.4 14.0 106 2.2 2.2 19.6 18.8 116 2.4 2.4 20.9 15.1 99 2.0 1.9 17.6 12.7 114 2.3 2.2 20.0 18.1
Connecticut 162 5.3 4.6 25.0 17.3 160 5.2 4.3 24.6 23.0 147 4.8 4.0 22.6 13.9 169 5.5 4.6 26.0 17.8 164 5.4 4.5 25.4 16.4
Delaware 47 5.8 5.1 23.9 27.2 58 7.1 6.0 28.4 18.0 54 6.6 5.6 26.6 18.2 64 7.7 7.4 31.0 27.8 46 5.5 4.6 22.1 16.5
District of Columbia 184 31.1 34.1 23.7 19.0 161 26.9 28.4 21.0 18.1 155 25.7 28.0 20.2 19.0 146 24.1 25.9 19.3 13.7 204 33.4 35.1 27.3 18.1
Florida 1,731 9.8 8.9 28.9 24.5 1,644 9.1 8.2 27.2 21.9 1,534 8.4 7.4 25.3 20.0 1,551 8.4 7.2 25.4 20.7 1,740 9.3 8.0 28.5 22.6
Georgia 670 7.9 7.7 25.2 23.2 656 7.6 7.3 23.9 21.6 661 7.6 7.3 23.5 20.1 642 7.3 6.9 22.5 19.2 705 7.9 7.5 24.3 21.6
Hawaii 30 2.5 2.3 21.1 14.7 31 2.6 2.5 21.9 36.3 31 2.6 2.2 22.6 15.4 39 3.3 2.7 28.5 22.1 28 2.4 2.0 20.7 13.3
Idaho 8 0.6 0.5 14.7 11.1 15 1.1 1.1 26.5 20.1 13 0.9 0.9 22.4 15.0 11 0.7 0.7 17.6 11.1 11 0.7 0.6 17.5 10.8
Illinois 410 3.8 3.6 23.0 19.8 381 3.6 3.3 21.4 19.2 428 4.0 3.7 23.8 20.1 410 3.8 3.5 22.9 19.0 527 5.0 4.5 29.6 23.7
Indiana 162 2.9 2.9 29.4 25.3 164 3.0 2.8 29.1 26.1 144 2.6 2.5 25.0 23.5 130 2.3 2.2 22.6 16.2 140 2.5 2.3 23.9 17.3
Iowa 28 1.1 1.0 19.3 15.5 31 1.2 1.2 20.5 14.2 37 1.4 1.3 24.1 16.2 45 1.7 1.5 29.2 20.9 49 1.9 1.7 31.8 24.9
Kansasb 37 1.5 1.5 23.9 18.2 37 1.5 1.5 23.4 25.7 40 1.7 1.5 24.7 26.7 30 1.2 1.2 18.6 22.2 24 1.0 0.9 14.1 9.3
Kentucky 95 2.6 2.4 27.1 22.9 108 2.9 2.7 30.2 23.2 102 2.7 2.6 28.4 25.0 84 2.2 2.1 23.0 18.1 117 3.1 3.1 31.0 29.1
Louisiana 331 8.5 8.6 31.2 29.6 313 8.1 8.0 29.2 28.6 331 8.6 8.3 30.5 26.1 297 7.7 7.5 27.1 26.2 335 8.7 8.4 30.5 26.3
Maine 16 1.4 1.2 20.4 11.8 24 2.1 1.7 29.6 22.8 16 1.4 1.3 19.3 13.9 32 2.7 2.3 37.8 34.0 19 1.6 1.2 22.5 12.3
Marylandc 515 10.2 9.3 29.0 23.4 474 9.4 8.5 26.5 19.5 499 9.8 8.7 27.9 21.7 455 8.9 7.9 25.5 18.8 489 9.6 8.5 27.5 21.1
Massachusetts 218 3.7 3.2 19.1 12.5 232 3.9 3.4 20.3 13.0 231 3.9 3.4 20.3 13.4 224 3.8 3.3 19.6 14.5 234 3.9 3.3 20.6 13.4
Michigan 228 2.7 2.5 28.0 24.0 226 2.7 2.5 27.5 23.3 242 2.9 2.5 29.2 24.8 217 2.6 2.2 25.7 22.3 260 3.1 2.7 30.6 27.7
Minnesota 57 1.2 1.1 15.1 14.8 70 1.5 1.4 18.0 14.6 66 1.4 1.3 16.7 12.0 58 1.2 1.2 14.5 14.2 68 1.4 1.2 16.7 12.2
Mississippi 164 6.6 6.5 35.6 31.2 174 7.0 7.0 37.0 32.0 186 7.5 7.5 39.0 34.2 133 5.4 5.4 27.6 21.3 171 6.9 6.6 35.4 31.6
Missouri 162 3.2 2.9 25.3 21.8 155 3.0 2.9 24.1 18.6 179 3.5 3.2 27.4 23.6 168 3.3 3.0 25.6 26.0 186 3.6 3.3 28.4 25.8
Montana 14 1.6 1.6 41.2 25.1 13 1.5 1.4 37.6 37.7 10 1.1 1.0 28.5 21.3 9 1.0 1.0 26.2 18.5 8 0.9 0.9 22.5 14.1
Nebraska 27 1.7 1.7 25.4 22.7 23 1.5 1.4 21.6 17.3 24 1.5 1.4 22.4 17.3 17 1.1 1.1 15.6 10.5 23 1.4 1.4 20.1 16.1
Nevada 117 4.8 4.6 26.3 26.4 137 5.5 5.1 29.1 29.4 135 5.3 4.9 27.6 24.6 119 4.6 4.4 23.5 21.0 141 5.3 4.8 27.1 24.2
New Hampshire 15 1.3 1.3 24.5 19.2 15 1.3 1.1 24.6 19.0 15 1.3 1.2 24.0 14.2 13 1.1 1.0 20.4 12.8 10 0.8 0.6 15.6 11.9
New Jersey 472 6.3 5.6 25.9 21.3 474 6.3 5.5 25.9 18.7 471 6.3 5.4 25.9 22.0 472 6.3 5.3 26.0 19.7 520 6.9 5.8 28.8 20.7
New Mexico 41 2.4 2.1 21.8 17.5 49 2.8 2.5 25.7 16.6 52 3.0 3.0 26.2 23.1 37 2.1 2.0 18.3 13.7 56 3.2 2.8 27.2 17.0
New York 1,535 9.2 8.3 20.6 16.5 1,470 8.8 7.8 19.9 15.0 1,410 8.5 7.5 19.2 13.3 1,447 8.7 7.5 19.9 14.4 1,924 11.7 9.9 26.7 19.9
North Carolinab 383 4.5 4.2 27.7 25.8 393 4.6 4.2 27.7 23.7 363 4.1 3.8 25.0 19.2 356 4.0 3.7 23.9 19.3 377 4.2 3.7 24.8 19.8
North Dakota 4 0.6 0.7 21.3 12.6 3 0.5 0.4 15.3 14.6 6 1.0 0.9 29.0 25.0 5 0.8 0.8 22.2 18.3 4 0.6 0.7 16.8 12.0
Ohio 254 2.6 2.5 24.6 20.0 278 2.8 2.7 26.2 22.6 289 2.9 2.8 26.8 23.1 276 2.8 2.6 24.8 23.4 320 3.2 2.9 28.4 25.2
Oklahoma 91 2.8 2.7 30.9 25.7 82 2.5 2.6 27.4 25.2 86 2.6 2.5 28.2 32.6 118 3.6 3.4 37.9 30.8 122 3.7 3.5 38.4 34.6
Oregon 84 2.4 2.3 21.6 15.4 85 2.4 2.2 21.5 14.1 89 2.5 2.3 22.3 15.7 104 2.9 2.6 25.6 19.6 95 2.6 2.3 23.8 18.9
Pennsylvania 461 4.2 3.8 22.8 19.3 474 4.3 3.9 24.0 18.8 423 3.9 3.4 21.3 14.9 444 4.1 3.5 22.2 15.6 500 4.6 3.9 25.0 17.6
Rhode Island 34 3.7 3.2 24.5 14.6 28 3.1 2.6 19.4 14.4 32 3.5 3.1 22.0 13.7 34 3.7 2.9 23.3 15.1 40 4.4 3.7 27.7 15.2
South Carolinab 278 6.7 6.3 31.0 25.7 263 6.2 5.6 28.9 23.3 240 5.6 5.3 26.0 19.7 232 5.3 4.8 24.7 18.4 189 4.3 3.8 20.0 17.4
South Dakota 6 0.9 0.8 23.3 21.7 3 0.4 0.5 11.2 8.0 11 1.5 1.6 37.9 32.9 8 1.1 1.2 26.2 16.7 3 0.4 0.5 9.8 6.7
Tennessee 245 4.4 4.2 29.3 25.4 259 4.6 4.4 30.5 27.3 275 4.8 4.6 31.4 27.1 246 4.3 4.1 28.0 21.5 299 5.1 4.8 33.1 30.2
Texas 1,095 4.8 4.9 24.4 22.1 1,147 5.0 5.0 25.0 23.5 1,109 4.8 4.8 23.7 22.7 1,142 4.8 4.8 24.0 21.1 1,181 4.9 4.8 24.5 21.2
Utah 39 1.6 1.8 27.0 20.7 19 0.8 0.8 13.5 9.4 36 1.4 1.6 24.5 38.5 31 1.2 1.3 20.8 15.6 22 0.8 0.9 14.4 10.5
Vermontb 11 2.0 1.5 30.6 16.6 5 0.9 0.8 13.5 11.2 8 1.5 1.1 20.9 11.1 8 1.5 1.4 21.2 14.8 8 1.5 1.4 20.9 23.2
Virginia 246 3.5 3.2 23.2 21.2 230 3.2 2.9 21.1 17.9 224 3.1 2.9 20.1 17.8 258 3.6 3.2 22.7 19.0 256 3.5 3.1 22.2 17.3
Washington 138 2.3 2.1 19.7 17.6 145 2.3 2.2 20.3 14.7 171 2.7 2.5 23.5 16.8 147 2.3 2.1 20.0 18.6 147 2.3 2.1 19.9 17.2
West Virginia 33 2.1 1.9 32.7 26.1 25 1.6 1.5 24.7 19.0 38 2.5 2.2 36.5 35.9 33 2.1 1.8 31.4 22.8 34 2.2 2.1 32.0 28.4
Wisconsin 68 1.4 1.3 22.7 17.1 77 1.6 1.5 25.1 18.0 65 1.3 1.2 21.2 17.3 66 1.3 1.2 21.0 15.1 75 1.5 1.4 23.4 15.7
Wyoming 4 0.8 0.9 23.0 12.8 4 0.8 0.7 22.3 51.9 7 1.5 1.4 39.1 26.1 4 0.8 0.6 22.1 13.0 7 1.4 1.3 37.6 28.6
Subtotal 12,971 4.8 4.5 24.5 20.8 12,833 4.7 4.4 24.0 20.1 12,649 4.6 4.3 23.4 19.4 12,440 4.5 4.1 22.9 18.9 13,875 5.0 4.5 25.4 20.6
U.S. dependent area
American Samoa 0 0.0 0.0 0.0 0.0 0 0.0 0.0 0.0 0.0 0 0.0 0.0 0.0 0.0 2 5.5 6.6 1000 365.5 0 0.0 0.0 0.0 0.0
Guamb 3 2.4 2.9 81.1 69.1 0 0.0 0.0 0.0 0.0 3 2.4 3.0 69.8 85.3 4 3.1 3.2 93.0 56.7 0 0.0 0.0 0.0 0.0
Northern Mariana Islands 0 0.0 0.0 0.0 0.0 0 0.0 0.0 0.0 0.0 0 0.0 0.0 0.0 0.0 0 0.0 0.0 0.0 0.0 0 0.0 0.0 0.0 0.0
Puerto Ricob 279 9.5 9.0 31.1 28.0 276 9.6 8.9 31.4 28.8 241 8.6 7.8 27.9 32.1 242 8.6 8.0 28.0 24.4 222 7.9 6.9 25.9 18.9
Republic of Palau 0 0.0 0.0 0.0 0.0 0 0.0 0.0 0.0 0.0 0 0.0 0.0 0.0 0.0 0 0.0 0.0 0.0 0.0 1 5.5 6.0 166.7 87.5
U.S. Virgin Islandsb 12 13.6 11.0 39.6 101.8 4 4.5 4.0 14.0 10.5 2 2.3 1.5 6.9 3.8 0 0.0 0.0 0.0 0.0 3 3.4 3.1 10.6 9.9
Subtotal 294 9.1 8.6 31.5 31.1 280 8.8 8.2 30.7 28.0 246 7.9 7.2 27.3 31.3 248 7.9 7.4 27.6 23.8 226 7.3 6.4 25.3 18.5
Total 13,265 4.8 4.6 24.6 21.0 13,113 4.8 4.4 24.1 20.2 12,895 4.6 4.3 23.5 19.5 12,688 4.5 4.1 23.0 18.9 14,101 5.0 4.5 25.4 20.6

Abbreviations: PWA, persons with diagnosed HIV infection ever classified as stage 3 (AIDS); pop, population; CDC, Centers for Disease Control and Prevention [footnotes only].
Note. Deaths of persons with diagnosed HIV infection ever classified as stage 3 (AIDS) may be due to any cause. Data are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Data for the year 2020 are preliminary and based on death data received by CDC as of December 2021.
a Denominator was calculated as (No. PWA at the end of [year X-1]) + (No. new diagnoses during year X).
b Data should be interpreted with caution due to incomplete ascertainment of deaths that occurred during the year 2020.
c Data should be interpreted with caution due to incomplete reporting of case information to CDC during December 2021.

Table 7a. Persons Aged ≥13 Years Surviving >3 Years After a Diagnosis of HIV Infection During 2012–2017, by Year of Diagnosis and Selected Characteristics—United States
Proportion survived >3 years
No. 2012 2013 2014 2015 2016 2017
Gender
Male 186,603 0.94 0.94 0.95 0.95 0.95 0.95
Female 44,915 0.93 0.92 0.94 0.94 0.94 0.94
Transgender womana 3,557 0.99 0.98 0.98 0.97 0.97 0.97
Transgender mana 144 * * * * * *
Additional gender identityb 64 * * * * * *
Age at diagnosis (yr)
13–24 52,537 0.99 0.99 0.99 0.99 0.99 0.99
25–34 75,522 0.97 0.97 0.97 0.98 0.98 0.98
35–44 46,306 0.95 0.94 0.95 0.95 0.95 0.95
45–54 38,254 0.90 0.90 0.91 0.92 0.91 0.92
≥55 22,664 0.81 0.80 0.82 0.82 0.83 0.84
Race/ethnicity
American Indian/Alaska Native 1,044 0.91 0.90 0.94 0.95 0.95 0.92
Asian 5,043 0.97 0.96 0.97 0.97 0.96 0.97
Black/African American 100,270 0.94 0.94 0.95 0.95 0.96 0.95
Hispanic/Latinoc 57,473 0.95 0.95 0.96 0.96 0.96 0.96
Native Hawaiian/other Pacific Islander 270 * * * * * *
White 60,546 0.94 0.93 0.94 0.94 0.93 0.94
Multiracial 10,637 0.95 0.95 0.95 0.95 0.95 0.95
Transmission categoryd
Male-to-male sexual contact 153,811 0.96 0.95 0.96 0.96 0.96 0.96
Injection drug use 13,975 0.87 0.86 0.87 0.89 0.88 0.88
Male 7,649 0.86 0.85 0.86 0.88 0.87 0.87
Female 6,327 0.89 0.88 0.89 0.91 0.89 0.90
Male-to-male sexual contact and injection drug use 9,208 0.94 0.94 0.96 0.95 0.94 0.95
Heterosexual contacte 57,809 0.93 0.92 0.93 0.93 0.94 0.93
Male 19,342 0.89 0.89 0.91 0.91 0.91 0.91
Female 38,467 0.94 0.93 0.94 0.95 0.95 0.95
Otherf 479 * * * * * *
Male 209 * * * * * *
Female 270 * * * * * *
Region of residence
Northeast 39,360 0.94 0.94 0.95 0.95 0.95 0.95
Midwest 31,036 0.95 0.94 0.95 0.95 0.95 0.95
South 119,643 0.94 0.94 0.94 0.95 0.95 0.95
West 45,244 0.95 0.94 0.95 0.95 0.95 0.95
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 193,248 0.95 0.94 0.95 0.95 0.95 0.95
Metropolitan areas (pop. 50,000–499,999) 26,677 0.93 0.92 0.94 0.94 0.94 0.94
Nonmetropolitan areas (pop. <50,000) 13,825 0.91 0.9 0.92 0.92 0.93 0.93
Total 235,283 0.94 0.94 0.95 0.95 0.95 0.95

Abbreviation: asterisk (*) indicates sample too small (<600 diagnoses during the 6-year period) for the calculation of meaningful survival estimates.
Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Data are based on residence at time of diagnosis. Data exclude persons whose month of diagnosis or month of death is unknown.
a “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
b Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
c Hispanic/Latino persons can be of any race.
d Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
e Sexual contact with a person known to have, or with a risk factor for, HIV infection.
fOther risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

Table 7b. Persons Aged ≥13 Years Surviving >3 Years After a Diagnosis of HIV Infection During 2012–2017, by Year of Diagnosis and Selected Characteristics—United States and 6 Dependent Areas
Proportion survived >3 years
No. 2012 2013 2014 2015 2016 2017
Gender
Male 189,417 0.94 0.94 0.95 0.95 0.95 0.95
Female 45,720 0.93 0.92 0.94 0.94 0.94 0.94
Transgender womana 3,573 0.99 0.98 0.98 0.97 0.97 0.97
Transgender mana 145 * * * * * *
Additional gender identityb 65 * * * * * *
Age at diagnosis (yr)
13–24 53,151 0.99 0.99 0.99 0.99 0.99 0.99
25–34 76,463 0.97 0.97 0.97 0.98 0.98 0.97
35–44 47,092 0.95 0.94 0.95 0.95 0.95 0.95
45–54 38,993 0.90 0.90 0.91 0.92 0.91 0.91
≥55 23,221 0.81 0.80 0.81 0.82 0.83 0.84
Race/ethnicity
American Indian/Alaska Native 1,044 0.91 0.90 0.94 0.95 0.95 0.92
Asian 5,054 0.97 0.96 0.97 0.97 0.97 0.97
Black/African American 100,325 0.94 0.94 0.95 0.95 0.96 0.95
Hispanic/Latinoc 61,002 0.95 0.94 0.95 0.96 0.96 0.96
Native Hawaiian/other Pacific Islander 284 * * * * * *
White 60,567 0.94 0.93 0.94 0.94 0.93 0.94
Multiracial 10,644 0.95 0.95 0.95 0.95 0.95 0.95
Transmission categoryd
Male-to-male sexual contact 155,586 0.96 0.95 0.96 0.96 0.96 0.96
Injection drug use 14,405 0.87 0.86 0.87 0.89 0.88 0.88
Male 7,986 0.85 0.84 0.85 0.88 0.86 0.86
Female 6,419 0.89 0.88 0.89 0.91 0.89 0.90
Male-to-male sexual contact and injection drug use 9,320 0.94 0.94 0.96 0.95 0.94 0.95
Heterosexual contacte 59,129 0.92 0.92 0.93 0.93 0.94 0.93
Male 19,949 0.89 0.89 0.91 0.91 0.91 0.91
Female 39,180 0.94 0.93 0.94 0.94 0.95 0.95
Otherf 480 * * * * * *
Male 209 * * * * * *
Female 271 * * * * * *
Region of residence
Northeast 39,360 0.94 0.94 0.95 0.95 0.95 0.95
Midwest 31,036 0.95 0.94 0.95 0.95 0.95 0.95
South 119,643 0.94 0.94 0.94 0.95 0.95 0.95
West 45,244 0.95 0.94 0.95 0.95 0.95 0.95
U.S. dependent areas 3,637 0.88 0.86 0.89 0.90 0.88 0.89
Totalf 238,920 0.94 0.94 0.95 0.95 0.95 0.95

Abbreviation: asterisk (*) indicates sample too small (<600 diagnoses during the 6-year period) for the calculation of meaningful survival estimates.
Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Data are based on residence at time of diagnosis. Data exclude persons whose month of diagnosis or month of death is unknown.
a “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
b Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
c Hispanic/Latino persons can be of any race.
d Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
e Sexual contact with a person known to have, or with a risk factor for, HIV infection.
f Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

Table 7c. Persons Aged ≥13 Years Surviving >3 Years After a Diagnosis of HIV Infection During 2012–2017, by Year of Diagnosis and Area of Residence—United States and 6 Dependent Areas
Proportion survived >3 years
Area of residence No. 2012 2013 2014 2015 2016 2017
Alabama 3,908 0.93 0.93 0.92 0.94 0.95 0.95
Alaska 178 * * * * * *
Arizona 4,147 0.92 0.94 0.96 0.94 0.94 0.94
Arkansas 1,685 0.96 0.92 0.92 0.93 0.96 0.97
California 29,416 0.95 0.94 0.95 0.96 0.96 0.96
Colorado 2,280 0.97 0.97 0.95 0.95 0.95 0.97
Connecticut 1,697 0.95 0.94 0.96 0.99 0.98 0.92
Delaware 699 0.93 0.96 0.96 0.97 0.94 0.94
District of Columbia 2,475 0.96 0.96 0.96 0.96 0.96 0.95
Florida 26,853 0.93 0.93 0.94 0.94 0.95 0.95
Georgia 14,939 0.93 0.94 0.95 0.94 0.95 0.95
Hawaii 542 * * * * * *
Idaho 213 * * * * * *
Illinois 9,100 0.96 0.95 0.95 0.96 0.96 0.96
Indiana 3,051 0.94 0.93 0.94 0.94 0.95 0.94
Iowa 707 0.94 0.92 0.93 0.97 0.95 0.92
Kansasa 848 0.95 0.90 0.96 0.94 0.95 0.98
Kentucky 2,101 0.93 0.92 0.92 0.95 0.93 0.93
Louisiana 6,492 0.92 0.94 0.94 0.94 0.95 0.95
Maine 273 * * * * * *
Marylandb 7,060 0.95 0.94 0.96 0.96 0.96 0.94
Massachusetts 3,833 0.98 0.97 0.97 0.97 0.95 0.96
Michigan 4,542 0.95 0.93 0.95 0.95 0.95 0.95
Minnesota 1,799 0.97 0.93 0.95 0.97 0.98 0.97
Mississippi 2,733 0.94 0.92 0.93 0.93 0.93 0.94
Missouri 2,931 0.95 0.94 0.96 0.96 0.95 0.93
Montana 126 * * * * * *
Nebraska 490 * * * * * *
Nevada 2,698 0.92 0.94 0.95 0.95 0.94 0.94
New Hampshire 219 * * * * * *
New Jersey 7,128 0.93 0.91 0.94 0.95 0.95 0.94
New Mexico 802 0.97 0.94 0.93 0.92 0.99 0.94
New York 18,406 0.95 0.95 0.95 0.96 0.95 0.96
North Carolinaa 7,800 0.94 0.95 0.95 0.94 0.95 0.96
North Dakota 152 * * * * * *
Ohio 5,835 0.95 0.95 0.94 0.94 0.93 0.95
Oklahoma 1,822 0.94 0.92 0.94 0.94 0.95 0.92
Oregon 1,372 0.93 0.96 0.93 0.96 0.95 0.94
Pennsylvania 7,263 0.93 0.93 0.93 0.94 0.96 0.96
Rhode Island 461 * * * * * *
South Carolinaa 4,261 0.95 0.93 0.93 0.94 0.94 0.94
South Dakota 193 * * * * * *
Tennessee 4,536 0.92 0.92 0.93 0.93 0.95 0.94
Texas 26,355 0.94 0.94 0.95 0.95 0.95 0.95
Utah 717 0.95 0.94 0.98 0.97 0.94 0.96
Vermonta 80 * * * * * *
Virginia 5,473 0.94 0.95 0.96 0.97 0.95 0.96
Washington 2,672 0.97 0.95 0.95 0.98 0.95 0.97
West Virginia 451 * * * * * *
Wisconsin 1,388 0.96 0.95 0.94 0.98 0.97 0.93
Wyoming 81 * * * * * *
Subtotal 235,283 0.94 0.94 0.95 0.95 0.95 0.95
U.S. dependent areas
American Samoa 0 * * * * * *
Guama 25 * * * * * *
Northern Mariana Islands 5 * * * * * *
Puerto Ricoa 3,509 0.88 0.86 0.89 0.90 0.88 0.89
Republic of Palau 3 * * * * * *
U.S. Virgin Islands 95 * * * * * *
Subtotal 3,637 0.88 0.86 0.89 0.90 0.88 0.89
Total 238,920 0.94 0.94 0.95 0.95 0.95 0.95

Abbreviation: asterisk (*) indicates sample too small (<600 diagnoses during the 6-year period) for the calculation of meaningful survival estimates.
Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Data are based on residence at time of diagnosis. Data exclude persons whose month of diagnosis or month of death is unknown.
a Data should be interpreted with caution due to incomplete ascertainment of deaths that occurred during the year 2020.
b Data should be interpreted with caution due to incomplete reporting of case information to CDC during December 2021.

Table 7d. Persons Aged ≥13 Years Surviving >3 Years After Stage 3 (AIDS) Classification During 2012–2017, by Year of Diagnosis and Area of Residence—United States
Proportion survived >3 years
No. 2012 2013 2014 2015 2016 2017
Gender
Male 91,020 0.87 0.86 0.85 0.86 0.86 0.86
Female 29,455 0.85 0.84 0.84 0.84 0.86 0.84
Transgender womana 1,490 0.94 0.92 0.92 0.91 0.92 0.93
Transgender mana 45 * * * * * *
Additional gender identityb 21 * * * * * *
Age at diagnosis (yr)
13–24 10,644 0.95 0.96 0.94 0.95 0.96 0.94
25–34 30,886 0.93 0.92 0.92 0.92 0.93 0.93
35–44 30,121 0.89 0.89 0.88 0.88 0.88 0.88
45–54 30,656 0.83 0.83 0.83 0.83 0.83 0.83
≥55 19,724 0.72 0.71 0.68 0.70 0.71 0.72
Race/ethnicity
American Indian/Alaska Native 480 * * * * * *
Asian 1,935 0.93 0.91 0.91 0.91 0.89 0.92
Black/African American 56,171 0.86 0.85 0.84 0.86 0.86 0.86
Hispanic/Latinoc 26,912 0.89 0.88 0.87 0.87 0.89 0.88
Native Hawaiian/other Pacific Islander 114 * * * * * *
White 29,570 0.84 0.84 0.83 0.82 0.82 0.82
Multiracial 6,849 0.89 0.89 0.87 0.86 0.86 0.84
Transmission categoryd
Male-to-male sexual contact 66,028 0.89 0.88 0.87 0.87 0.88 0.88
Injection drug use 11,991 0.78 0.77 0.76 0.76 0.76 0.76
Male 6,618 0.77 0.75 0.74 0.74 0.74 0.75
Female 5,373 0.79 0.79 0.78 0.78 0.79 0.77
Male-to-male sexual contact and injection drug use 5,856 0.86 0.84 0.85 0.84 0.85 0.85
Heterosexual contacte 36,987 0.85 0.84 0.84 0.85 0.86 0.85
Male 13,469 0.83 0.83 0.82 0.84 0.83 0.83
Female 23,518 0.86 0.85 0.85 0.86 0.87 0.86
Otherf 1,169 0.91 0.93 0.91 0.92 0.91 0.91
Male 556 * * * * * *
Female 613 0.94 0.93 0.92 0.90 0.93 0.93
Region of residence
Northeast 21,816 0.88 0.87 0.86 0.87 0.87 0.87
Midwest 15,644 0.88 0.88 0.87 0.87 0.87 0.86
South 63,855 0.85 0.85 0.84 0.84 0.85 0.85
West 20,716 0.87 0.87 0.86 0.85 0.86 0.85
Population area of residence
Metropolitan statistical areas (pop. ≥500,000) 98,816 0.87 0.87 0.85 0.86 0.86 0.86
Metropolitan areas (pop. 50,000–499,999) 14,329 0.84 0.83 0.82 0.84 0.83 0.84
Nonmetropolitan areas (pop. <50,000) 8,247 0.83 0.83 0.81 0.81 0.84 0.82
Totalf 122,031 0.86 0.86 0.85 0.85 0.86 0.86

Abbreviation: asterisk (*) indicates sample too small (<600 diagnoses during the 6-year period) for the calculation of meaningful survival estimates; pop, population.
Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Data are based on residence when infection was classified as stage 3 (AIDS) classification. Data exclude persons whose month of diagnosis or month of death is unknown.
a “Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
b Additional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
c Hispanic/Latino persons can be of any race.
d Transmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
e Sexual contact with a person known to have, or with a risk factor for, HIV infection.
f Other risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

Table 7e. Persons aged ≥13 years with HIV surviving >3 years after stage 3 (AIDS) classification during 2012–2017, by year of diagnosis and selected characteristics—United States and 6 dependent areas
Proportion survived >3 years
No. 2012 2013 2014 2015 2016 2017
Gender
Male 92,472 0.86 0.86 0.85 0.85 0.86 0.86
Female 30,029 0.85 0.84 0.84 0.84 0.86 0.84
Transgender womana 1,494 0.94 0.92 0.92 0.91 0.92 0.93
Transgender mana 45 * * * * * *
Additional gender identityb 21 * * * * * *
Age at diagnosis (yr)
13–24 10,759 0.95 0.96 0.94 0.95 0.95 0.94
25–34 31,227 0.92 0.92 0.92 0.92 0.93 0.93
35–44 30,655 0.89 0.89 0.87 0.88 0.88 0.88
45–54 31,266 0.83 0.83 0.83 0.82 0.83 0.83
≥55 20,154 0.71 0.71 0.68 0.70 0.71 0.72
Race/ethnicity
American Indian/Alaska Native 480 * * * * * *
Asian 1,942 0.93 0.91 0.91 0.91 0.90 0.92
Black/African American 56,212 0.86 0.85 0.84 0.86 0.86 0.86
Hispanic/Latinoc 28,872 0.88 0.88 0.86 0.86 0.88 0.87
Native Hawaiian/other Pacific Islander 123 * * * * * *
White 29,581 0.84 0.84 0.83 0.82 0.82 0.82
Multiracial 6,851 0.89 0.89 0.87 0.86 0.86 0.84
Transmission categoryd
Male-to-male sexual contact 66,648 0.89 0.88 0.87 0.87 0.88 0.88
Injection drug use 12,458 0.77 0.77 0.75 0.75 0.76 0.75
    Male 6,974 0.76 0.75 0.74 0.73 0.74 0.75
    Female 5,484 0.79 0.79 0.77 0.77 0.79 0.76
Male-to-male sexual contact and injection drug use 5,945 0.86 0.84 0.85 0.84 0.84 0.85
Heterosexual contacte 37,816 0.85 0.84 0.84 0.85 0.85 0.85
    Male 13,850 0.83 0.82 0.81 0.83 0.83 0.83
    Female 23,966 0.86 0.85 0.85 0.86 0.87 0.86
Otherf 1,195 0.92 0.93 0.91 0.92 0.91 0.92
    Male 567 * * * * * *
    Female 628 0.94 0.93 0.92 0.89 0.93 0.93
Region of residence
Northeast 21,816 0.88 0.87 0.86 0.87 0.87 0.87
Midwest 15,644 0.88 0.88 0.87 0.87 0.87 0.86
South 63,855 0.85 0.85 0.84 0.84 0.85 0.85
West 20,716 0.87 0.87 0.86 0.85 0.86 0.85
U.S. dependent areas 2,030 0.74 0.77 0.74 0.72 0.73 0.79
Totalf 124,061 0.86 0.86 0.85 0.85 0.86 0.85

Abbreviation: asterisk (*) indicates sample too small (<600 diagnoses during the 6-year period) for the calculation of meaningful survival estimates.
Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Data are based on residence when infection was classified as stage 3 (AIDS) classification. Data exclude persons whose month of diagnosis or month of death is unknown.
a“Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
bAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
cHispanic/Latino persons can be of any race.
dTransmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column subtotals and total.
eSexual contact with a person known to have, or with a risk factor for, HIV infection.
fOther risk factors, including hemophilia, blood transfusion, and risk factor not reported or not identified. Data not displayed because the numbers were too small to be meaningful.

Table 7f. Persons aged ≥13 years with HIV surviving >3 years after stage 3 (AIDS) classification during 2012–2017, by year of diagnosis and area of residence—United States and 6 dependent areas
Proportion survived >3 years
Area of residence No. 2012 2013 2014 2015 2016 2017
Alabama 2,062 0.80 0.82 0.81 0.83 0.84 0.86
Alaska 98 * * * * * *
Arizona 1,832 0.82 0.84 0.85 0.80 0.83 0.83
Arkansas 795 0.86 0.87 0.77 0.84 0.89 0.89
California 13,151 0.87 0.87 0.85 0.86 0.86 0.85
Colorado 1,117 0.91 0.89 0.88 0.84 0.87 0.88
Connecticut 1,038 0.89 0.88 0.88 0.93 0.91 0.84
Delaware 453 * * * * * *
District of Columbia 1,313 0.88 0.88 0.83 0.84 0.90 0.83
Florida 14,697 0.85 0.82 0.81 0.83 0.85 0.84
Georgia 7,955 0.85 0.86 0.86 0.87 0.87 0.87
Hawaii 264 * * * * * *
Idaho 114 * * * * * *
Illinois 4,472 0.89 0.89 0.86 0.87 0.88 0.87
Indiana 1,509 0.87 0.85 0.86 0.83 0.84 0.82
Iowa 405 * * * * * *
Kansasa 414 * * * * * *
Kentucky 1,015 0.83 0.81 0.84 0.82 0.86 0.85
Louisiana 3,591 0.83 0.84 0.81 0.84 0.86 0.86
Maine 138 * * * * * *
Marylandb 4,151 0.87 0.87 0.88 0.87 0.85 0.86
Massachusetts 1,926 0.93 0.91 0.90 0.92 0.88 0.87
Michigan 2,319 0.86 0.85 0.88 0.83 0.87 0.83
Minnesota 971 0.91 0.90 0.90 0.91 0.96 0.94
Mississippi 1,769 0.82 0.84 0.82 0.83 0.83 0.83
Missouri 1,438 0.91 0.87 0.90 0.88 0.86 0.88
Montana 71 * * * * * *
Nebraska 266 * * * * * *
Nevada 1,314 0.80 0.87 0.83 0.83 0.82 0.84
New Hampshire 106 * * * * * *
New Jersey 3,881 0.85 0.84 0.86 0.85 0.85 0.86
New Mexico 384 * * * * * *
New York 10,442 0.88 0.88 0.86 0.86 0.88 0.87
North Carolinaa 4,214 0.86 0.87 0.83 0.83 0.83 0.86
North Dakota 74 * * * * * *
Ohio 2,968 0.86 0.89 0.85 0.89 0.85 0.87
Oklahoma 955 0.81 0.76 0.84 0.86 0.87 0.83
Oregon 741 0.88 0.88 0.86 0.89 0.86 0.82
Pennsylvania 3,983 0.88 0.85 0.86 0.86 0.88 0.87
Rhode Island 251 * * * * * *
South Carolinaa 2,472 0.88 0.84 0.82 0.85 0.84 0.84
South Dakota 105 * * * * * *
Tennessee 2,434 0.85 0.85 0.83 0.83 0.85 0.86
Texas 13,153 0.86 0.86 0.85 0.85 0.86 0.86
Utah 321 * * * * * *
Vermonta 51 * * * * * *
Virginia 2,562 0.84 0.90 0.84 0.85 0.87 0.85
Washington 1,256 0.92 0.91 0.89 0.86 0.88 0.88
West Virginia 264 * * * * * *
Wisconsin 703 0.91 0.85 0.82 0.91 0.86 0.83
Wyoming 53 * * * * * *
Subtotal 122,031 0.86 0.86 0.85 0.85 0.86 0.86
U.S. dependent areas
American Samoa 0 * * * * * *
Guam 14 * * * * * *
Northern Mariana Islands 5 * * * * * *
Puerto Ricoa 1,942 0.74 0.76 0.73 0.72 0.73 0.78
Republic of Palau 1 * * * * * *
U.S. Virgin Islands 68 * * * * * *
Subtotal 2,030 0.74 0.77 0.74 0.72 0.73 0.79
Total 124,061 0.86 0.86 0.85 0.85 0.86 0.85

Abbreviation: asterisk (*) indicates sample too small (<600 diagnoses during the 6-year period) for the calculation of meaningful survival estimates; pop, population.
Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Data are based on residence when infection was classified as stage 3 (AIDS) classification.
Data exclude persons whose month of diagnosis or month of death is unknown.
aData should be interpreted with caution due to incomplete ascertainment of deaths that occurred during the year 2020.
bData should be interpreted with caution due to incomplete reporting of case information to CDC during December 2021.

Table 8a. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage in 2020 (COVID-19 pandemic) among persons aged ≥16 years, by selected characteristics—United States and Puerto Rico
No. prescribed PrEPa No. with PrEP indicationsb PrEP coveragec(%)
Sex assigned at birth
Male 276,810 989,200 28.0
Female 23,667 227,010 10.4
Age (yr)
16–24 38,420 246,290 15.6
25–34 119,125 434,680 27.4
35–44 72,044 238,470 30.2
45–54 40,603 173,420 23.4
≥55 30,313 123,350 24.6
Race/ethnicityd
Black/African American 42,568 468,540 9.1
Hispanic/Latinoe 49,306 312,820 15.7
Other 12,254 131,180 9.3
White 196,478 300,650 65.4
Total 300,606 1,216,210 24.7

Abbreviations: PrEP, preexposure prophylaxis; n/a, not available; FDA, Food and Drug Administration [footnotes only].
Note. PrEP coverage data are considered preliminary. Data for years 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/local jurisdictions.
aEstimated using data from IQVIA pharmacy database reported through September 2021 based on an algorithm that included FDA approved drugs for PrEP. Data for which values are unknown were not reported thus values may not sum to column total.
bEstimated using 2018 data from National HIV Surveillance System (NHSS), National Health and Nutrition Examination Survey, and U.S. Census Bureau’s American Community Survey (ACS). Data are rounded to the nearest 10. Data for which values are unknown were not reported thus values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator. The 2018 denominators were used for 2020 PrEP coverage data.
cPrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.
dRace/ethnicity data were only available for <40% of persons prescribed PrEP in each year. Number prescribed PrEP and PrEP coverage for race/ethnicity reported in the table were adjusted by applying the distribution of records with known race/ethnicity to records with missing race/ethnicity.
eHispanic/Latino persons can be of any race.

Table 8b. Number of persons prescribed PrEP, number of persons with PrEP indications, and PrEP coverage in 2020 (COVID-19 pandemic) among persons aged ≥16 years, by area of residence—United States and Puerto Rico
Area of residence No. prescribed PrEPa No. with PrEP indicationsb PrEP coveragec(%)
Alabama 1,918 11,020 17.4
Alaska 244 1,780 13.7
Arizona 5,051 25,780 19.6
Arkansas 870 5,130 17.0
California 42,304 165,030 25.6
Colorado 4,765 25,120 19.0
Connecticut 2,477 9,560 25.9
Delaware 467 4,400 10.6
District of Columbia 5,953 12,950 46.0
Florida 34,581 125,330 27.6
Georgia 9,745 39,030 25.0
Hawaii 903 4,360 20.7
Idaho 660 4,790 13.8
Illinois 15,938 55,860 28.5
Indiana 3,198 22,170 14.4
Iowa 1,516 4,760 31.8
Kansas 944 5,060 18.7
Kentucky 1,668 12,990 12.8
Louisiana 3,603 15,920 22.6
Maine 663 3,950 16.8
Maryland 4,798 27,300 17.6
Massachusetts 9,372 24,900 37.6
Michigan 4,687 29,570 15.9
Minnesota 4,190 21,720 19.3
Mississippi 1,098 4,530 24.2
Missouri 3,570 18,370 19.4
Montana 299 2,290 13.1
Nebraska 725 2,180 33.3
Nevada 2,496 11,390 21.9
New Hampshire 649 3,020 21.5
New Jersey 5,921 25,280 23.4
New Mexico 1,237 6,800 18.2
New York 34,090 72,640 46.9
North Carolina 6,160 32,490 19.0
North Dakota 216 1,520 14.2
Ohio 6,833 40,320 16.9
Oklahoma 1,524 11,030 13.8
Oregon 3,819 19,750 19.3
Pennsylvania 10,608 36,490 29.1
Puerto Rico 368 9,700 3.8
Rhode Island 1,153 3,880 29.7
South Carolina 2,120 10,390 20.4
South Dakota 144 910 15.8
Tennessee 5,168 22,460 23.0
Texas 27,520 123,790 22.2
Utah 2,370 6,840 34.6
Vermont 321 1,060 30.3
Virginia 5,131 31,430 16.3
Washington 10,025 40,050 25.0
West Virginia 522 5,250 9.9
Wisconsin 2,521 12,980 19.4
Wyoming 99 890 11.1

Abbreviations: PrEP, preexposure prophylaxis; n/a, not available.
Note. PrEP coverage data are considered preliminary. Data for years 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on filling PrEP prescriptions in state/local jurisdictions.
aEstimated using data from IQVIA pharmacy database reported through September 2021 based on an algorithm that included FDA approved drugs for PrEP. Data for which values are unknown were not reported thus values may not sum to column total.
bEstimated using 2018 data from National HIV Surveillance System (NHSS), National Health and Nutrition Examination Survey, and U.S. Census Bureau’s American Community Survey (ACS). Data are rounded to the nearest 10. Data for which values are unknown were not reported thus values may not sum to column total. The data sources used to estimate the number of persons with indications for PrEP have different schedules of data availability. Consequently, the availability of a denominator may lag the availability of a numerator. The 2018 denominators were used for 2020 PrEP coverage data.
cPrEP coverage, reported as a percentage, was calculated as the number who have been prescribed PrEP divided by the estimated number of persons who had indications for PrEP.

Table 9a. Perinatally acquired HIV infection, by year of birth and mother’s race/ethnicity, 2016–2020—United States
2016 2017 2018 2019 2020 (COVID-19 pandemic)
Race/ethnicitya No. Rate No. Rate No. Rate No. Rate No. Rate
Black/African American 33 5.9 27 4.8 19 3.4 17 3.1 21 4.0
Hispanic/Latinob 11 1.2 7 0.8 7 0.8 7 0.8 8 0.9
White 3 0.1 6 0.3 6 0.3 5 0.3 6 0.3
Otherc 7 1.9 6 1.6 6 1.7 3 0.8 1 0.3
Total 54 1.4 46 1.2 38 1.0 32 0.9 36 1.0

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Rates are per 100,000 live births. Because of delays in the reporting of births and diagnoses of HIV infection attributed to perinatal exposure, these numbers may be subject to change. Please use caution when interpreting perinatally acquired HIV infection numbers.
aLive-birth data reflect race/ethnicity of the infant’s mother.
bHispanic/Latino persons can be of any race.
cIncludes American Indian or Alaska Native, Asian, Native Hawaiian or other Pacific Islander, and multiracial persons.

Table 9b. Perinatally acquired HIV infection among persons born in the United States, by year of birth and mother’s race/ethnicity, 2016–2020—United States
2016 2017 2018 2019 2020 (COVID-19 pandemic)
Race/ethnicitya No. Rate No. Rate No. Rate No. Rate No. Rate
Black/African American 30 5.4 26 4.6 18 3.3 17 3.1 20 3.8
Hispanic/Latinob 10 1.1 7 0.8 7 0.8 7 0.8 8 0.9
White 3 0.1 6 0.3 6 0.3 5 0.3 6 0.3
Otherc 6 1.6 6 1.6 5 1.4 3 0.8 1 0.3
Total 49 1.2 45 1.2 36 0.9 32 0.9 35 1.0

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Rates are per 100,000 live births. Because of delays in the reporting of births and diagnoses of HIV infection attributed to perinatal exposure, these numbers may be subject to change. Please use caution when interpreting perinatally acquired HIV infection numbers.
aLive-birth data reflect race/ethnicity of the infant’s mother.
bHispanic/Latino persons can be of any race.
cIncludes American Indian or Alaska Native, Asian, Native Hawaiian or other Pacific Islander, and multiracial persons.

Table 10. Monitoring national HIV prevention goals by using data from the National HIV Surveillance System (NHSS) and other surveillance systems
Ending the HIV Epidemic in the U.S. Indicators — Targets through 2025 2017a 2018 2019 2020 (COVID-19 Pandemic)
Reduce new HIV infections by 75%b 37,000 36,200 34,800 —
Increase knowledge of status to 95%b 85.8 86.3 86.7 —
Reduce new HIV diagnoses by 75%c 38,351 37,417 36,528 30,346
Increase linkage to HIV medical care within 1 month of diagnosis to 95% 77.8 80.2 81.3 82.4
Increase viral suppression among people with diagnosed HIV to 95% 63.1 64.7 65.5 64.6
Increase PrEP coverage to at least 50%d 13.2 18.1 22.5 24.7
National HIV/AIDS Strategy Indicators —Targets through 2025
Indicator 1: Increase knowledge of status to 95%b 85.8 86.3 86.7 —
Indicator 2: Reduce new HIV infections by 75%b 37,000 36,200 34,800 —
Indicator 3: Reduce new HIV diagnoses by 75%c 38,351 37,417 36,528 30,346
Indicator 4: Increase PrEP coverage to 50%d 13.2 18.1 22.5 24.7
Indicator 5: Increase linkage to care within 1 month of diagnosis to 95% 77.8 80.2 81.3 82.4
Indicator 6: Increase viral suppression among people with diagnosed HIV to 95% 63.1 64.7 65.5 64.6
Indicator 6a: Increase viral suppression among MSM diagnosed with HIV to 95% 66.1 67.3 68.1 64.2
Indicator 6b: Increase viral suppression among Black MSM diagnosed with HIV to 95% 58.4 60.6 61.6 61.4
Indicator 6c: Increase viral suppression among Latino MSM diagnosed with HIV to 95% 64.9 65.9 66.6 65.5
Indicator 6d: Increase viral suppression among American Indian/Alaska Native MSM diagnosed with HIV to 95% 67.3 66.9 64.7 64.7
Indicator 6e: Increase viral suppression among Black women diagnosed with HIV to 95% 59.3 61.4 62.4 61.9
Indicator 6f: Increase viral suppression among transgender women in HIV medical care to 95%e 80.5 81.1 82.9 84.2
Indicator 6g: Increase viral suppression among people who inject drugs diagnosed with HIV to 95% 54.9 56.3 56.9 55.3
Indicator 6h: Increase viral suppression among youth aged 13–24 diagnosed with HIV to 95% 57.1 60.3 63.3 63.5
Indicator 7: Decrease stigma among people with diagnosed HIV by 50%f — 31.2 30.7 28.4
Indicator 8: Increase the median percentage of secondary schools that implement at least 4 out of 7 LGBTQ-supportive policies and practices to 65%g — 59.8 — —
Indicator 9: Increase good or better self-rated health among persons with diagnosed HIV to 95%h — 71.5 70.6 71.5
Indicator 10: Reduce unmet need for mental health services from a mental health professional among persons with diagnosed HIV by 50%i 24.2 19.8 20.8 21.0
Indicator 11: Reduce hunger/food insecurity among persons with diagnosed HIV by 50%j 21.1 19.5 19.9 16.4
Indicator 12: Reduce unemployment among persons with diagnosed HIV by 50%k 14.9 13.9 13.7 18.1
Indicator 13: Reduce unstable housing or homelessness among persons with diagnosed HIV by 50%l – 21.0 19.8 17.2

Abbreviations: MSM, gay, bisexual, and other men who have sex with men; PrEP, preexposure prophylaxis; CDC, Centers for Disease Control and Prevention [footnotes only].

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Em dash (—) denotes data not available. Information on Ending the HIV Epidemic in the U.S. can be found at https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview. For data on EHE Phase I jurisdictions, see https://www.cdc.gov/hiv/pdf/library/reports/ehe-core-indicators/cdc-hiv-ehe-core-indicators-2019.pdf. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions.
Information on National HIV/AIDS Strategy (2022–2025) can be found at https://www.hiv.gov/federal-response/national-hiv-aids-strategy/national-hiv-aids-strategy-2022-2025#:~:text=The%20National%20HIV%2FAIDS%20Strategy,the%20United%20States%20by%202030.

aBaseline data for EHE indicators, published at https://www.cdc.gov/hiv/pdf/library/reports/surveillance-data-tables/vol-1-no-1/cdc-hiv-surveillance-tables-vol-1-no-1.pdf. Baseline data for PrEP coverage, published at: https://www.cdc.gov/hiv/pdf/library/reports/surveillance-data-tables/vol-2-no-2/cdc-hiv-surveillance-tables-vol-2-no-2.pdf. Baseline data for NHAS indicators, published at https://hivgov-prod-v3.s3.amazonaws.com/s3fs-public/NHAS-2022-2025.pdf.
bCDC. Estimated HIV incidence and prevalence in the United States, 2015–2019. HIV Surveillance Supplemental Report 2021;26(No. 1). https://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Published May 2021.
cPerson ≥13 years only. CDC. HIV Surveillance Report, 2020; vol. 33. https://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Published May 2022.
dPrEP coverage, reported as a percentage, was calculated as the number of persons classified as having been been prescribed PrEP divided by the estimated number of persons who had indications for PrEP. PrEP coverage for 2017 used a 2017 denominator. PrEP coverage for 2018, 2019, 2020 used a 2018 denominator.
eHealth Resources and Services Administration. Ryan White HIV/AIDS Program Annual Client-Level Data Report 2020. http://hab.hrsa.gov/data/data-reports. Published December 2021.; 2017 baseline data can be found at: https://ryanwhite.hrsa.gov/sites/default/files/ryanwhite/data/rwhap-annual-client-level-data-report-2017.pdf
fDefined as the weighted median score on a 10-item scale ranging from 0 (no stigma) to 100 (high stigma) that measures 4 dimensions of HIV stigma: personalized stigma during the past 12 months, current disclosure concerns, current negative self-image, and current perceived public attitudes about people living with HIV, measured among persons aged ≥18 years with diagnosed HIV infection living in the United States and Puerto Rico. The HIV stigma scale utilized for this indicator is discussed in Wright K, Naar-King S, Lam P, Templin T, Frey M. Stigma scale revised: reliability and validity of a brief measure of stigma for HIV+ youth. J Adolesc Health 2007;40(1). Data are collected through CDC’s Medical Monitoring Project (MMP). Data collected on HIV stigma using this revised scale started with 2018 MMP data collection cycle; consequently 2018 is the baseline year for HIV stigma. For more information about MMP, see http://www.cdc.gov/hiv/statistics/systems/mmp/.
gSchool policies and practices known to improve health outcomes for both LGBTQ youth and all students: (1) having a Gay/Straight Alliance (GSA) or similar club, (2) identifying safe spaces, (3) prohibiting harassment based on sexual orientation or gender identity, (4) encouraging staff to attend professional development; (5) facilitating access to out-of-school health service providers, (6) facilitating access to out-ofschool social and psychological service providers, and (7) providing LGBTQ-relevant curricula or supplementary materials.
hDefined as the weighted percentage of persons aged ≥18 years with diagnosed HIV infection living in the United States and Puerto Rico who rated their health as good, very good, or excellent (as opposed to poor or fair) at the time of interview. Data are collected through CDC’s Medical Monitoring Project (MMP). For more information about MMP, see http://www.cdc.gov/hiv/statistics/systems/mmp/.
iDefined as the weighted percentage of persons aged ≥18 years with diagnosed HIV infection living in the United States and Puerto Rico who needed but did not receive services from a mental health professional, among those who indicated needing mental health services (i.e., receiving or needing but not receiving) during the past 12 months. Data are collected through CDC’s Medical Monitoring Project (MMP). For more information about MMP, see http://www.cdc.gov/hiv/statistics/systems/mmp/.
jDefined as the weighted percentage of persons aged ≥18 years with diagnosed HIV infection living in the United States and Puerto Rico who reported going without food due to lack of money during the past 12 months. Data are collected through CDC’s Medical Monitoring Project (MMP). For more information about MMP, see http://www.cdc.gov/hiv/statistics/systems/mmp/.
kDefined as the weighted percentage of persons aged ≥18 years with diagnosed HIV infection living in the United States and Puerto Rico who reported being unemployed at the time of interview. Data are collected through CDC’s Medical Monitoring Project (MMP). For more information about MMP, see http://www.cdc.gov/hiv/statistics/systems/mmp/.
lDefined as the weighted percentage of persons aged ≥18 years with diagnosed HIV infection living in the United States and Puerto Rico who reported experiencing unstable housing (i.e., moving 2 or more times, being evicted, or moving in with others due to financial problems) or homelessness (i.e., living on the street, in a shelter, in a single-room–occupancy hotel, or in a car) during the past 12 months. Data are collected through CDC’s Medical Monitoring Project (MMP). For more information about MMP, see http://www.cdc.gov/hiv/statistics/systems/mmp/.

Table 11. Status of CD4 and viral load reporting by HIV surveillance reporting area, as of December 2021—50 states, District of Columbia, and U.S. dependent areas
CD4 count (cells/µL) or CD4 percentage Viral load
Lab reporting requireda Reportable levelb Lab reporting requireda Reportable levelb
Alabama Yes All values Yes Any result
Alaska Yes All values Yes Any result
American Samoa No — No —
Arizona Yes All values Yes Any result
Arkansas Yes All values Yes Any result
California Yes All values Yes Any result
Colorado Yes All values Yes Any result
Connecticut Yes All values Yes Any result
Delaware Yes All values Yes Any result
District Columbia Yes All values Yes Any result
Federated States of Micronesia No — No —
Florida Yes All values Yes Any result
Georgia Yes All values Yes Any result
Guam Yes All values Yes Any result
Hawaii Yes All values Yes Any result
Idaho Yes <200 or <14% Yes Detectable
Illinois Yes All values Yes Any result
Indiana Yes All values Yes Any result
Iowa Yes All values Yes Any result
Kansas Yes All values Yes Any result
Kentucky Yes All values Yes Any result
Louisiana Yes All values Yes Any result
Maine Yes All values Yes Any result
Marshall Islands No — No —
Maryland Yes All values Yes Any result
Massachusetts Yes All values Yes Any result
Michigan Yes All values Yes Any result
Minnesota Yes All values Yes Any result
Mississippi Yes All values Yes Any result
Missouri Yes All values Yes Any result
Montana Yes All values Yes Any result
Nebraska Yes All values Yes Any result
Nevada Yes All values Yes Any result
New Hampshire Yes All values Yes Any result
New Jersey Yes <200 or <14% Yes Any result
New Mexico Yes All values Yes Any result
New York Yes All values Yes Any result
North Carolina Yes All values Yes Any result
North Dakota Yes All values Yes Any result
Northern Mariana Islands No — No —
Ohio Yes All values Yes Any result
Oklahoma Yes All values Yes Any result
Oregon Yes All values Yes Any result
Pennsylvania Yes All values Yes Any result
Puerto Rico Yes All values Yes Any result
Republic of Palau No — No —
Rhode Island Yes All values Yes Any result
South Carolina Yes All values Yes Any result
South Dakota Yes All values Yes Any result
Tennessee Yes All values Yes Any result
Texas Yes All values Yes Any result
U.S. Virgin Islands Yes <200 or <14% Yes Detectable
Utah Yes All values Yes Any result
Vermont Yes All values Yes Any result
Virginia Yes All values Yes Any result
Washington Yes All values Yes Any result
West Virginia Yes All values Yes Any result
Wisconsin Yes All values Yes Any result
Wyoming Yes All values Yes Any result

Abbreviation: CD4, CD4+ T-lymphocyte count (cells/μL) or percentage.
aLaws, regulations, or statutes in most areas require laboratories to report, but in some instances the language is not specific.
bLevel at which CD4 or viral load reporting is required by laws, regulations, or statutes.

Top of Page
View Page In: Monitoring Selected National HIV Prevention and Care Objectives By Using HIV Surveillance Data United States and 6 Dependent Areas, 2020
Page last reviewed: August 26, 2022
Content source: Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention